BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60. [PMID: 20175033 DOI: 10.1055/s-0030-1247132] [Cited by in Crossref: 2016] [Cited by in F6Publishing: 1962] [Article Influence: 168.0] [Reference Citation Analysis]
Number Citing Articles
1 Wada Y, Takami Y, Tateishi M, Ryu T, Mikagi K, Saitsu H. The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. PLoS One 2016;11:e0146456. [PMID: 26745625 DOI: 10.1371/journal.pone.0146456] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
2 Nomura T, Tani J, Deguchi A, Nakahara M, Oura K, Tadokoro T, Fujita K, Mimura S, Sakamoto T, Morishita A, Yoneyama H, Kobara H, Sanomura T, Nishiyama Y, Okano K, Suzuki Y, Takahashi S, Shibata T, Tsutsui K, Himoto T, Masaki T. Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion. Mol Clin Oncol 2019;11:447-54. [PMID: 31602300 DOI: 10.3892/mco.2019.1920] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Jebar AH, Vile RG, Melcher AA, Griffin S, Selby PJ, Errington-mais F. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma. Journal of General Virology 2015;96:1533-50. [DOI: 10.1099/vir.0.000098] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
4 Su TS, Lu HZ, Cheng T, Zhou Y, Huang Y, Gao YC, Tang MY, Jiang HY, Lian ZP, Hou EC, Liang P. Long-term survival analysis in combined transarterial embolization and stereotactic body radiation therapy versus stereotactic body radiation monotherapy for unresectable hepatocellular carcinoma >5 cm. BMC Cancer 2016;16:834. [PMID: 27809890 DOI: 10.1186/s12885-016-2894-9] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
5 Stevens CL, Awad A, Abbas SM, Watters DAK. Systematic review and meta-analysis of hepatic resection versus transarterial chemoembolization for solitary large hepatocellular carcinoma. HPB (Oxford) 2017;19:653-8. [PMID: 28427829 DOI: 10.1016/j.hpb.2017.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
6 Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, Endo I, Nakatsura T. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. Oncoimmunology. 2017;6:e1346764. [PMID: 29123959 DOI: 10.1080/2162402x.2017.1346764] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
7 Paul SB, Sharma H. Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma. J Clin Exp Hepatol 2014;4:S112-21. [PMID: 25755602 DOI: 10.1016/j.jceh.2014.03.048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
8 Ciancio A, Ribaldone DG, Dotta A, Giordanino C, Sacco M, Fagoonee S, Pellicano R, Saracco GM. Long-term follow-up of diabetic and non-diabetic patients with chronic hepatitis C successfully treated with direct-acting antiviral agents. Liver Int 2021;41:276-87. [PMID: 32998174 DOI: 10.1111/liv.14676] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yan XH, Yue ZD, Zhao HW, Wang L, Fan ZH, Wu YF, Meng MM, Zhang K, Jiang L, Ding HG, Zhang YN, Yang YP, Liu FQ. Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension. World J Gastrointest Surg 2022; 14(6): 567-579 [DOI: 10.4240/wjgs.v14.i6.567] [Reference Citation Analysis]
10 Choi C, Seong J. Predictive factors of palliative radiotherapy response and survival in patients with spinal metastases from hepatocellular carcinoma. Gut Liver. 2015;9:94-102. [PMID: 25071067 DOI: 10.5009/gnl14009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
11 Golfieri R, Bezzi M, Verset G, Fucilli F, Mosconi C, Cappelli A, Paccapelo A, Lucatelli P, Magand N, Rode A, De Baere T. Balloon-Occluded Transarterial Chemoembolization: In Which Size Range Does It Perform Best? A Comparison of Its Efficacy versus Conventional Transarterial Chemoembolization, Using Propensity Score Matching. Liver Cancer 2021;10:522-34. [PMID: 34721513 DOI: 10.1159/000516613] [Reference Citation Analysis]
12 Schmitz S, Lurje G, Ulmer F, Andert A, Bruners P, Schulze-hagen M, Neumann U, Schoening W. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation. Hepatobiliary & Pancreatic Diseases International 2019;18:228-36. [DOI: 10.1016/j.hbpd.2019.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Yan L, Ren Y, Qian K, Kan X, Zhang H, Chen L, Liang B, Zheng C. Sequential transarterial chemoembolization and early radiofrequency ablation improves clinical outcomes for early-intermediate hepatocellular carcinoma in a 10-year single-center comparative study. BMC Gastroenterol 2021;21:182. [PMID: 33879085 DOI: 10.1186/s12876-021-01765-x] [Reference Citation Analysis]
14 Cucchetti A, Cappelli A, Mosconi C, Zhong J, Cescon M, Pinna AD, Golfieri R. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study. Liver Int 2017;37:1056-64. [DOI: 10.1111/liv.13382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
15 Yan L, Chen L, Qian K, Kan X, Zhang H, Liang B, Zheng C. Caudate Lobe Hepatocellular Carcinoma Treated with Sequential Transarterial Chemoembolization and Iodine 125 Seeds Implantation: A Single-Center Retrospective Study. Cancer Manag Res 2021;13:3901-12. [PMID: 34012296 DOI: 10.2147/CMAR.S309310] [Reference Citation Analysis]
16 Zhu D, Yuan D, Wang Z, Chen S. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients. Medicine (Baltimore). 2019;98:e15682. [PMID: 31261491 DOI: 10.1097/md.0000000000015682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Dituri F, Mazzocca A, Peidro FJ, Papappicco P, Fabregat I, De Santis F, Paradiso A, Sabba C, Giannelli G. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II. PLoS One. 2013;8:e67109. [PMID: 23826206 DOI: 10.1371/journal.pone.0067109] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
18 Sze DY, Iagaru AH, Gambhir SS, De Haan HA, Reid TR. Response to Intra-Arterial Oncolytic Virotherapy with the Herpes Virus NV1020 Evaluated by [ 18 F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography. Human Gene Therapy 2012;23:91-7. [DOI: 10.1089/hum.2011.141] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
19 Miller JP, Ramaswamy R, Akinwande O. Using principal component analysis for the prediction of tumor response to transarterial chemoembolization. Abdom Radiol (NY) 2019;44:2594-601. [PMID: 31004201 DOI: 10.1007/s00261-019-01982-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Granito A, Facciorusso A, Sacco R, Bartalena L, Mosconi C, Cea UV, Cappelli A, Antonino M, Modestino F, Brandi N, Tovoli F, Piscaglia F, Golfieri R, Renzulli M. TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. J Pers Med 2021;11:1041. [PMID: 34683182 DOI: 10.3390/jpm11101041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
21 Chevallier P, Baudin G, Anty R, Guibal A, Chassang M, Avril L, Tran A. Treatment of hepatocellular carcinomas by thermal ablation and hepatic transarterial chemoembolization. Diagnostic and Interventional Imaging 2015;96:637-46. [DOI: 10.1016/j.diii.2015.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
22 Lee TY, Lin CC, Chen CY, Wang TE, Lo GH, Chang CS, Chao Y. Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial. Medicine (Baltimore). 2017;96:e7655. [PMID: 28906355 DOI: 10.1097/md.0000000000007655] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
23 Tajiri K, Futsukaichi Y, Kobayashi S, Nagata K, Yasumura S, Takahara T, Minemura M, Yasuda I. Efficacy of on-demand intrahepatic arterial therapy in combination with sorafenib for advanced hepatocellular carcinoma. Onco Targets Ther 2019;12:2205-14. [PMID: 30988625 DOI: 10.2147/OTT.S191741] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Su T, Liang P, Liang J, Lu H, Jiang H, Cheng T, Huang Y, Tang Y, Deng X. Long-Term Survival Analysis of Stereotactic Ablative Radiotherapy Versus Liver Resection for Small Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics 2017;98:639-46. [DOI: 10.1016/j.ijrobp.2017.02.095] [Cited by in Crossref: 52] [Cited by in F6Publishing: 40] [Article Influence: 10.4] [Reference Citation Analysis]
25 Hur S, Lee JM, Kim SJ, Park JH, Han JK, Choi BI. 80-kVp CT using Iterative Reconstruction in Image Space algorithm for the detection of hypervascular hepatocellular carcinoma: phantom and initial clinical experience. Korean J Radiol 2012;13:152-64. [PMID: 22438682 DOI: 10.3348/kjr.2012.13.2.152] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 3.5] [Reference Citation Analysis]
26 Yang Z, Zou R, Zheng Y, Qiu J, Shen J, Liao Y, Zhang Y, Wang C, Wang Y, Yuan Y, Li K, Zuo D, He W, Liu W, Li B, Yuan Y. Lipiodol deposition in portal vein tumour thrombus predicts treatment outcome in HCC patients after transarterial chemoembolisation. Eur Radiol 2019;29:5752-62. [PMID: 30993438 DOI: 10.1007/s00330-019-06157-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
27 Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croisé-Laurent V, Barraud H, Ayav A, Bronowicki JP, Peiffert D. Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. Radiother Oncol. 2015;115:211-216. [PMID: 26028227 DOI: 10.1016/j.radonc.2015.04.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 68] [Article Influence: 11.7] [Reference Citation Analysis]
28 Okubo H, Ando H, Ishizuka K, Kitagawa R, Okubo S, Saito H, Kokubu S, Miyazaki A, Ikejima K, Shiina S, Nagahara A. Carnitine insufficiency is associated with fatigue during lenvatinib treatment in patients with hepatocellular carcinoma. PLoS One 2020;15:e0229772. [PMID: 32126131 DOI: 10.1371/journal.pone.0229772] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
29 Chai B, Wang W, Wang F, Zhou G, Zheng C. Transcatheter chemoembolization plus percutaneous radiofrequency ablation versus laparoscopic radiofrequency ablation: improved outcome for inoperable hepatocellular carcinoma. Int J Hyperthermia 2021;38:1685-94. [PMID: 34843653 DOI: 10.1080/02656736.2021.1970825] [Reference Citation Analysis]
30 Ohki T, Kondo M, Karasawa Y, Kawamura S, Maeshima S, Kojima K, Seki M, Toda N, Shioda Y, Tagawa K. Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index. Adv Ther 2017;34:1097-108. [PMID: 28389996 DOI: 10.1007/s12325-017-0524-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
31 Gerwing M, Herrmann K, Helfen A, Schliemann C, Berdel WE, Eisenblätter M, Wildgruber M. The beginning of the end for conventional RECIST - novel therapies require novel imaging approaches. Nat Rev Clin Oncol 2019;16:442-58. [PMID: 30718844 DOI: 10.1038/s41571-019-0169-5] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 15.0] [Reference Citation Analysis]
32 Granata V, Fusco R, Setola SV, Piccirillo M, Leongito M, Palaia R, Granata F, Lastoria S, Izzo F, Petrillo A. Early radiological assessment of locally advanced pancreatic cancer treated with electrochemotherapy. World J Gastroenterol 2017; 23(26): 4767-4778 [PMID: 28765698 DOI: 10.3748/wjg.v23.i26.4767] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 24] [Article Influence: 6.6] [Reference Citation Analysis]
33 Zwirtz K, Hardt J, Acker G, Baur ADJ, Pavel M, Huang K, Brenner W, Prasad V. Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT. Pharmaceutics 2022;14:1278. [PMID: 35745849 DOI: 10.3390/pharmaceutics14061278] [Reference Citation Analysis]
34 Borgheresi A, Gonzalez-Aguirre A, Brown KT, Getrajdman GI, Erinjeri JP, Covey A, Yarmohammadi H, Ziv E, Sofocleous CT, Boas FE. Does Enhancement or Perfusion on Preprocedure CT Predict Outcomes After Embolization of Hepatocellular Carcinoma? Acad Radiol 2018;25:1588-94. [PMID: 29602726 DOI: 10.1016/j.acra.2018.02.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
35 Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology. 2016;150:835-853. [PMID: 26795574 DOI: 10.1053/j.gastro.2015.12.041] [Cited by in Crossref: 781] [Cited by in F6Publishing: 771] [Article Influence: 130.2] [Reference Citation Analysis]
36 Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Marshall K, Lin M, Gebauer B, Chapiro J, Salem R, Geschwind JF. Renal Cell Carcinoma Metastatic to the Liver: Early Response Assessment after Intraarterial Therapy Using 3D Quantitative Tumor Enhancement Analysis. Transl Oncol 2016;9:377-83. [PMID: 27641641 DOI: 10.1016/j.tranon.2016.07.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: A meta-analysis and systemic review. Radiother Oncol. 2018;129:123-129. [PMID: 29606524 DOI: 10.1016/j.radonc.2018.02.030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
38 Xu C, Liu J, Xing L, Liu S. [Clinical significance of serum cytokeratin 19 fragment in the prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi 2010;13:954-61. [PMID: 20959068 DOI: 10.3779/j.issn.1009-3419.2010.10.05] [Reference Citation Analysis]
39 Sanuki N, Takeda A, Oku Y, Mizuno T, Aoki Y, Eriguchi T, Iwabuchi S, Kunieda E. Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 2014;53:399-404. [PMID: 23962244 DOI: 10.3109/0284186X.2013.820342] [Cited by in Crossref: 165] [Cited by in F6Publishing: 95] [Article Influence: 20.6] [Reference Citation Analysis]
40 Liu YS, Ou MC, Tsai YS, Lin XZ, Wang CK, Tsai HM, Chuang MT. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Korean J Radiol. 2015;16:125-132. [PMID: 25598680 DOI: 10.3348/kjr.2015.16.1.125] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
41 Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 31991869 DOI: 10.3390/cancers12020293] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
42 van Breugel JMM, Geschwind JF, Mirpour S, Savic LJ, Zhang X, Duran R, Lin M, Miszczuk M, Liapi E, Chapiro J. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model. Theranostics 2019;9:3674-86. [PMID: 31281506 DOI: 10.7150/thno.32943] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
43 Choi HS, Kang KM, Jeong BK, Jeong H, Lee YH, Ha IB, Song JH. Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease. Asia Pac J Clin Oncol 2021;17:209-15. [PMID: 32757461 DOI: 10.1111/ajco.13361] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lei J, Zhong J, Luo Y, Yan L, Zhu J, Wang W, Li B, Wen T, Yang J; Liver Surgery Group. Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation. Oncotarget 2017;8:91328-42. [PMID: 29207647 DOI: 10.18632/oncotarget.20511] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
45 Biolato M, Marrone G, Miele L, Gasbarrini A, Grieco A. Liver transplantation for intermediate hepatocellular carcinoma: An adaptive approach. World J Gastroenterol 2017; 23(18): 3195-3204 [PMID: 28566879 DOI: 10.3748/wjg.v23.i18.3195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Ikeda A, Aoki K, Kawamura M, Yamaguchi D, Kokuryu H. Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma. Intern Med 2021;60:403-7. [PMID: 33518611 DOI: 10.2169/internalmedicine.5552-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Park SH, Kim JC. Tracking SBRT for liver tumors with a gimbaled linac system: a single institution experience. Acta Oncol 2017;56:1786-9. [PMID: 28557541 DOI: 10.1080/0284186X.2017.1332427] [Reference Citation Analysis]
48 Hu Z, Yu N, Wang H, Li S, Yan J, Zhang G. Pre-radiofrequency ablation MRI imaging features predict the local tumor progression in hepatocellular carcinoma. Medicine (Baltimore). 2020;99:e23924. [PMID: 33350797 DOI: 10.1097/md.0000000000023924] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Chang PY, Huang CC, Hung CH, Yu CY, Wu DK, Hwang JI, Liang PC, Wu RH, Tsai WL, Lin YJ, Liu YS, Liang HL, Lee RC, Chen CH. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. Liver Cancer 2018;7:312-22. [PMID: 30488021 DOI: 10.1159/000487608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Guiu B, Jouve JL, Schmitt A, Minello A, Bonnetain F, Cassinotto C, Piron L, Cercueil JP, Loffroy R, Latournerie M, Wendremaire M, Lepage C, Boulin M. Intra-arterial idarubicin_lipiodol without embolisation in hepatocellular carcinoma: The LIDA-B phase I trial. J Hepatol. 2018;68:1163-1171. [PMID: 29427728 DOI: 10.1016/j.jhep.2018.01.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
51 Dioguardi Burgio M, Ronot M, Bruno O, Francoz C, Paradis V, Castera L, Durand F, Soubrane O, Vilgrain V. Correlation of tumor response on computed tomography with pathological necrosis in hepatocellular carcinoma treated by chemoembolization before liver transplantation. Liver Transpl 2016;22:1491-500. [DOI: 10.1002/lt.24615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
52 Gomes AS, Monteleone PA, Sayre JW, Finn RS, Sadeghi S, Tong MJ, Britten CD, Busuttil RW. Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients. AJR Am J Roentgenol 2017;209:722-32. [PMID: 28705059 DOI: 10.2214/AJR.17.18219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
53 Sebastian NT, Miller ED, Yang X, Diaz DA, Tan Y, Dowell J, Spain J, Rikabi A, Elliott E, Knopp M, Williams TM. A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination With Transarterial Chemoembolization for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2020;108:1276-83. [PMID: 32712254 DOI: 10.1016/j.ijrobp.2020.07.033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
54 Shampain KL, Hackett CE, Towfighi S, Aslam A, Masch WR, Harris AC, Chang SD, Khanna K, Mendiratta V, Gabr AM, Owen D, Mendiratta-Lala M. SBRT for HCC: Overview of technique and treatment response assessment. Abdom Radiol (NY) 2021;46:3615-24. [PMID: 33963419 DOI: 10.1007/s00261-021-03107-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. 2017;23:128-137. [PMID: 28494528 DOI: 10.3350/cmh.2016.0071] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
56 Huang M, Lin Q, Wang H, Chen J, Bai M, Wang L, Zhu K, Jiang Z, Guan S, Li Z, Qian J, Li M, Pang P, Shan H. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study. Eur Radiol. 2016;26:3428-3436. [PMID: 26792430 DOI: 10.1007/s00330-015-4198-x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
57 Brandi G, Venturi M, De Lorenzo S, Garuti F, Frega G, Palloni A, Garajovà I, Abbati F, Saccoccio G, Golfieri R, Pantaleo MA, Barbera MA. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases. Cancer Commun (Lond) 2018;38:41. [PMID: 29941039 DOI: 10.1186/s40880-018-0312-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
58 Tsauo J, Noh SY, Shin JH, Gwon DI, Han K, Lee JM, Jeon UB, Kim YH. Retrograde transvenous obliteration for the prevention of variceal rebleeding in patients with hepatocellular carcinoma: a multicentre retrospective study. Clin Radiol 2021;76:681-7. [PMID: 34140137 DOI: 10.1016/j.crad.2021.05.011] [Reference Citation Analysis]
59 Spreafico C, Cascella T, Facciorusso A, Sposito C, Rodolfo L, Morosi C, Civelli EM, Vaiani M, Bhoori S, Pellegrinelli A. Transarterial chemoembolization for hepatocellular carcinoma with a new generation of beads: clinical-radiological outcomes and safety profile. Cardiovasc Intervent Radiol. 2015;38:129-134. [PMID: 24870698 DOI: 10.1007/s00270-014-0907-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 4.8] [Reference Citation Analysis]
60 Hayano K, Lee SH, Sahani DV. Imaging for assessment of treatment response in hepatocellular carcinoma: Current update. Indian J Radiol Imaging 2015;25:121-8. [PMID: 25969635 DOI: 10.4103/0971-3026.155835] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
61 Terzi E, Giamperoli A, Iavarone M, Leoni S, De Bonis L, Granito A, Forgione A, Tovoli F, Piscaglia F. Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5). Cancers (Basel) 2022;14:336. [PMID: 35053498 DOI: 10.3390/cancers14020336] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Gasljevic G, Edhemovic I, Cemazar M, Brecelj E, Gadzijev EM, Music MM, Sersa G. Histopathological findings in colorectal liver metastases after electrochemotherapy. PLoS One 2017;12:e0180709. [PMID: 28686650 DOI: 10.1371/journal.pone.0180709] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
63 Kim HO, Yim NY, Kim JK, Kang YJ, Lee BC, Kim JW. Change in Perfusion Angiography During Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Predicts Short-Term Outcomes. American Journal of Roentgenology 2019;213:746-54. [DOI: 10.2214/ajr.18.20499] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Bruix J, Reig M, Rimola J, Forner A, Burrel M, Vilana R, Ayuso C. Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques. Hepatology 2011;54:2238-44. [PMID: 21932394 DOI: 10.1002/hep.24670] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 7.5] [Reference Citation Analysis]
65 Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E, Tawada A, Nagai K, Nakagawa T, Sugawara T, Hanaoka H, Kanai F, Yokosuka O. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology 2018;67:575-85. [PMID: 28746788 DOI: 10.1002/hep.29403] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
66 Kim MJ, Choi JI, Lee JS, Park JW. Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:1201-1206. [PMID: 21371120 DOI: 10.1111/j.1440-1746.2011.06709.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
67 Chen D, Soh CK, Goh WH, Wang Z, Wang H. Synthesis and biological evaluation of 6-phenylpurine linked hydroxamates as novel histone deacetylase inhibitors. Bioorg Chem 2020;98:103724. [PMID: 32171983 DOI: 10.1016/j.bioorg.2020.103724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
68 Karahan Şen NP, Alataş Ö, Gülcü A, Özdoğan Ö, Derebek E, Çapa Kaya G. The role of volumetric and textural analysis of pretreatment 18F-fluorodeoxyglucose PET/computerized tomography images in predicting complete response to transarterial radioembolization in hepatocellular cancer. Nucl Med Commun 2022. [PMID: 35506284 DOI: 10.1097/MNM.0000000000001572] [Reference Citation Analysis]
69 Gaia S, Ciruolo M, Ribaldone DG, Rolle E, Migliore E, Mosso E, Vola S, Risso A, Fagoonee S, Saracco GM, Carucci P. Higher Efficiency of Percutaneous Microwave (MWA) Than Radiofrequency Ablation (RFA) in Achieving Complete Response in Cirrhotic Patients with Early Hepatocellular Carcinoma. Curr Oncol 2021;28:1034-44. [PMID: 33669107 DOI: 10.3390/curroncol28020101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
70 Vallati GE, Trobiani C, Teodoli L, Lai Q, Cappelli F, Ungania S, Catalano C, Lucatelli P. Sarcopenia Worsening One Month after Transarterial Radioembolization Predicts Progressive Disease in Patients with Advanced Hepatocellular Carcinoma. Biology (Basel) 2021;10:728. [PMID: 34439960 DOI: 10.3390/biology10080728] [Reference Citation Analysis]
71 Lewin M, Fartoux L, Vignaud A, Arrivé L, Menu Y, Rosmorduc O. The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. Eur Radiol. 2011;21:281-290. [PMID: 20683597 DOI: 10.1007/s00330-010-1914-4] [Cited by in Crossref: 97] [Cited by in F6Publishing: 96] [Article Influence: 8.1] [Reference Citation Analysis]
72 Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis. BMJ Open 2022;12:e052294. [DOI: 10.1136/bmjopen-2021-052294] [Reference Citation Analysis]
73 Murakami E, Aikata H, Miyaki D, Nagaoki Y, Hashimoto Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K. Comparison of Sorafenib response evaluation with RECIST, mRECIST and RECICL for hepatocellular carcinoma. Kanzo 2011;52:322-4. [DOI: 10.2957/kanzo.52.322] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
74 Li JL, Ye WT, Yan LF, Liu ZY, Cao XM, Liang CH. Influence of tube voltage, tube current and newer iterative reconstruction algorithms in CT perfusion imaging in rabbit liver VX2 tumors. Diagn Interv Radiol 2020;26:264-70. [PMID: 32490833 DOI: 10.5152/dir.2019.19147] [Reference Citation Analysis]
75 Basile A, Carrafiello G, Ierardi AM, Tsetis D, Brountzos E. Quality-Improvement Guidelines for Hepatic Transarterial Chemoembolization. Cardiovasc Intervent Radiol 2012;35:765-74. [DOI: 10.1007/s00270-012-0423-z] [Reference Citation Analysis]
76 Wu Y, Qi H, Cao F, Shen L, Chen S, Xie L, Huang T, Song Z, Zhou D, Fan W. TACE-Sorafenib With Thermal Ablation Has Survival Benefits in Patients With Huge Unresectable Hepatocellular Carcinoma. Front Pharmacol 2020;11:1130. [PMID: 32903854 DOI: 10.3389/fphar.2020.01130] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Pinter M, Sieghart W. Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? Memo 2018;11:185-92. [PMID: 30220924 DOI: 10.1007/s12254-018-0431-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Chen EY, Raghunathan V, Prasad V. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. JAMA Intern Med 2019;179:915-21. [PMID: 31135822 DOI: 10.1001/jamainternmed.2019.0583] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 20.5] [Reference Citation Analysis]
79 Shim JH, Lee HC, Won HJ, Shin YM, Kim KM, Lim YS, Suh DJ. Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol. 2012;56:406-411. [PMID: 21782761 DOI: 10.1016/j.jhep.2011.04.028] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
80 Koeberle D, Dufour JF, Demeter G, Li Q, Ribi K, Samaras P, Saletti P, Roth AD, Horber D, Buehlmann M, Wagner AD, Montemurro M, Lakatos G, Feilchenfeldt J, Peck-Radosavljevic M, Rauch D, Tschanz B, Bodoky G;  Swiss Group for Clinical Cancer Research (SAKK). Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol. 2016;27:856-861. [PMID: 26884590 DOI: 10.1093/annonc/mdw054] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 10.2] [Reference Citation Analysis]
81 Schoenberg MB, Anger HJW, Bucher JN, Denk G, De Toni EN, Seidensticker M, Andrassy J, Angele MK, Werner J, Guba MO. Liver Transplantation for Extended Criteria Hepatocellular Carcinoma Using Stable Response to Locoregional Therapy and Alpha-Fetoprotein as Selection Criteria. Visc Med 2020;36:506-15. [PMID: 33447607 DOI: 10.1159/000506752] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL. Z Gastroenterol 2022;60:81-107. [PMID: 35042249 DOI: 10.1055/a-1589-7520] [Reference Citation Analysis]
83 Zhang ZH, Zhang W, Gu JY, Liu QX, Ma JQ, Liu LX, Wang JH, Luo JJ, Yan ZP. Treatment of Hepatocellular Carcinoma with Tumor Thrombus with the Use of Iodine-125 Seed Strand Implantation and Transarterial Chemoembolization: A Propensity-Score Analysis. J Vasc Interv Radiol. 2018;29:1085-1093. [PMID: 29754851 DOI: 10.1016/j.jvir.2018.02.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
84 Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, Park SY, Yang JM. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. J Gastroenterol. 2015;50:445-454. [PMID: 25027973 DOI: 10.1007/s00535-014-0978-3] [Cited by in Crossref: 81] [Cited by in F6Publishing: 76] [Article Influence: 10.1] [Reference Citation Analysis]
85 Trevisani F, Brandi G, Garuti F, Barbera MA, Tortora R, Casadei Gardini A, Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F, Sacco R, Di Costanzo GG. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol 2018;144:403-14. [PMID: 29249005 DOI: 10.1007/s00432-017-2556-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
86 Chao J, Zhu Q, Chen D, An X, Liu A, Zhou F, Yuan L, Wang Z, Sun H. Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection. Front Oncol 2021;11:667555. [PMID: 33869071 DOI: 10.3389/fonc.2021.667555] [Reference Citation Analysis]
87 Darnell A, Belmonte E, Reig M, Brú C. Evaluating the response to locoregional and systemic treatment for hepatocellular carcinoma. Radiologia (Engl Ed) 2018;60:424-36. [PMID: 30196841 DOI: 10.1016/j.rx.2018.05.004] [Reference Citation Analysis]
88 Song MJ. Bae SH, Lee SW, Song DS, Kim HY, Yoo IeR, Choi JI, Lee YJ, Chun HJ, Lee HG, Choi JY, Yoon SK. 18F-fluorodeoxyglucose PET/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:865-873. [PMID: 23436073 DOI: 10.1007/s00259-013-2366-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
89 Yang B, Jie L, Yang T, Chen M, Gao Y, Zhang T, Zhang Y, Wu H, Liao Z. TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study. Front Oncol 2021;11:821599. [PMID: 35004336 DOI: 10.3389/fonc.2021.821599] [Reference Citation Analysis]
90 Xu W, Liu K, Chen M, Sun JY, McCaughan GW, Lu XJ, Ji J. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives.Ther Adv Med Oncol. 2019;11:1758835919862692. [PMID: 31384311 DOI: 10.1177/1758835919862692] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
91 Azuma S, Uojima H, Chuma M, Shao X, Hidaka H, Nakazawa T, Kondo M, Numata K, Iwabuchi S, Kako M, Maeda S, Koizumi W, Atsuda K. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib. Sci Rep 2020;10:17054. [PMID: 33051476 DOI: 10.1038/s41598-020-73930-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
92 Kondo M, Morimoto M, Ishii T, Nozaki A, Fukuda H, Numata K, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Shibuya A, Okuse C, Suzuki M, Sakamaki K, Morita S, Maeda S, Tanaka K. Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting. J Dig Dis 2015;16:143-51. [PMID: 25495751 DOI: 10.1111/1751-2980.12221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
93 Sato Y, Nishiofuku H, Yasumoto T, Nakatsuka A, Matsuo K, Kodama Y, Okubo H, Abo D, Takaki H, Inaba Y, Yamakado K. Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study. J Vasc Interv Radiol 2018;29:1061-7. [PMID: 29934260 DOI: 10.1016/j.jvir.2018.03.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
94 Baleato-gonzález S, García-figueiras R. Criterios específicos de respuesta tumoral. Radiología 2018;60:64-81. [DOI: 10.1016/j.rx.2018.01.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
95 Edhemovic I, Brecelj E, Gasljevic G, Marolt Music M, Gorjup V, Mali B, Jarm T, Kos B, Pavliha D, Grcar Kuzmanov B, Cemazar M, Snoj M, Miklavcic D, Gadzijev EM, Sersa G. Intraoperative electrochemotherapy of colorectal liver metastases. J Surg Oncol. 2014;110:320-327. [PMID: 24782355 DOI: 10.1002/jso.23625] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 11.6] [Reference Citation Analysis]
96 Lee IJ, Lee JH, Lee YB, Kim YJ, Yoon JH, Yin YH, Lee M, Hur S, Kim HC, Jae HJ, Chung JW. Effectiveness of drug-eluting bead transarterial chemoembolization versus conventional transarterial chemoembolization for small hepatocellular carcinoma in Child-Pugh class A patients. Ther Adv Med Oncol 2019;11:1758835919866072. [PMID: 31447948 DOI: 10.1177/1758835919866072] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
97 Shen PC, Chang WC, Lo CH, Yang JF, Lee MS, Dai YH, Lin CS, Fan CY, Huang WY. Comparison of Stereotactic Body Radiation Therapy and Transarterial Chemoembolization for Unresectable Medium-Sized Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2019;105:307-18. [PMID: 31175903 DOI: 10.1016/j.ijrobp.2019.05.066] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
98 Abdelmaksoud MH, Louie JD, Hwang GL, Kothary N, Minor DR, Sze DY. Yttrium-90 radioembolization of renal cell carcinoma metastatic to the liver. J Vasc Interv Radiol. 2012;23:323-330.e1. [PMID: 22277275 DOI: 10.1016/j.jvir.2011.11.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
99 Gordic S, Corcuera-Solano I, Stueck A, Besa C, Argiriadi P, Guniganti P, King M, Kihira S, Babb J, Thung S, Taouli B. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology. J Hepatol. 2017;67:1213-1221. [PMID: 28823713 DOI: 10.1016/j.jhep.2017.07.030] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
100 Djokic M, Cemazar M, Bosnjak M, Dezman R, Badovinac D, Miklavcic D, Kos B, Stabuc M, Stabuc B, Jansa R, Popovic P, Smid LM, Sersa G, Trotovsek B. A Prospective Phase II Study Evaluating Intraoperative Electrochemotherapy of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3778. [PMID: 33333941 DOI: 10.3390/cancers12123778] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
101 Schicho A, Pereira PL, Michalik K, Beyer LP, Stroszczynski C, Wiggermann P. Safety and efficacy of transarterial chemoembolization with degradable starch microspheres (DSM-TACE) in the treatment of secondary liver malignancies. Onco Targets Ther 2018;11:345-50. [PMID: 29391811 DOI: 10.2147/OTT.S147852] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
102 Jung J, Kong M, Hong SE. Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis. Onco Targets Ther 2014;7:1769-75. [PMID: 25328410 DOI: 10.2147/OTT.S69618] [Reference Citation Analysis]
103 Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M;  KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940-952. [PMID: 29875066 DOI: 10.1016/s1470-2045(18)30351-6] [Cited by in Crossref: 742] [Cited by in F6Publishing: 527] [Article Influence: 185.5] [Reference Citation Analysis]
104 Morris PD, Laurence JM, Yeo D, Crawford M, Strasser SI, Mccaughan GW, Sandroussi C. Can response to locoregional therapy help predict longterm survival after liver transplantation for hepatocellular carcinoma? A systematic review: MORRIS et al. Liver Transpl 2017;23:375-85. [DOI: 10.1002/lt.24689] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
105 Adhoute X, Pénaranda G, Raoul J, Pietri O, Bronowicki J, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M. Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. European Journal of Gastroenterology & Hepatology 2019;31:1414-23. [DOI: 10.1097/meg.0000000000001420] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
106 Di Costanzo GG, de Stefano G, Tortora R, Farella N, Addario L, Lampasi F, Lanza AG, Cordone G, Imparato M, Caporaso N. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncology 2015;11:943-51. [DOI: 10.2217/fon.14.291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
107 Matsui Y, Fujiwara H, Hiraki T, Iguchi T, Komaki T, Tanaka T, Yagi T, Gobara H, Kanazawa S. Histological findings in non-tumoral liver and tumor after chemoembolization with drug-eluting beads. Minim Invasive Ther Allied Technol 2020;29:217-23. [PMID: 31187680 DOI: 10.1080/13645706.2019.1626250] [Reference Citation Analysis]
108 Silva MF, Sherman M. Criteria for liver transplantation for HCC: what should the limits be? J Hepatol 2011;55:1137-47. [PMID: 21718672 DOI: 10.1016/j.jhep.2011.05.012] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
109 De Souza A, Daly KP, Yoo J, Saif MW. Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer. Case Rep Oncol Med 2015;2015:461823. [PMID: 25866690 DOI: 10.1155/2015/461823] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
110 Kim DH, Cho E, Cho SB, Choi SK, Kim S, Yu J, Koh YI, Sim DW, Jun CH. Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review. Medicine (Baltimore) 2018;97:e12866. [PMID: 30334999 DOI: 10.1097/MD.0000000000012866] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
111 Tang T, Qiu J, Li G, Huang M, Li Y, Li Y, Gu S. Aspartate aminotransferase-to-platelet ratio predicts response to transarterial chemoembolisation and prognosis in hepatocellular carcinoma patients. Clinical Radiology 2018;73:259-65. [DOI: 10.1016/j.crad.2017.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
112 Letzen BS, Malpani R, Miszczuk M, de Ruiter QMB, Petty CW, Rexha I, Nezami N, Laage-Gaupp F, Lin M, Schlachter TR, Chapiro J. Lipiodol as an intra-procedural imaging biomarker for liver tumor response to transarterial chemoembolization: Post-hoc analysis of a prospective clinical trial. Clin Imaging 2021;78:194-200. [PMID: 34022765 DOI: 10.1016/j.clinimag.2021.05.007] [Reference Citation Analysis]
113 Vroomen LGPH, Scheffer HJ, Melenhorst MCAM, de Jong MC, van den Bergh JE, van Kuijk C, van Delft F, Kazemier G, Meijerink MR. MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation. Eur Radiol. 2017;27:2521-2531. [PMID: 27659702 DOI: 10.1007/s00330-016-4581-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.7] [Reference Citation Analysis]
114 Lai Q, Inostroza M, Rico Juri JM, Goffette P, Lerut J. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer. HPB (Oxford) 2015;17:1085-95. [PMID: 26373980 DOI: 10.1111/hpb.12486] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
115 Baek MY, Yoo JJ, Jeong SW, Jang JY, Kim YK, Jeong SO, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Park SY. Clinical outcomes of patients with a single hepatocellular carcinoma less than 5 cm treated with transarterial chemoembolization. Korean J Intern Med 2019;34:1223-32. [PMID: 30360019 DOI: 10.3904/kjim.2018.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
116 Tabone M, Calvo A, Russolillo N, Langella S, Carbonatto P, Lo Tesoriere R, Richetta E, Pellerito R, Ferrero A. Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience. J Gastrointest Oncol 2020;11:84-90. [PMID: 32175109 DOI: 10.21037/jgo.2019.06.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
117 Lee MW, Raman SS, Asvadi NH, Siripongsakun S, Hicks RM, Chen J, Worakitsitisatorn A, McWilliams J, Tong MJ, Finn RS, Agopian VG, Busuttil RW, Lu DSK. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis. Hepatology 2017;65:1979-90. [PMID: 28170115 DOI: 10.1002/hep.29098] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 11.6] [Reference Citation Analysis]
118 Chao Y, Chung YH, Han G, Yoon JH, Yang J, Wang J, Shao GL, Kim BI, Lee TY. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136:1458-1467. [PMID: 25099027 DOI: 10.1002/ijc.29126] [Cited by in Crossref: 69] [Cited by in F6Publishing: 83] [Article Influence: 8.6] [Reference Citation Analysis]
119 Lv WF, Liu KC, Lu D, Zhou CZ, Cheng DL, Xiao JK, Zhang XM, Zhang ZF. Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis. Cancer Manag Res 2018;10:4719-26. [PMID: 30410405 DOI: 10.2147/CMAR.S166527] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
120 Perera S, Kelly D, O'Kane GM. Non-immunotherapy options for the first-line management of hepatocellular carcinoma: exploring the evolving role of sorafenib and lenvatinib in advanced disease. Curr Oncol 2020;27:S165-72. [PMID: 33343210 DOI: 10.3747/co.27.7159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
121 Orlacchio A, Chegai F, Merolla S, Francioso S, Giudice CD, Angelico M, Tisone G, Simonetti G. Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization. World J Hepatol 2015; 7(12): 1694-1700 [PMID: 26140089 DOI: 10.4254/wjh.v7.i12.1694] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
122 Mannina EM, Cardenes HR, Lasley FD, Goodman B, Zook J, Althouse S, Cox JA, Saxena R, Tector J, Maluccio M. Role of Stereotactic Body Radiation Therapy Before Orthotopic Liver Transplantation: Retrospective Evaluation of Pathologic Response and Outcomes. International Journal of Radiation Oncology*Biology*Physics 2017;97:931-8. [DOI: 10.1016/j.ijrobp.2016.12.036] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 4.2] [Reference Citation Analysis]
123 Albrecht KC, Aschenbach R, Diamantis I, Eckardt N, Teichgräber U. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres. J Cancer Res Clin Oncol 2021;147:23-32. [PMID: 32880029 DOI: 10.1007/s00432-020-03370-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Fuentes D, Ahmed K, Lin JS, Abdel-Wahab R, Kaseb AO, Hassan M, Szklaruk J, Morshid A, Hazle JD, Qayyum A, Elsayes KM. Automated Volumetric Assessment of Hepatocellular Carcinoma Response to Sorafenib: A Pilot Study. J Comput Assist Tomogr 2019;43:499-506. [PMID: 31082956 DOI: 10.1097/RCT.0000000000000866] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
125 Abdel-Moety A, Baddour N, Salem P, Rady A, El-Shendidi A. ARID1A expression in hepatocellular carcinoma and relation to tumor recurrence after microwave ablation. Clin Exp Hepatol 2022;8:49-59. [PMID: 35415261 DOI: 10.5114/ceh.2022.114172] [Reference Citation Analysis]
126 Yang H, Seon J, Sung PS, Oh JS, Lee HL, Jang B, Chun HJ, Jang JW, Bae SH, Choi JY, Yoon SK. Dexamethasone Prophylaxis to Alleviate Postembolization Syndrome after Transarterial Chemoembolization for Hepatocellular Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Study. Journal of Vascular and Interventional Radiology 2017;28:1503-1511.e2. [DOI: 10.1016/j.jvir.2017.07.021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
127 Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187-1195. [PMID: 25681552 DOI: 10.1016/j.jhep.2015.02.010] [Cited by in Crossref: 118] [Cited by in F6Publishing: 110] [Article Influence: 16.9] [Reference Citation Analysis]
128 Malagari K, Pomoni M, Moschouris H, Kelekis A, Charokopakis A, Bouma E, Spyridopoulos T, Chatziioannou A, Sotirchos V, Karampelas T. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 μm. Safety and efficacy study. Cardiovasc Intervent Radiol. 2014;37:165-175. [PMID: 24263774 DOI: 10.1007/s00270-013-0777-x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 7.2] [Reference Citation Analysis]
129 Bekki Y, Marti J, Toshima T, Lewis S, Kamath A, Argiriadi P, Simpson W, Facciuto L, Patel RS, Gunasekaran G, Kim E, Schiano TD, Facciuto ME. A comparative study of portal vein embolization versus radiation lobectomy with Yttrium-90 micropheres in preparation for liver resection for initially unresectable hepatocellular carcinoma. Surgery 2021;169:1044-51. [PMID: 33648768 DOI: 10.1016/j.surg.2020.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
130 Núñez KG, Sandow T, Fort D, Patel J, Hibino M, Carmody I, Cohen AJ, Thevenot P. Baseline Alpha-Fetoprotein, Alpha-Fetoprotein-L3, and Des-Gamma-Carboxy Prothrombin Biomarker Status in Bridge to Liver Transplant Outcomes for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4765. [PMID: 34638251 DOI: 10.3390/cancers13194765] [Reference Citation Analysis]
131 Ribeiro de Souza A, Reig M, Bruix J. Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy 2016;17:1923-36. [DOI: 10.1080/14656566.2016.1225722] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
132 Orlacchio A, Chegai F, Del Giudice C, Massaccesi M, Costanzo E, Di Caprera E, Simonetti G. Radiofrequency thermoablation of HCC larger than 3 cm and less than 5 cm proximal to the gallbladder without gallbladder isolation: a single center experience. Biomed Res Int 2014;2014:896527. [PMID: 25247192 DOI: 10.1155/2014/896527] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
133 Rezai P, Pisaneschi MJ, Feng C, Yaghmai V. A radiologist's guide to treatment response criteria in oncologic imaging: functional, molecular, and disease-specific imaging biomarkers. AJR Am J Roentgenol 2013;201:246-56. [PMID: 23883206 DOI: 10.2214/AJR.12.9878] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
134 Colagrande S, Regini F, Taliani GG, Nardi C, Inghilesi AL. Advanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-up. World J Hepatol 2015; 7(8): 1041-1053 [PMID: 26052393 DOI: 10.4254/wjh.v7.i8.1041] [Cited by in Crossref: 25] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
135 Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. World J Hepatol 2020; 12(12): 1349-1357 [PMID: 33442460 DOI: 10.4254/wjh.v12.i12.1349] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
136 Heng-jun G, Yao-jun Z, Min-shan C, Mei-xian C, Jun-ting H, Li X, Lau WY. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma. Liver Int 2014;34:612-20. [DOI: 10.1111/liv.12307] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
137 De Simone P, Crocetti L, Pezzati D, Bargellini I, Ghinolfi D, Carrai P, Leonardi G, Della Pina C, Cioni D, Pollina L. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc. 2014;46:241-244. [PMID: 24507059 DOI: 10.1016/j.transproceed.2013.10.035] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
138 Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012;57:101-107. [PMID: 22414760 DOI: 10.1016/j.jhep.2012.02.016] [Cited by in Crossref: 144] [Cited by in F6Publishing: 143] [Article Influence: 14.4] [Reference Citation Analysis]
139 Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol. 2011;29:3949-3952. [PMID: 21911718 DOI: 10.1200/jco.2011.37.9651] [Cited by in Crossref: 43] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
140 Kim NH, Lee T, Cho YK, Kim BI, Kim HJ. Impact of clinically evident portal hypertension on clinical outcome of patients with hepatocellular carcinoma treated by transarterial chemoembolization: Clinically evident portal hypertension. Journal of Gastroenterology and Hepatology 2018;33:1397-406. [DOI: 10.1111/jgh.14083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
141 Toskich B, Vidal LL, Olson MT, Lewis JT, LeGout JD, Sella DM, Montazeri SA, Devcic Z, Lewis AR, Frey GT, Ritchie CA, Paz-Fumagalli R, Croome KP, Patel TC. Pathologic Response of Hepatocellular Carcinoma Treated with Yttrium-90 Glass Microsphere Radiation Segmentectomy Prior to Liver Transplantation: A Validation Study. J Vasc Interv Radiol 2021;32:518-526.e1. [PMID: 33551304 DOI: 10.1016/j.jvir.2020.12.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
142 Yang T, Chen Q, Kuang L, Fu Z, Wang Y, Chen Y, Yang L, Xu Y. Effectiveness and safety of ultrasound-guided high-intensity focused ultrasound ablation for the treatment of colorectal cancer liver metastases. Int J Hyperthermia 2022;39:829-34. [PMID: 35732289 DOI: 10.1080/02656736.2022.2086712] [Reference Citation Analysis]
143 McCaughan GW, Munn SR. Liver transplantation in Australia and New Zealand. Liver Transpl 2016;22:830-8. [PMID: 27028552 DOI: 10.1002/lt.24446] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
144 Pellegrinelli J, Chevallier O, Manfredi S, Dygai-Cochet I, Tabouret-Viaud C, Nodari G, Ghiringhelli F, Riedinger JM, Popoff R, Vrigneaud JM, Cochet A, Aho S, Latournerie M, Loffroy R. Transarterial Radioembolization of Hepatocellular Carcinoma, Liver-Dominant Hepatic Colorectal Cancer Metastases, and Cholangiocarcinoma Using Yttrium90 Microspheres: Eight-Year Single-Center Real-Life Experience. Diagnostics (Basel) 2021;11:122. [PMID: 33466706 DOI: 10.3390/diagnostics11010122] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Mendiratta-Lala M, Masch W, Shankar PR, Hartman HE, Davenport MS, Schipper MJ, Maurino C, Cuneo KC, Lawrence TS, Owen D. Magnetic Resonance Imaging Evaluation of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy: Long Term Imaging Follow-Up. Int J Radiat Oncol Biol Phys 2019;103:169-79. [PMID: 30213751 DOI: 10.1016/j.ijrobp.2018.09.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
146 Lu M, Yao W, Zhang T, Fan W, Zhong Z, Li J, Zhang F. Feasibility and Efficacy of Microwave Ablation Combined with Iodine-125 Seed Implantation in Local Control of Recurrent Retroperitoneal Liposarcomas: Initial Clinical Experience. Oncologist. 2017;22:1500-1505. [PMID: 28701568 DOI: 10.1634/theoncologist.2016-0499] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
147 Li Z, Hao D, Jiao D, Zhang W, Han X. Transcatheter Arterial Chemoembolization Combined with Simultaneous Cone-beam Computed Tomography-guided Microwave Ablation in the Treatment of Small Hepatocellular Carcinoma: Clinical Experiences From 50 Procedures. Acad Radiol 2021;28 Suppl 1:S64-70. [PMID: 33060007 DOI: 10.1016/j.acra.2020.08.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
148 Zopfs D, Graffe J, Reimer RP, Schäfer S, Persigehl T, Maintz D, Borggrefe J, Haneder S, Lennartz S, Große Hokamp N. Quantitative distribution of iodinated contrast media in body computed tomography: data from a large reference cohort. Eur Radiol 2021;31:2340-8. [PMID: 32997173 DOI: 10.1007/s00330-020-07298-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
149 Tang J, Sui CJ, Wang DF, Lu XY, Luo GJ, Zhao Q, Lian QY, Jeong S, Lin XM, Zhu YJ, Zheng B, Wu R, Wang Q, Liu XL, Liu JF, Xia Q, Wu G, Gu J, Wang HY, Chen L. Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma. Theranostics 2020;10:5384-97. [PMID: 32373219 DOI: 10.7150/thno.41616] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
150 Hu S, Tu J, Jia Z, Huang Y, Jiang G. Transarterial embolization/chemoembolization therapy for hepatocellular carcinoma fed by adrenal artery: Preliminary results. Medicine 2016;95:e5762. [DOI: 10.1097/md.0000000000005762] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
151 Cannella R, Cammà C, Matteini F, Celsa C, Giuffrida P, Enea M, Comelli A, Stefano A, Cammà C, Midiri M, Lagalla R, Brancatelli G, Vernuccio F. Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC. Diagnostics 2022;12:1308. [DOI: 10.3390/diagnostics12061308] [Reference Citation Analysis]
152 Xie Y, Tian H, Xiang H. Is transcatheter arterial chemoembolization plus sorafenib better than chemoembolization plus placebo in the treatment of hepatocellular carcinoma? Tumori 2021;107:292-303. [PMID: 32729385 DOI: 10.1177/0300891620945029] [Reference Citation Analysis]
153 Bargellini I, Scalise P, Boni G, Traino CA, Bozzi E, Lorenzoni G, Crocetti L, Cioni R. Yttrium-90 Radioembolization for Hepatocellular Carcinoma with Portal Vein Invasion: Validation of the Milan Prognostic Score. J Vasc Interv Radiol 2020;31:2028-32. [PMID: 33121865 DOI: 10.1016/j.jvir.2020.06.027] [Reference Citation Analysis]
154 Zhang Y, Huang G, Wang Y, Liang L, Peng B, Fan W, Yang J, Huang Y, Yao W, Li J. Is Salvage Liver Resection Necessary for Initially Unresectable Hepatocellular Carcinoma Patients Downstaged by Transarterial Chemoembolization? Ten Years of Experience. Oncologist 2016;21:1442-9. [PMID: 27486202 DOI: 10.1634/theoncologist.2016-0094] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
155 Bova V, Miraglia R, Maruzzelli L, Vizzini GB, Luca A. Predictive factors of downstaging of hepatocellular carcinoma beyond the Milan criteria treated with intra-arterial therapies. Cardiovasc Intervent Radiol 2013;36:433-9. [PMID: 22864644 DOI: 10.1007/s00270-012-0458-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
156 Ochi M, Kamoshida T, Ohkawara A, Ohkawara H, Kakinoki N, Hirai S, Yanaka A. Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib. World J Gastroenterol 2018; 24(28): 3155-3162 [PMID: 30065561 DOI: 10.3748/wjg.v24.i28.3155] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
157 Zheng SG, Xu HX, Liu LN. Management of hepatocellular carcinoma: The role of contrast-enhanced ultrasound. World J Radiol 2014; 6(1): 7-14 [PMID: 24578787 DOI: 10.4329/wjr.v6.i1.7] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
158 Lee JM, Trevisani F, Vilgrain V, Wald C. Imaging diagnosis and staging of hepatocellular carcinoma. Liver Transpl 2011;17 Suppl 2:S34-43. [PMID: 21739567 DOI: 10.1002/lt.22369] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
159 Cai WL, Hong GB. Quantitative image analysis for evaluation of tumor response in clinical oncology. Chronic Dis Transl Med 2018;4:18-28. [PMID: 29756120 DOI: 10.1016/j.cdtm.2018.01.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
160 Finkelmeier F, Scheiner B, Leyh C, Best J, Fründt TW, Czauderna C, Beutel A, Bettinger D, Weiß J, Meischl T, Kütting F, Waldschmidt DT, Radu P, Schultheiß M, Peiffer KH, Ettrich TJ, Weinmann A, Wege H, Venerito M, Dufour JF, Lange CM, Pinter M, Waidmann O. Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer 2021;10:360-9. [PMID: 34414123 DOI: 10.1159/000515490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
161 Entezari P, Gabr A, Kennedy K, Salem R, Lewandowski RJ. Radiation Lobectomy: An Overview of Concept and Applications, Technical Considerations, Outcomes. Semin Intervent Radiol 2021;38:419-24. [PMID: 34629708 DOI: 10.1055/s-0041-1735530] [Reference Citation Analysis]
162 Xu Y, Yang Y, Li L, Ye F, Zhao X. The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy. Front Oncol 2022;12:905260. [PMID: 35686094 DOI: 10.3389/fonc.2022.905260] [Reference Citation Analysis]
163 Lucatelli P, Ginnani Corradini L, De Rubeis G, Rocco B, Basilico F, Cannavale A, Nardis PG, Corona M, Saba L, Catalano C, Bezzi M. Balloon-Occluded Transcatheter Arterial Chemoembolization (b-TACE) for Hepatocellular Carcinoma Performed with Polyethylene-Glycol Epirubicin-Loaded Drug-Eluting Embolics: Safety and Preliminary Results. Cardiovasc Intervent Radiol 2019;42:853-62. [PMID: 30843093 DOI: 10.1007/s00270-019-02192-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
164 Zou X, Fan W, Xue M, Li J. Evaluation of the Benefits of TACE Combined with Sorafenib for Hepatocellular Carcinoma Based on Untreatable TACE (unTACEable) Progression. Cancer Manag Res 2021;13:4013-29. [PMID: 34040442 DOI: 10.2147/CMAR.S304591] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
165 Jin C, Yang W, Ran L, Zhang J, Zhu H. Feasibility of High-Intensity Focused Ultrasound for Hepatocellular Carcinoma after Stereotactic Body Radiation Therapy: Initial Experience. Ultrasound Med Biol 2020;46:2744-51. [PMID: 32747074 DOI: 10.1016/j.ultrasmedbio.2020.06.013] [Reference Citation Analysis]
166 Vouche M, Habib A, Ward TJ, Kim E, Kulik L, Ganger D, Mulcahy M, Baker T, Abecassis M, Sato KT, Caicedo JC, Fryer J, Hickey R, Hohlastos E, Lewandowski RJ, Salem R. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology 2014;60:192-201. [PMID: 24691943 DOI: 10.1002/hep.27057] [Cited by in Crossref: 171] [Cited by in F6Publishing: 151] [Article Influence: 21.4] [Reference Citation Analysis]
167 Iavarone M, Cabibbo G, Biolato M, Della Corte C, Maida M, Barbara M, Basso M, Vavassori S, Craxì A, Grieco A, Cammà C, Colombo M. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology 2015;62:784-91. [PMID: 25645399 DOI: 10.1002/hep.27729] [Cited by in Crossref: 78] [Cited by in F6Publishing: 78] [Article Influence: 11.1] [Reference Citation Analysis]
168 Chiang CL, Chan ACY, Chiu KWH, Kong FS. Combined Stereotactic Body Radiotherapy and Checkpoint Inhibition in Unresectable Hepatocellular Carcinoma: A Potential Synergistic Treatment Strategy. Front Oncol 2019;9:1157. [PMID: 31799176 DOI: 10.3389/fonc.2019.01157] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
169 Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol. 2013;58:169-177. [PMID: 22944253 DOI: 10.1016/j.jhep.2012.08.022] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
170 Abdelmaksoud AHK, Abdelaziz AO, Nabeel MM, Hamza I, Elbaz TM, Shousha HI, Abdelhady RSM, Lithy R. Hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein thrombosis: a case-control study. Clin Radiol 2021;76:709.e1-6. [PMID: 34116796 DOI: 10.1016/j.crad.2021.03.022] [Reference Citation Analysis]
171 Takeda A, Sanuki N, Eriguchi T, Kobayashi T, Iwabutchi S, Matsunaga K, Mizuno T, Yashiro K, Nisimura S, Kunieda E. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:372-379. [PMID: 23927053 DOI: 10.1111/jgh.12350] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
172 Choi WM, Choi J, Lee D, Shim JH, Lim YS, Lee HC, Chung YH, Lee YS, Park SR, Ryu MH, Ryoo BY, Lee SJ, Kim KM. Regorafenib Versus Nivolumab After Sorafenib Failure: Real-World Data in Patients With Hepatocellular Carcinoma. Hepatol Commun. 2020;4:1073-1086. [PMID: 32626838 DOI: 10.1002/hep4.1523] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
173 Shah RM, Sheikh S, Shah J, Vivian E, Mejia A, Shahin I, Mantry PS. Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center. J Gastrointest Oncol 2021;12:1718-31. [PMID: 34532122 DOI: 10.21037/jgo-20-435] [Reference Citation Analysis]
174 Sho T, Suda G, Ogawa K, Kimura M, Shimazaki T, Maehara O, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Kobayashi T, Meguro T, Saga A, Miyagishima T, Yokoo H, Kamiyama T, Taketomi A, Sakamoto N. Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. JGH Open. 2020;4:54-60. [PMID: 32055698 DOI: 10.1002/jgh3.12209] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 7.7] [Reference Citation Analysis]
175 Bruno S, Di Marco V, Iavarone M, Roffi L, Boccaccio V, Crosignani A, Cabibbo G, Rossi S, Calvaruso V, Aghemo A, Giacomelli L, Craxì A, Colombo M, Maisonneuve P. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response. Liver Int 2017;37:1526-34. [DOI: 10.1111/liv.13452] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
176 Zhang Y, Jiang L, Wen J, Liu D, Huang G, Wang Y, Fan W, Li J. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology 2018;29:1654-61. [DOI: 10.1016/j.jvir.2018.07.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
177 Hyun D, Cho SK, Shin SW, Park KB, Park HS, Choo SW, Do YS. Selective Versus Non-selective Transarterial Chemoembolization via the Intercostal Artery for the Treatment of Hepatocellular Carcinoma. Cardiovasc Intervent Radiol 2020;43:587-96. [PMID: 31912214 DOI: 10.1007/s00270-019-02405-4] [Reference Citation Analysis]
178 Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol 2013; 19(43): 7515-7530 [PMID: 24282343 DOI: 10.3748/wjg.v19.i43.7515] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 66] [Article Influence: 8.4] [Reference Citation Analysis]
179 Kim TH, Park JW, Kim BH, Kim DY, Moon SH, Kim SS, Lee JH, Woo SM, Koh YH, Lee WJ, Kim CM. Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget. 2017;9:4034-4043. [PMID: 29423102 DOI: 10.18632/oncotarget.23428] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.4] [Reference Citation Analysis]
180 Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, Vitale A. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016; 22(1): 232-252 [PMID: 26755873 DOI: 10.3748/wjg.v22.i1.232] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
181 Bakopoulos A, Koliakos N, Tsilimigras DI, Schizas D, Moris D, Angelopoulos A, Spanakos S, Spartalis E, Patapis P, Skandalakis P, Troupis T. Management of ruptured liver segment IV hepatocellular carcinoma: is transarterial embolization (TAE) superior to chemoembolization (TACE)?-the jury is still out. Ann Transl Med 2018;6:272. [PMID: 30094258 DOI: 10.21037/atm.2018.06.01] [Reference Citation Analysis]
182 Hernandez-Villafuerte K, Fischer A, Latimer N. CHALLENGES AND METHODOLOGIES IN USING PROGRESSION FREE SURVIVAL AS A SURROGATE FOR OVERALL SURVIVAL IN ONCOLOGY. Int J Technol Assess Health Care 2018;34:300-16. [PMID: 29987997 DOI: 10.1017/S0266462318000338] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
183 Wang Z, Zhang H, Zhao H, Wang X, Tsauo J, Luo X, Li X. Repeated transcatheter arterial chemoembolization is safe for hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Diagn Interv Radiol. 2014;20:487-491. [PMID: 25297389 DOI: 10.5152/dir.2014.13493] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
184 Ma X, Yang PZ, Jiang PS, Huo PB, Cao Q, Chai PS, Wang PH. Effectiveness and safety of a robot-assisted 3D personalized template in 125I seed brachytherapy of thoracoabdominal tumors. J Contemp Brachytherapy 2018;10:368-79. [PMID: 30237820 DOI: 10.5114/jcb.2018.77957] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
185 Kulik L. Is radioembolization ready for the barcelona clinic liver cancer staging system? Hepatology 2010;52:1528-30. [PMID: 21038408 DOI: 10.1002/hep.24030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
186 Ponti A, Denys A, Digklia A, Schaefer N, Hocquelet A, Knebel J, Michielin O, Dromain C, Duran R. First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver. J Nucl Med 2020;61:350-6. [DOI: 10.2967/jnumed.119.230870] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
187 Yim SY, Chun HS, Lee JS, Lim J, Kim TH, Kim BK, Kim SU, Park JY, Ahn SH, Kim GM, Won JY, Seo YS, Kim YH, Um SH, Kim DY. Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients. Cancers 2022;14:385. [DOI: 10.3390/cancers14020385] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
188 Delumeau S, Lebigot J, Ridereau-zins C, Bouvier A, Boursier J, Aubé C. Aspects et évaluation post-thérapeutiques des lésions du foie après traitement non chirurgical. Journal de Radiologie 2011;92:632-58. [DOI: 10.1016/j.jradio.2011.04.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
189 Xia D, Wang Q, Bai W, Wang E, Wang Z, Mu W, Sun J, Huang M, Yin G, Li H, Zhao H, Zhang C, Li J, Wu J, Zhu X, Yang S, Pan X, Li J, Li Z, Xu G, Shi H, Zhang H, Zhang Y, Ding R, Yu H, Zheng L, Yang X, Wang G, You N, Feng L, Zhang S, Huang W, Xu T, Fan W, Li X, Yang X, Zhou W, Wang W, Li X, Wang Z, Luo B, Niu J, Yuan J, Lv Y, Li K, Guo W, Yin Z, Fan D, Xia J, Han G; China HCC-TACE Study Group. Optimal time point of response assessment for predicting survival is associated with tumor burden in hepatocellular carcinoma receiving repeated transarterial chemoembolization. Eur Radiol 2022. [PMID: 35381853 DOI: 10.1007/s00330-022-08716-4] [Reference Citation Analysis]
190 Chapiro J, Duran R, Lin M, Schernthaner RE, Wang Z, Gorodetski B, Geschwind JF. Identifying Staging Markers for Hepatocellular Carcinoma before Transarterial Chemoembolization: Comparison of Three-dimensional Quantitative versus Non-three-dimensional Imaging Markers. Radiology 2015;275:438-47. [PMID: 25531387 DOI: 10.1148/radiol.14141180] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
191 Shiozawa K, Watanabe M, Ikehara T, Kogame M, Kikuchi Y, Igarashi Y, Sumino Y. Therapeutic evaluation of sorafenib for hepatocellular carcinoma using contrast-enhanced ultrasonography: Preliminary result. Oncol Lett. 2016;12:579-584. [PMID: 27347183 DOI: 10.3892/ol.2016.4669] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
192 Nada Y, Rashad N, Eissa M, Ghonaim A, Farag K, Saadawi I, Sheha A, El Gewaity M, Abdel-Rahman O. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. Expert Rev Gastroenterol Hepatol 2018;12:99-107. [PMID: 29124987 DOI: 10.1080/17474124.2018.1403898] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
193 Morisco F, Camera S, Guarino M, Tortora R, Cossiga V, Vitiello A, Cordone G, Caporaso N, Di Costanzo GG; Italian Liver Cancer (ITA.LI.CA) group. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case-control study. Oncotarget 2018;9:17483-90. [PMID: 29707122 DOI: 10.18632/oncotarget.24756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
194 Kang JW, Kim JH, Ko GY, Gwon DI, Yoon HK, Sung KB. Transarterial chemoembolization for hepatocellular carcinoma after transjugular intrahepatic portosystemic shunt. Acta Radiol 2012;53:545-50. [PMID: 22547388 DOI: 10.1258/ar.2012.110476] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
195 Martin-Liberal J, Hierro C, Ochoa de Olza M, Rodon J. Immuno-Oncology: The Third Paradigm in Early Drug Development. Target Oncol 2017;12:125-38. [PMID: 27995439 DOI: 10.1007/s11523-016-0471-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
196 Baimas-George M, Watson M, Sulzer J, Salibi P, Murphy KJ, Levi D, Martinie JB, Vrochides D, Baker EH, Ocuin L, Iannitti DA. Pathologic response translates to improved patient survival after locoregional treatment for hepatocellular carcinoma: the importance of minimally invasive microwave ablation. Surg Endosc 2021;35:3122-30. [PMID: 32588344 DOI: 10.1007/s00464-020-07747-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
197 Guo W, Chen S, Wu Z, Zhuang W, Yang J. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study. Technol Cancer Res Treat 2020;19:1533033820965587. [PMID: 33089769 DOI: 10.1177/1533033820965587] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
198 Catalano O. Cancer Measurement at Ultrasound: State of the Art. Ultrasound Q 2017;33:116-24. [PMID: 27984513 DOI: 10.1097/RUQ.0000000000000266] [Reference Citation Analysis]
199 Mohr I, Vogeler M, Pfeiffenberger J, Sprengel SD, Klauss M, Radeleff B, Teufel A, Chang D, Springfeld C, Longerich T, Merle U, Mehrabi A, Weiss KH, Mieth M. Clinical effects and safety of different transarterial chemoembolization methods for bridging and palliative treatments in hepatocellular carcinoma. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-021-03900-3] [Reference Citation Analysis]
200 Seol SW, Yu JI, Park HC, Lim DH, Oh D, Noh JM, Cho WK, Paik SW. Treatment outcome of hepatic re-irradiation in patients with hepatocellular carcinoma. Radiat Oncol J. 2015;33:276-283. [PMID: 26756027 DOI: 10.3857/roj.2015.33.4.276] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
201 Li S, Wang Q, Mei J, Wang J, Zhong XP, Ling Y, Guo Z, Lu LH, Wei W, Guo R. Risk factors of extra-hepatic progression after transarterial chemoembolization for hepatocellular carcinoma patients: a retrospective study in 654 cases. J Cancer 2019;10:5007-14. [PMID: 31598173 DOI: 10.7150/jca.35355] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
202 Zhang T, Zhao YT, Wang Z, Li CR, Jin J, Jia AY, Wang SL, Song YW, Liu YP, Ren H, Fang H, Bao H, Liu XF, Yu ZH, Li YX, Wang WH. Efficacy and Safety of Intensity-Modulated Radiotherapy Following Transarterial Chemoembolization in Patients With Unresectable Hepatocellular Carcinoma. Medicine (Baltimore) 2016;95:e3789. [PMID: 27227954 DOI: 10.1097/MD.0000000000003789] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
203 Ebbers SC, Braat AJAT, Moelker A, Stokkel MPM, Lam MGEH, Barentsz MW. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial). Trials 2020;21:141. [PMID: 32024533 DOI: 10.1186/s13063-019-3888-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
204 Kang TW, Lim HK, Lee MW, Kim YS, Rhim H, Lee WJ, Gwak GY, Paik YH, Lim HY, Kim MJ. Aggressive Intrasegmental Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation: Risk Factors and Clinical Significance. Radiology. 2015;276:274-285. [PMID: 25734550 DOI: 10.1148/radiol.15141215] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 8.6] [Reference Citation Analysis]
205 Zuo TY, Liu FY, Wang MQ, Chen XX. Transcatheter Arterial Chemoembolization Combined with Simultaneous Computed Tomography-guided Radiofrequency Ablation for Large Hepatocellular Carcinomas. Chin Med J (Engl) 2017;130:2666-73. [PMID: 29133753 DOI: 10.4103/0366-6999.218002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
206 Zhu LZ, Xu S, Qian HL. Transarterial embolization and low-dose continuous hepatic arterial infusion chemotherapy with oxaliplatin and raltitrexed for hepatocellular carcinoma with major portal vein tumor thrombus. World J Gastroenterol 2018; 24(23): 2501-2507 [PMID: 29930471 DOI: 10.3748/wjg.v24.i23.2501] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
207 Richter G, Radeleff B, Stroszczynski C, Pereira P, Helmberger T, Barakat M, Huppert P. Safety and Feasibility of Chemoembolization with Doxorubicin-Loaded Small Calibrated Microspheres in Patients with Hepatocellular Carcinoma: Results of the MIRACLE I Prospective Multicenter Study. Cardiovasc Intervent Radiol 2018;41:587-93. [PMID: 29167967 DOI: 10.1007/s00270-017-1839-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
208 Giorgio A, Gatti P, Montesarchio L, Merola MG, Amendola F, Calvanese A, Iaquinto G, Fontana M, Ciracì E, Semeraro S, Santoro B, Coppola C, Matteucci P, Giorgio V. Microwave Ablation in Intermediate Hepatocellular Carcinoma in Cirrhosis: An Italian Multicenter Prospective Study. J Clin Transl Hepatol 2018;6:251-7. [PMID: 30271736 DOI: 10.14218/JCTH.2018.00013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
209 Nagamatsu H, Sumie S, Niizeki T, Tajiri N, Iwamoto H, Aino H, Nakano M, Shimose S, Satani M, Okamura S. Hepatic arterial infusion chemoembolization therapy for advanced hepatocellular carcinoma: multicenter phase II study. Cancer Chemother Pharmacol. 2016;77:243-250. [PMID: 26754678 DOI: 10.1007/s00280-015-2892-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
210 Roccarina D, Garcovich M, Ainora ME, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World J Hepatol 2015; 7(14): 1866-1874 [PMID: 26207168 DOI: 10.4254/wjh.v7.i14.1866] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
211 Diaz-padilla I, Siu LL. Brivanib alaninate for cancer. Expert Opinion on Investigational Drugs 2011;20:577-86. [DOI: 10.1517/13543784.2011.565329] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
212 Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Koh YH, Lee WJ, Park SJ, Kim JY, Kim DY, Kim CM. Phase I dose-escalation study of proton beam therapy for inoperable hepatocellular carcinoma. Cancer Res Treat. 2015;47:34-45. [PMID: 25381830 DOI: 10.4143/crt.2013.218] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 4.4] [Reference Citation Analysis]
213 Boige V, Malka D, Bourredjem A, Dromain C, Baey C, Jacques N, Pignon JP, Vimond N, Bouvet-Forteau N, De Baere T, Ducreux M, Farace F. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012;17:1063-1072. [PMID: 22707516 DOI: 10.1634/theoncologist.2011-0465] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
214 Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E;  ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238-iv255. [PMID: 30285213 DOI: 10.1093/annonc/mdy308] [Cited by in Crossref: 230] [Cited by in F6Publishing: 204] [Article Influence: 76.7] [Reference Citation Analysis]
215 Cheng AL, Amarapurkar D, Chao Y, Chen P, Geschwind J, Goh KL, Han K, Kudo M, Lee HC, Lee R, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan C, Tanwandee T, Teng G, Park J. Re-evaluating transarterial chemoembolization for the treatment of Hepatocellular Carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int 2014;34:174-83. [DOI: 10.1111/liv.12314] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 4.2] [Reference Citation Analysis]
216 Lin W, Zhu C, Yao J, Liu Y, Lin H, Liu Y. Multifactorial Analysis of Clinical Prognosis of Liver Metastasis and Vascular Intervention Combined with Ablation in Colorectal Cancer. J Oncol 2022;2022:9690401. [PMID: 35726221 DOI: 10.1155/2022/9690401] [Reference Citation Analysis]
217 Zhang Y, Fan W, Wang Y, Huang G, Li J. Apatinib for Patients With Sorafenib-Refractory Advanced Hepatitis B Virus Related Hepatocellular Carcinoma: Results of a Pilot Study. Cancer Control. 2019;26:1073274819872216. [PMID: 31466465 DOI: 10.1177/1073274819872216] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
218 Park BV, Gaba RC, Huang YH, Chen YF, Guzman G, Lokken RP. Histology of Hepatocellular Carcinoma: Association with Clinical Features, Radiological Findings, and Locoregional Therapy Outcomes. J Clin Imaging Sci 2019;9:52. [PMID: 31819829 DOI: 10.25259/JCIS_111_2019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, White S, Rilling W, Gamblin TC. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. HPB (Oxford). 2017;19:659-666. [PMID: 28552299 DOI: 10.1016/j.hpb.2017.04.016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
220 Mendiratta-Lala M, Aslam A, Maturen KE, Westerhoff M, Sun Y, Maurino C, Parikh ND, Sonnenday CJ, Stein EB, Shampain KL, Kaza RK, Cuneo K, Masch W, Do RKG, Lawrence TS, Owen D. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy with Radiologic-Pathologic Explant Correlation in patients with SBRT treated hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02902-3. [PMID: 34644607 DOI: 10.1016/j.ijrobp.2021.10.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
221 Choi WM, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Yoo C, Park SR, Ryu MH, Ryoo BY, Choi J. Effectiveness and Safety of Nivolumab in Child-Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. Cancers (Basel) 2020;12:E1968. [PMID: 32698355 DOI: 10.3390/cancers12071968] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
222 Brown KT. Does Neutrophil/Leukocyte Ratio Predict Distant Metastases or Only Local Progression? J Vasc Interv Radiol 2020;31:867. [PMID: 32229079 DOI: 10.1016/j.jvir.2020.01.014] [Reference Citation Analysis]
223 Ochi H, Hiraoka A, Hirooka M, Koizumi Y, Amano M, Azemoto N, Watanabe T, Yoshida O, Tokumoto Y, Mashiba T, Yokota T, Abe M, Michitaka K, Hiasa Y, Joko K. Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria. J Gastroenterol 2021;56:90-100. [PMID: 33278003 DOI: 10.1007/s00535-020-01747-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
224 Swinburne NC, Biederman DM, Besa C, Tabori NE, Fischman AM, Patel RS, Nowakowski FS, Gunasekaran G, Schwartz ME, Lookstein RA, Kim E. Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: Review of Safety, Response Evaluation Criteria in Solid Tumors 1.1 Imaging Response and Survival. Cancer Biotherapy and Radiopharmaceuticals 2017;32:161-8. [DOI: 10.1089/cbr.2017.2189] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
225 Liu F, Chen M, Mei J, Xu L, Guo R, Lin X, Zhang Y, Peng Z. Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. J Oncol 2019;2019:6298502. [PMID: 31636667 DOI: 10.1155/2019/6298502] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
226 Padia SA, Johnson GE, Agopian VG, DiNorcia J, Srinivasa RN, Sayre J, Shin DS. Yttrium-90 radiation segmentectomy for hepatic metastases: A multi-institutional study of safety and efficacy. J Surg Oncol 2021;123:172-8. [PMID: 32944980 DOI: 10.1002/jso.26223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
227 Kelley RK, Gane E, Assenat E, Siebler J, Galle PR, Merle P, Hourmand IO, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Faivre S, Benhadji KA, Giannelli G. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma. Clin Transl Gastroenterol 2019;10:e00056. [PMID: 31295152 DOI: 10.14309/ctg.0000000000000056] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 29.5] [Reference Citation Analysis]
228 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 66.0] [Reference Citation Analysis]
229 Kibe Y, Takeda A, Tsurugai Y, Eriguchi T. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies. Acta Oncol 2020;59:888-94. [PMID: 32216593 DOI: 10.1080/0284186X.2020.1741679] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
230 Sho T, Suda G, Ogawa K, Kimura M, Kubo A, Tokuchi Y, Kitagataya T, Maehara O, Ohnishi S, Shigesawa T, Nakamura A, Yamada R, Ohara M, Kawagishi N, Natsuizaka M, Nakai M, Morikawa K, Furuya K, Baba M, Yamamoto Y, Suzuki K, Izumi T, Meguro T, Terashita K, Ito J, Miyagishima T, Sakamoto N. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Hepatol Res 2021;51:979-89. [PMID: 34245216 DOI: 10.1111/hepr.13693] [Reference Citation Analysis]
231 O'Rourke JM, Shetty S, Shah T, Perera MTPR. Liver transplantation for hepatocellular carcinoma: pushing the boundaries. Transl Gastroenterol Hepatol 2019;4:1. [PMID: 30854488 DOI: 10.21037/tgh.2018.12.07] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
232 Wörns MA, Galle PR. Sorafenib for the treatment of hepatocellular carcinoma. Hepat Oncol 2014;1:189-204. [PMID: 30190954 DOI: 10.2217/hep.13.20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
233 Zhu K, Chen J, Lai L, Meng X, Zhou B, Huang W, Cai M, Shan H. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study. Radiology. 2014;272:284-293. [PMID: 24708192 DOI: 10.1148/radiol.14131946] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 9.4] [Reference Citation Analysis]
234 Somma F, D'Angelo R, Serra N, Gatta G, Grassi R, Fiore F. Use of Ethanol in the Trans-Arterial Lipiodol Embolization (TAELE) of Intermediated-Stage HCC: Is This Safer than Conventional Trans-Arterial Chemo-Embolization (c-TACE)? PLoS One 2015;10:e0129573. [PMID: 26110810 DOI: 10.1371/journal.pone.0129573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
235 Abdelaziz AO, Nabil MM, Abdelmaksoud AH, Shousha HI, Cordie AA, Hassan EM, Omran DA, Leithy R, Elbaz TM. De-novo versus recurrent hepatocellular carcinoma following direct-acting antiviral therapy for hepatitis C virus. Eur J Gastroenterol Hepatol. 2018;30:39-43. [PMID: 29064851 DOI: 10.1097/meg.0000000000001004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
236 Gummadi S, Stanczak M, Lyshchik A, Forsberg F, Shaw CM, Eisenbrey JR. Contrast-enhanced ultrasound identifies early extrahepatic collateral contributing to residual hepatocellular tumor viability after transarterial chemoembolization. Radiol Case Rep 2018;13:713-8. [PMID: 29721125 DOI: 10.1016/j.radcr.2018.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
237 Hosein PJ, Echenique A, Loaiza-Bonilla A, Froud T, Barbery K, Rocha Lima CM, Yrizarry JM, Narayanan G. Percutaneous irreversible electroporation for the treatment of colorectal cancer liver metastases with a proposal for a new response evaluation system. J Vasc Interv Radiol. 2014;25:1233-1239.e2. [PMID: 24861662 DOI: 10.1016/j.jvir.2014.04.007] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
238 Silk T, Silk M, Wu J. Up to seven criteria in selection of systemic therapy for hepatocellular carcinoma. World J Gastroenterol 2022; 28(23): 2561-2568 [DOI: 10.3748/wjg.v28.i23.2561] [Reference Citation Analysis]
239 Patchett N, Furlan A, Marsh JW. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib. Jpn J Clin Oncol 2016;46:839-44. [PMID: 27317737 DOI: 10.1093/jjco/hyw078] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
240 Yao XS, Yan D, Jiang XX, Li X, Zeng HY, Li H. Short-term outcomes of radiofrequency ablation for hepatocellular carcinoma using cone-beam computed tomography for planning and image guidance. World J Clin Cases 2021; 9(7): 1580-1591 [PMID: 33728301 DOI: 10.12998/wjcc.v9.i7.1580] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
241 He AR, Goldenberg AS. Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therap Adv Gastroenterol 2013;6:447-58. [PMID: 24179481 DOI: 10.1177/1756283X13498540] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
242 Fan W, Zhu B, Zheng X, Yue S, Lu M, Fan H, Qiao L, Li F, Yuan G, Wu Y, Zou X, Wang H, Xue M, Li J. Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization. J Cancer Res Clin Oncol 2022. [PMID: 35788728 DOI: 10.1007/s00432-022-04107-w] [Reference Citation Analysis]
243 Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology 2010;52:762-73. [PMID: 20564355 DOI: 10.1002/hep.23725] [Cited by in Crossref: 343] [Cited by in F6Publishing: 336] [Article Influence: 28.6] [Reference Citation Analysis]
244 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
245 Scheiner B, Pomej K, Kirstein MM, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fründt TW, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenhüner AR, Mertens JC, Rahbari NN, Kütting F, Waldschmidt DT, Ebert MP, Teufel A, De Dosso S, Pinato DJ, Pressiani T, Meischl T, Balcar L, Müller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour JF, Peck-Radosavljevic M, Vogel A, Pinter M. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol 2021:S0168-8278(21)02100-0. [PMID: 34648895 DOI: 10.1016/j.jhep.2021.09.035] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
246 Cohen NA, Kim TS, DeMatteo RP. Principles of Kinase Inhibitor Therapy for Solid Tumors. Ann Surg 2017;265:311-9. [PMID: 27058947 DOI: 10.1097/SLA.0000000000001740] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
247 Martí-Bonmatí L, Sanz-Requena R, de Gracia BP, Carot-Sierra JM. Magnetic resonance pharmacokinetic imaging clusterization of hepatocellular carcinomas as a means to grade tumor aggressiveness. Expert Rev Gastroenterol Hepatol. 2012;6:711-716. [PMID: 23237256 DOI: 10.1586/egh.12.51] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
248 Raphael MJ, Karanicolas PJ. Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When? J Clin Oncol 2022;:JCO2102505. [PMID: 35649228 DOI: 10.1200/JCO.21.02505] [Reference Citation Analysis]
249 Zhang Y, Zhang MW, Fan XX, Mao DF, Ding QH, Zhuang LH, Lv SY. Drug-eluting beads transarterial chemoembolization sequentially combined with radiofrequency ablation in the treatment of untreated and recurrent hepatocellular carcinoma. World J Gastrointest Surg 2020; 12(8): 355-368 [PMID: 32903981 DOI: 10.4240/wjgs.v12.i8.355] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
250 Bouvier A, Ozenne V, Aubé C, Boursier J, Vullierme MP, Thouveny F, Farges O, Vilgrain V. Transarterial chemoembolisation: effect of selectivity on tolerance, tumour response and survival. Eur Radiol 2011;21:1719-26. [PMID: 21479978 DOI: 10.1007/s00330-011-2118-2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
251 Wörns MA, Galle PR. HCC therapies--lessons learned. Nat Rev Gastroenterol Hepatol 2014;11:447-52. [PMID: 24492278 DOI: 10.1038/nrgastro.2014.10] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 13.1] [Reference Citation Analysis]
252 Hwang S, Song GW, Ahn CS, Kim KH, Moon DB, Ha TY, Jung DH, Park GC, Yoon YI, Lee SG. Quantitative Prognostic Prediction Using ADV Score for Hepatocellular Carcinoma Following Living Donor Liver Transplantation. J Gastrointest Surg 2021. [PMID: 33532981 DOI: 10.1007/s11605-021-04939-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
253 Ohki T, Sato K, Kondo M, Goto E, Sato T, Kondo Y, Akamatsu M, Sato S, Yoshida H, Koike Y, Obi S. Impact of Adverse Events on the Progression-Free Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. Drugs Real World Outcomes 2020;7:141-9. [PMID: 32048238 DOI: 10.1007/s40801-020-00179-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
254 Monsky WL, Padia SA, Hardy AH. Dual-balloon infusion microcatheter for selective drug-eluting bead transarterial chemoembolization: initial feasibility study. Diagn Interv Radiol 2017;23:454-60. [PMID: 29097347 DOI: 10.5152/dir.2017.17059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
255 Kinoshita A, Hagiwara N, Osawa A, Akasu T, Matsumoto Y, Ueda K, Saeki C, Oikawa T, Koike K, Saruta M. Poor tolerability of lenvatinib in elderly patients ≥80 years old with hepatocellular carcinoma: A multicenter observational study. J Oncol Pharm Pract 2022;:10781552221077039. [PMID: 35112972 DOI: 10.1177/10781552221077039] [Reference Citation Analysis]
256 Song MJ, Bae SH, Yoo IR, Park CH, Jang JW, Chun HJ, Choi BG, Lee HG, Choi JY, Yoon SK. Predictive value of 18F-fluorodeoxyglucose PET/CT for transarterial chemolipiodolization of hepatocellular carcinoma. World J Gastroenterol 2012; 18(25): 3215-3222 [PMID: 22783045 DOI: 10.3748/wjg.v18.i25.3215] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
257 Wei J, Cui W, Fan W, Wang Y, Li J. Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation. Front Oncol 2020;10:1285. [PMID: 32850395 DOI: 10.3389/fonc.2020.01285] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
258 Solis-Hernandez MP, Fernandez Del Valle A, Carmona-Bayonas A, Garcia-Carbonero R, Custodio A, Benavent M, Alonso Gordoa T, Nuñez-Valdovino B, Sanchez Canovas M, Matos I, Alonso V, Lopez C, Viudez A, Izquierdo M, Calvo-Temprano D, Grande E, Capdevila J, Jimenez-Fonseca P. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study). Br J Cancer 2019;121:537-44. [PMID: 31477779 DOI: 10.1038/s41416-019-0558-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
259 Ji R, Ng KK, Chen W, Yang W, Zhu H, Cheung TT, Chiang CL, Wong TCL, Kong FM, Wu G, Lo CM. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e28545. [PMID: 35089192 DOI: 10.1097/MD.0000000000028545] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Liu Y, Litière S, de Vries EG, Sargent D, Shankar L, Bogaerts J, Seymour L. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer 2014;50:260-6. [PMID: 24239447 DOI: 10.1016/j.ejca.2013.10.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
261 Lee YC, Wang JH, Chen CH, Hung CH, Lo KC, Yen YH, Kee KM, Hu TH, Lu SN, Kuo YH. Sorafenib use in hepatitis B virus- or hepatitis C virus-related hepatocellular carcinoma: A propensity score matching study. Kaohsiung J Med Sci 2021. [PMID: 34166565 DOI: 10.1002/kjm2.12413] [Reference Citation Analysis]
262 Kolamunnage-Dona R, Berhane S, Potts H, Williams EH, Tanner J, Janowitz T, Hoare M, Johnson P. Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma. J Hepatol 2021:S0168-8278(21)00350-0. [PMID: 34052255 DOI: 10.1016/j.jhep.2021.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
263 Habibollahi P, Hunt S, Bitterman T, Gade TP, Soulen MC, Nadolski G. Definitive locoregional therapy (LRT) versus bridging LRT and liver transplantation with wait-and-not-treat approach for very early stage hepatocellular carcinoma. Diagn Interv Radiol 2018;24:213-8. [PMID: 30091712 DOI: 10.5152/dir.2018.17418] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
264 Riaz A, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora R, Kulik L, Desai K, Thornburg B, Mouli S, Hickey R, Miller FH, Yaghmai V, Ganger D, Lewandowski RJ, Salem R. Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. Hepatology 2018;67:873-83. [PMID: 28833344 DOI: 10.1002/hep.29480] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
265 Cornelis FH, Martin M, Saut O, Buy X, Kind M, Palussiere J, Colin T. Precision of manual two-dimensional segmentations of lung and liver metastases and its impact on tumour response assessment using RECIST 1.1. Eur Radiol Exp 2017;1:16. [PMID: 29708185 DOI: 10.1186/s41747-017-0015-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
266 Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2019;16:617-630. [PMID: 31371809 DOI: 10.1038/s41575-019-0179-x] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 24.7] [Reference Citation Analysis]
267 Di Costanzo GG, Tortora R. Intermediate hepatocellular carcinoma: How to choose the best treatment modality? World J Hepatol 2015; 7(9): 1184-1191 [PMID: 26019734 DOI: 10.4254/wjh.v7.i9.1184] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
268 Malagari K, Moschouris H, Kiakidis T, Harward S, Kelekis A, Vrakas S, Koundouras D, Filipiadis D, Glantzounis G, Emmanouil E, Chatziioannou A, Vergadis V, Elefsiniotis I, Koskinas J, Dourakis S, Kelekis N. Five-Years Outcome Analysis of 142 Consecutive Hepatocellular Carcinoma Patients Treated with Doxorubicin Eluting Microspheres 30-60 μm: Results from a Single-Centre Prospective Phase II Trial. Cardiovasc Intervent Radiol 2019;42:1551-62. [PMID: 31321482 DOI: 10.1007/s00270-019-02260-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
269 Song MJ, Bae SH, Lee JS, Lee SW, Song DS, You CR, Choi JY, Yoon SK. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Korean J Intern Med. 2016;31:242-252. [PMID: 26874512 DOI: 10.3904/kjim.2015.112] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
270 Chen LC, Lin HY, Lee MS, Chiou WY, Huang LW, Chew CH, Hsu FC, Hung SK. Effectiveness of individual audio-visual coaching, respiratory modulated stereotactic body radiotherapy for localized hepatocellular carcinoma: Analysis of 29 cases from a single academic radiotherapy center. Tzu Chi Med J 2021;33:380-7. [PMID: 34760635 DOI: 10.4103/tcmj.tcmj_247_20] [Reference Citation Analysis]
271 King MJ, Tong A, Dane B, Huang C, Zhan C, Shanbhogue K. Response assessment of hepatocellular carcinoma treated with yttrium-90 radioembolization: inter-reader variability, comparison with 3D quantitative approach, and role in the prediction of clinical outcomes. European Journal of Radiology 2020;133:109351. [DOI: 10.1016/j.ejrad.2020.109351] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
272 Zhan QF, Ling SB, Deng YN, Shan QN, Ye QW, Xu SJ, Jiang GJ, Lu D, Wei XY, Zhuang L, Zhang W, Shen T, Cen BN, Xie HY, Liu JM, Wu J, Zheng SS, Yang Y, Xu X. Hangzhou criteria as downstaging criteria in hepatocellular carcinoma before liver transplantation: A multicenter study from China. Hepatobiliary Pancreat Dis Int. 2020;19:349-357. [PMID: 32622826 DOI: 10.1016/j.hbpd.2020.06.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
273 Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation. Eur J Cancer. 2013;49:826-834. [PMID: 22995582 DOI: 10.1016/j.ejca.2012.08.022] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
274 Di Costanzo GG, Tortora R, Morisco F, Addario L, Guarino M, Cordone G, Falco L, Caporaso N. Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma. Target Oncol. 2017;12:61-67. [PMID: 27503006 DOI: 10.1007/s11523-016-0454-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
275 Kawabe N, Hashimoto S, Nakano T, Nakaoka K, Fukui A, Yoshioka K. Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open 2021;5:705-11. [PMID: 34124389 DOI: 10.1002/jgh3.12573] [Reference Citation Analysis]
276 Kimura T, Takeda A, Sanuki N, Ariyoshi K, Yamaguchi T, Imagumbai T, Katoh N, Eriguchi T, Oku Y, Ozawa S, Tsurugai Y, Kokubo M, Shimizu S, Ishikura S. Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. Hepatology Research 2021;51:461-71. [DOI: 10.1111/hepr.13595] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
277 Ippolito D, Pecorelli A, Querques G, Drago SG, Maino C, Franzesi CT, Hatzidakis A, Sironi S. Dynamic Computed Tomography Perfusion Imaging: Complementary Diagnostic Tool in Hepatocellular Carcinoma Assessment From Diagnosis to Treatment Follow-up. Acad Radiol 2019;26:1675-85. [PMID: 30852079 DOI: 10.1016/j.acra.2019.02.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
278 Sacco R, Mismas V, Romano A, Bertini M, Bertoni M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Giacomelli L, Marceglia S, Bargellini I. Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients. World J Hepatol 2015; 7(1): 33-39 [PMID: 25624994 DOI: 10.4254/wjh.v7.i1.33] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
279 Wong TC, Chiang CL, Lee AS, Lee VH, Yeung CS, Ho CH, Cheung TT, Ng KK, Chok SH, Chan AC, Dai WC, Wong FC, Luk MY, Leung TW, Lo CM. Better survival after stereotactic body radiation therapy following transarterial chemoembolization in nonresectable hepatocellular carcinoma: A propensity score matched analysis. Surg Oncol. 2019;28:228-235. [PMID: 30851906 DOI: 10.1016/j.suronc.2019.01.006] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
280 Guo Y, Ren Y, Chen L, Sun T, Zhang W, Sun B, Zhu L, Xiong F, Zheng C. Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma. BMC Cancer 2022;22:270. [PMID: 35287627 DOI: 10.1186/s12885-022-09325-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
281 Ou HY, Wu YN, Yu CY, Chen CL, Hsu HW, Weng CC, Leung-Chit Tsang L, Huang TL, Tong YS, Lim WX, Cheng YF. Transarterial Chemoembolization Using 100-μm Drug-Eluting Microspheres in Patients with Hepatocellular Carcinoma: A Prospective Study and Midterm Follow-up. J Vasc Interv Radiol 2020;31:1784-91. [PMID: 33023805 DOI: 10.1016/j.jvir.2020.06.009] [Reference Citation Analysis]
282 Pelizzaro F, Soldà F, Cardin R, Imondi A, Sartori A, Penzo B, Sammarco A, Aliberti C, Vitale A, Cillo U, Farinati F. SCCA-IgM in hepatocellular carcinoma patients treated with transarterial chemoembolization: gender-related differences. Biomark Med 2020;14:855-67. [PMID: 32808827 DOI: 10.2217/bmm-2019-0564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Tada T, Kumada T, Hiraoka A, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Sci Rep 2021;11:14474. [PMID: 34262065 DOI: 10.1038/s41598-021-93794-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
284 Terzi E, Piscaglia F, Forlani L, Mosconi C, Renzulli M, Bolondi L, Golfieri R; BLOG-Bologna Liver Oncology Group, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy. TACE performed in patients with a single nodule of hepatocellular carcinoma. BMC Cancer 2014;14:601. [PMID: 25139639 DOI: 10.1186/1471-2407-14-601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
285 Tomonari T, Sato Y, Tanaka H, Tanaka T, Fujino Y, Mitsui Y, Hirao A, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Kagiwada H, Kitazawa M, Fukui K, Horimoto K, Takayama T. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. Oncotarget 2020;11:2531-42. [PMID: 32655838 DOI: 10.18632/oncotarget.27640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
286 Xu H, Min X, Ren Y, Yang L, Liu F. Comparative Study of Drug-eluting Beads versus Conventional Transarterial Chemoembolization for Treating Peculiar Anatomical Sites of Gastric Cancer Liver Metastasis. Med Sci Monit 2020;26:e922988. [PMID: 32474569 DOI: 10.12659/MSM.922988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
287 Kim HD, An J, Kim JH, Gwon DI, Shin JH, Ko GY, Yoon HK, Sung KB, Kim KM, Lee HC. Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma. J Vasc Interv Radiol 2016;27:504-13. [PMID: 26896049 DOI: 10.1016/j.jvir.2015.12.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
288 Jia KF, Wang H, Yu CL, Yin WL, Zhang XD, Wang F, Sun C, Shen W. ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00015-7. [PMID: 35260337 DOI: 10.1016/j.hbpd.2022.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Yamashige D, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Muraishi N, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kumada H. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment. Oncology 2021;99:169-76. [PMID: 33207358 DOI: 10.1159/000510754] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
290 Kibe Y, Takeda A, Tsurugai Y, Eriguchi T, Oku Y, Kimura Y, Nakamura N. Feasibility of marker-less stereotactic body radiotherapy for hepatocellular carcinoma. Acta Oncol 2022;61:104-10. [PMID: 34788194 DOI: 10.1080/0284186X.2021.2001566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
291 Kim N, Cheng J, Jung I, Liang J, Shih YL, Huang WY, Kimura T, Lee VHF, Zeng ZC, Zhenggan R, Kay CS, Heo SJ, Won JY, Seong J. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol. 2020;73:121-129. [PMID: 32165253 DOI: 10.1016/j.jhep.2020.03.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 18.5] [Reference Citation Analysis]
292 Mahvash A, Chartier S, Turco M, Habib P, Griffith S, Brown S, Kappadath SC. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02204-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
293 Tomaselli D, Lucidi A, Rotili D, Mai A. Epigenetic polypharmacology: A new frontier for epi-drug discovery. Med Res Rev 2020;40:190-244. [PMID: 31218726 DOI: 10.1002/med.21600] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 12.3] [Reference Citation Analysis]
294 Pelizzaro F, Haxhi S, Penzo B, Vitale A, Giannini EG, Sansone V, Rapaccini GL, Di Marco M, Caturelli E, Magalotti D, Sacco R, Celsa C, Campani C, Mega A, Guarino M, Gasbarrini A, Svegliati-baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Front Oncol 2022;12:822507. [DOI: 10.3389/fonc.2022.822507] [Reference Citation Analysis]
295 Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology. 2012;262:43-58. [PMID: 22190656 DOI: 10.1148/radiol.11110144] [Cited by in Crossref: 211] [Cited by in F6Publishing: 202] [Article Influence: 21.1] [Reference Citation Analysis]
296 Zhang X, Long Q. Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients. Medicine (Baltimore) 2017;96:e6694. [PMID: 28445272 DOI: 10.1097/MD.0000000000006694] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
297 Pavel M, Sanchez Cabus S, Crespo G, Ferrer J, Fondevila C, Fuster J, Garcia-valdecasas J. Role of Adult Living Donor Liver Transplantation in the Treatment of Hepatocellular Carcinoma Within and Beyond Milan Criteria: A Comparative Study. Transplantation Proceedings 2018;50:1386-95. [DOI: 10.1016/j.transproceed.2018.02.093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
298 Huang Y, Lu Y, Lu S. Sequential bilateral PVTT successfully controlled by radiotherapy and sorafenib, respectively. Kaohsiung J Med Sci 2019;35:63-4. [DOI: 10.1016/j.kjms.2018.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
299 Vaira V, Roncalli M, Carnaghi C, Faversani A, Maggioni M, Augello C, Rimassa L, Pressiani T, Spagnuolo G, Di Tommaso L. MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma. Liver Int. 2015;35:1077-1086. [PMID: 25040368 DOI: 10.1111/liv.12636] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.0] [Reference Citation Analysis]
300 Lei XF, Ke Y, Bao TH, Tang HR, Wu XS, Shi ZT, Lin J, Zhang ZX, Gu H, Wang L. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study. World J Clin Cases 2018; 6(5): 74-83 [PMID: 29774219 DOI: 10.12998/wjcc.v6.i5.74] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
301 Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Current Oncology 2022;29:3259-71. [DOI: 10.3390/curroncol29050266] [Reference Citation Analysis]
302 Gordic S, Wagner M, Zanato R, Hectors S, Besa C, Kihira S, Kim E, Taouli B. Prediction of hepatocellular carcinoma response to 90Yttrium radioembolization using volumetric ADC histogram quantification: preliminary results. Cancer Imaging 2019;19:29. [PMID: 31142363 DOI: 10.1186/s40644-019-0216-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
303 Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther 2018;48:431-9. [PMID: 29920698 DOI: 10.1111/apt.14848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
304 Raoul JL, Gilabert M, Adhoute X, Edeline J. An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. Expert Opin Pharmacother. 2017;18:1467-1476. [PMID: 28893090 DOI: 10.1080/14656566.2017.1378346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
305 Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, Okusaka T; Japan Interventional Radiology in Oncology Study Group (JIVROSG); Korea Interventional Radiology in Oncology Study Group (KIVROSG). Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea. J Vasc Interv Radiol. 2013;24:490-500. [PMID: 23466316 DOI: 10.1016/j.jvir.2013.01.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
306 Li Y, Xu Z, An C, Chen H, Li X. Multi-Task Deep Learning Approach for Simultaneous Objective Response Prediction and Tumor Segmentation in HCC Patients with Transarterial Chemoembolization. JPM 2022;12:248. [DOI: 10.3390/jpm12020248] [Reference Citation Analysis]
307 de Mestier L, Zappa M, Hentic O, Vilgrain V, Ruszniewski P. Liver transarterial embolizations in metastatic neuroendocrine tumors. Rev Endocr Metab Disord. 2017;18:459-471. [PMID: 28975561 DOI: 10.1007/s11154-017-9431-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
308 Claudon M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolsøe CP, Piscaglia F, Wilson SR, Barr RG, Chammas MC, Chaubal NG, Chen MH, Clevert DA, Correas JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leen EL, Mattrey RF, Moriyasu F, Solbiati L, Weskott HP, Xu HX; World Federation for Ultrasound in Medicine., European Federation of Societies for Ultrasound. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol 2013;39:187-210. [PMID: 23137926 DOI: 10.1016/j.ultrasmedbio.2012.09.002] [Cited by in Crossref: 416] [Cited by in F6Publishing: 382] [Article Influence: 41.6] [Reference Citation Analysis]
309 Hwang SH, Hong HS, Kim D, Kim GM, Lee HW, Lee M, Kim DY, Park MA, Yun M. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization. Clin Nucl Med 2022. [PMID: 35384891 DOI: 10.1097/RLU.0000000000004128] [Reference Citation Analysis]
310 Hu J, Wang E, Liu L, Wang Q, Xia D, Bai W, Tie J, Li X, Yuan J, Yang S, Jiang D, Shi J, Sun Y, Wang J, Zhang C, Niu J, Li K, He C, Guo W, Lv Y, Chen H, Yuan X, Yu T, Wang Z, Luo B, Han N, Zhu Y, Yin Z, Fan D, Zhang Z, Yang K, Han G. Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells. Invest New Drugs 2020;38:1247-56. [PMID: 31832851 DOI: 10.1007/s10637-019-00885-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
311 Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma 2019;6:31-9. [PMID: 30775342 DOI: 10.2147/JHC.S168953] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
312 Ranieri G, Niccoli Asabella A, Altini C, Fazio V, Caporusso L, Marech I, Vinciarelli G, Macina F, de Ceglia D, Fanelli M, Ammendola M, Rubini G, Gadaleta CD. A pilot study employing hepatic intra-arterial irinotecan injection of drug-eluting beads as salvage therapy in liver metastatic colorectal cancer patients without extrahepatic involvement: the first southern Italy experience. Onco Targets Ther 2016;9:7527-35. [PMID: 28003766 DOI: 10.2147/OTT.S112670] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
313 Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803 [PMID: 31662820 DOI: 10.4251/wjgo.v11.i10.788] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
314 Ren Y, Cao Y, Ma H, Kan X, Zhou C, Liu J, Shi Q, Feng G, Xiong B, Zheng C. Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study. BMC Cancer 2019;19:983. [PMID: 31640620 DOI: 10.1186/s12885-019-6237-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
315 Froelich MF, Heinemann V, Sommer WH, Holch JW, Schoeppe F, Hesse N, Baumann AB, Kunz WG, Reiser MF, Ricke J, D’anastasi M, Stintzing S, Modest DP, Kazmierczak PM, Hofmann FO. CT attenuation of liver metastases before targeted therapy is a prognostic factor of overall survival in colorectal cancer patients. Results from the randomised, open-label FIRE-3/AIO KRK0306 trial. Eur Radiol 2018;28:5284-92. [DOI: 10.1007/s00330-018-5454-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
316 Di Costanzo GG, Tortora R, Iodice L, Lanza AG, Lampasi F, Tartaglione MT, Picciotto FP, Mattera S, De Luca M. Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice. Dig Liver Dis. 2012;44:788-792. [PMID: 22579445 DOI: 10.1016/j.dld.2012.04.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
317 Chan LS, Sze DY, Poultsides GA, Louie JD, Abdelrazek Mohammed MA, Wang DS. Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma. Cardiovasc Intervent Radiol 2017;40:1383-91. [DOI: 10.1007/s00270-017-1648-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
318 Ha Y, Han S, Shim JH, Ko GY, Yoon HK, Sung KB, Lee D, Kim KM, Lim YS, Chung YH, Lee YS, Lee HC. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. J Vasc Interv Radiol 2015;26:1093-1101.e1. [PMID: 26077020 DOI: 10.1016/j.jvir.2015.04.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
319 Hirmas N, Leyh C, Sraieb M, Barbato F, Schaarschmidt BM, Umutlu L, Nader M, Wedemeyer H, Ferdinandus J, Rischpler C, Herrmann K, Costa PF, Lange CM, Weber M, Fendler WP. 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. J Nucl Med 2021;62:1235-41. [PMID: 33509970 DOI: 10.2967/jnumed.120.257915] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
320 Lucatelli P, De Rubeis G, Rocco B, Basilico F, Cannavale A, Abbatecola A, Nardis PG, Corona M, Brozzetti S, Catalano C, Bezzi M. Balloon occluded TACE (B-TACE) vs DEM-TACE for HCC: a single center retrospective case control study. BMC Gastroenterol 2021;21:51. [PMID: 33535972 DOI: 10.1186/s12876-021-01631-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
321 Lee M, Baek SE, Moon J, Roh YH, Lim JS, Park MS, Kim MJ, Kim H. Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis. Oncotarget 2016;7:38513-22. [PMID: 27229529 DOI: 10.18632/oncotarget.9567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
322 Zhao H, Zhang H, Du Y, Gu X. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy. Tumour Biol 2014;35:12679-88. [PMID: 25227663 DOI: 10.1007/s13277-014-2592-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
323 Takeda K, Tsurumaru Y, Yamamoto Y, Araki K, Kogure Y, Mori K, Nakagawa K, Shimizu T, Matsuda G, Niino H, Sekido H, Kobayashi S, Morimoto M, Kunisaki C, Endo I. Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report. Clin J Gastroenterol 2020;13:428-33. [PMID: 31970661 DOI: 10.1007/s12328-019-01077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
324 Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baère T, Dodd GD, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee FT, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN; International Working Group on Image-guided Tumor Ablation; Interventional Oncology Sans Fronti res Expert Panel; Technology Assessment Committee of the Society of Interventional Radiology,; Standard of Practice Committee of the Cardiovascular and Inter. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. Radiology. 2014;273:241-260. [PMID: 24927329 DOI: 10.1148/radiol.14132958] [Cited by in Crossref: 485] [Cited by in F6Publishing: 467] [Article Influence: 60.6] [Reference Citation Analysis]
325 Salem R, Lewandowski RJ. Chemoembolization and radioembolization for hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2013;11:604-11; quiz e43-44. [PMID: 23357493 DOI: 10.1016/j.cgh.2012.12.039] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
326 Daniele G, Costa N, Lorusso V, Costa-Maia J, Pache I, Pirisi M. Methodological assessment of HCC literature. Ann Oncol 2013;24 Suppl 2:ii6-14. [PMID: 23715943 DOI: 10.1093/annonc/mdt052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
327 Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol. 2013;9:1533-1548. [PMID: 24106903 DOI: 10.2217/fon.13.171] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
328 Patella F, Pesapane F, Fumarola E, Zannoni S, Brambillasca P, Emili I, Costa G, Anderson V, Levy EB, Carrafiello G, Wood BJ. Assessment of the response of hepatocellular carcinoma to interventional radiology treatments. Future Oncol 2019;15:1791-804. [PMID: 31044615 DOI: 10.2217/fon-2018-0747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
329 Salvalaggio PR, Felga G, Axelrod DA, Della Guardia B, Almeida MD, Rezende MB. List and Liver Transplant Survival According to Waiting Time in Patients With Hepatocellular Carcinoma: Time on the List and Survival in HCC Recipients. American Journal of Transplantation 2015;15:668-77. [DOI: 10.1111/ajt.13011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
330 Sullivan DC, Schwartz LH, Zhao B. The imaging viewpoint: how imaging affects determination of progression-free survival. Clin Cancer Res 2013;19:2621-8. [PMID: 23669422 DOI: 10.1158/1078-0432.CCR-12-2936] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
331 Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev 2022;1:CD013345. [PMID: 34981511 DOI: 10.1002/14651858.CD013345.pub2] [Reference Citation Analysis]
332 Zhang M, Lai W, Zhang J, Hu B, Huang L, Chu C. Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma. Dis Markers 2022;2022:6957580. [PMID: 35845129 DOI: 10.1155/2022/6957580] [Reference Citation Analysis]
333 Poursaid A, Jensen MM, Huo E, Ghandehari H. Polymeric materials for embolic and chemoembolic applications. J Control Release 2016;240:414-33. [PMID: 26924353 DOI: 10.1016/j.jconrel.2016.02.033] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 8.3] [Reference Citation Analysis]
334 Shropshire EL, Chaudhry M, Miller CM, Allen BC, Bozdogan E, Cardona DM, King LY, Janas GL, Do RK, Kim CY, Ronald J, Bashir MR. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy. Radiology. 2019;292:226-234. [PMID: 31038409 DOI: 10.1148/radiol.2019182135] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
335 Lee JS, Choi HJ, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Chung YE, Park MS, Kim MJ, Rhee H, Kim SU. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization. Gut Liver 2020;14:765-74. [PMID: 32050313 DOI: 10.5009/gnl19197] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
336 Park C, Kim JH, Kim PH, Kim SY, Gwon DI, Chu HH, Park M, Hur J, Kim JY, Kim DJ. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. Korean J Radiol 2021;22:213-24. [PMID: 32901464 DOI: 10.3348/kjr.2020.0325] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
337 Hameed B, Mehta N, Sapisochin G, Roberts JP, Yao FY. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl. 2014;20:945-951. [PMID: 24797281 DOI: 10.1002/lt.23904] [Cited by in Crossref: 145] [Cited by in F6Publishing: 138] [Article Influence: 18.1] [Reference Citation Analysis]
338 Edeline J, Lenoir L, Boudjema K, Rolland Y, Boulic A, Le Du F, Pracht M, Raoul JL, Clément B, Garin E. Volumetric changes after (90)y radioembolization for hepatocellular carcinoma in cirrhosis: an option to portal vein embolization in a preoperative setting? Ann Surg Oncol. 2013;20:2518-2525. [PMID: 23494107 DOI: 10.1245/s10434-013-2906-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 5.8] [Reference Citation Analysis]
339 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
340 Riaz A, Salem R. Laboratory and Imaging Prognostic Indicators following Arterial Locoregional Therapies for Hepatocellular Carcinoma Survival. J Vasc Interv Radiol 2019;30:1893-4. [PMID: 31757337 DOI: 10.1016/j.jvir.2019.09.003] [Reference Citation Analysis]
341 Saake M, Lell MM, Eller A, Wuest W, Heinz M, Uder M, Schmid A. Imaging Hepatocellular Carcinoma with Dynamic CT Before and After Transarterial Chemoembolization: Optimal Scan Timing of Arterial Phase. Acad Radiol 2015;22:1516-21. [PMID: 26411380 DOI: 10.1016/j.acra.2015.08.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
342 Miyayama S, Yamashiro M, Nagai K, Tohyama J, Kawamura K, Yoshida M, Sakuragawa N. Evaluation of tumor recurrence after superselective conventional transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of computed tomography and gadoxetate disodium-enhanced magnetic resonance imaging: CT vs Gd-EOB-MRI for recurrent HCC after cTACE. Hepatol Res 2016;46:890-8. [DOI: 10.1111/hepr.12632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
343 Dai X, Schlemmer HP, Schmidt B, Höh K, Xu K, Ganten TM, Ganten MK. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Radiol 2013;82:327-34. [PMID: 23246016 DOI: 10.1016/j.ejrad.2012.11.013] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.0] [Reference Citation Analysis]
344 Minocha J, Lewandowski RJ. Assessing Imaging Response to Therapy. Radiologic Clinics of North America 2015;53:1077-88. [DOI: 10.1016/j.rcl.2015.05.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
345 Vilarinho S, Taddei TH. New frontier in liver cancer treatment: oncolytic viral therapy. Hepatology 2014;59:343-6. [PMID: 23836532 DOI: 10.1002/hep.26605] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
346 Chaudhry M, McGinty KA, Mervak B, Lerebours R, Li C, Shropshire E, Ronald J, Commander L, Hertel J, Luo S, Bashir MR, Burke LMB. The LI-RADS Version 2018 MRI Treatment Response Algorithm: Evaluation of Ablated Hepatocellular Carcinoma. Radiology. 2020;294:320-326. [PMID: 31845843 DOI: 10.1148/radiol.2019191581] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
347 Decaens T, Barone C, Assenat E, Wermke M, Fasolo A, Merle P, Blanc JF, Grando V, Iacobellis A, Villa E, Trojan J, Straub J, Bruns R, Berghoff K, Scheele J, Raymond E, Faivre S. Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression. Br J Cancer 2021;125:190-9. [PMID: 33824476 DOI: 10.1038/s41416-021-01334-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
348 Ma J, Zeng S, Zhang Y, Deng G, Qu Y, Guo C, Yin L, Han Y, Shen H. BMP4 enhances hepatocellular carcinoma proliferation by promoting cell cycle progression via ID2/CDKN1B signaling. Mol Carcinog 2017;56:2279-89. [PMID: 28543546 DOI: 10.1002/mc.22681] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
349 Saeki I, Yamamoto N, Yamasaki T, Takami T, Maeda M, Fujisawa K, Iwamoto T, Matsumoto T, Hidaka I, Ishikawa T, Uchida K, Tani K, Sakaida I. Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. World J Gastroenterol 2016; 22(40): 8967-8977 [PMID: 27833388 DOI: 10.3748/wjg.v22.i40.8967] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
350 Zhang EL, Zhang ZY, Li J, Huang ZY. Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient. Onco Targets Ther 2020;13:12477-87. [PMID: 33311988 DOI: 10.2147/OTT.S284092] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
351 Auer TA, Sofue K, Ueshima E, Rauer N, Yamaguchi T, Gebauer B, Hamm B, Murakami T, Althoff C. Transarterial Chemoebolization in Hepatocellular Carcinoma: A Binational Japanese-German Study. JHC 2022;Volume 9:695-705. [DOI: 10.2147/jhc.s359705] [Reference Citation Analysis]
352 Yu CY, Ou HY, Weng CC, Huang TL, Chen TY, Leung-Chit L, Hsu HW, Chen CL, Cheng YF. Drug-Eluting Bead Transarterial Chemoembolization as Bridge Therapy for Hepatocellular Carcinoma Before Living-Donor Liver Transplantation. Transplant Proc. 2016;48:1045-1048. [PMID: 27320552 DOI: 10.1016/j.transproceed.2015.12.078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
353 Kim BK, Cheon J, Kim H, Kang B, Ha Y, Kim DY, Hwang SG, Chon YE, Chon HJ. Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study. Cancers (Basel) 2022;14:1747. [PMID: 35406518 DOI: 10.3390/cancers14071747] [Reference Citation Analysis]
354 Schiavon LL, Ejima FH, Menezes MR, Bittencourt PL, Moreira AM, Farias AQ, Chagas AL, Assis AM, Mattos ÂZ, Salomão BC, Terra C, Martins FPB, Carnevale FC, Rezende GFDM, Paulo GA, Pereira GHS, Leal Filho JMDM, Meneses J, Costa LSND, Carneiro MV, Álvares-DA-Silva MR, Soares MVA, Pereira OI, Ximenes RO, Durante RFS, Ferreira VA, Lima VM; Members of the Pannel of the 1st Joint Meeting of the SBH, SOBED and SOBRICE. RECOMMENDATIONS FOR INVASIVE PROCEDURES IN PATIENTS WITH DISEASES OF THE LIVER AND BILIARY TRACT: REPORT OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN SOCIETY OF DIGESTIVE ENDOSCOPY (SOBED) AND BRAZILIAN SOCIETY OF INTERVENTIONAL RADIOLOGY AND ENDOVASCULAR SURGERY (SOBRICE). Arq Gastroenterol 2019;56:213-31. [PMID: 31460590 DOI: 10.1590/S0004-2803.201900000-42] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Bargellini I, Sacco R, Bozzi E, Bertini M, Ginanni B, Romano A, Cicorelli A, Tumino E, Federici G, Cioni R. Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. Eur J Radiol. 2012;81:1173-1178. [PMID: 21466931 DOI: 10.1016/j.ejrad.2011.03.046] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 4.7] [Reference Citation Analysis]
356 Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller C. Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr. 2011;123:542-551. [PMID: 21800047 DOI: 10.1007/s00508-011-0033-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
357 Mercan-stanciu A, Isac T, Rababoc R, Rusie D, Toma L, Vacaroiu IA, Tulin R, Iliescu EL. Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals. Cureus. [DOI: 10.7759/cureus.25487] [Reference Citation Analysis]
358 Zheng LL, Tao CC, Tao ZG, Zhang K, Wu AK, Wu JX, Rong WQ. Research progress regarding programmed cell death 1/programmed cell death ligand 1 inhibitors combined with targeted therapy for treating hepatocellular carcinoma. World J Gastrointest Surg 2021; 13(10): 1136-1148 [PMID: 34754383 DOI: 10.4240/wjgs.v13.i10.1136] [Reference Citation Analysis]
359 Zhao G, Liu S, Chen S, Ren Z, Li C, Bian J, Wu J, Zhou J, Zhang Y. Assessment of efficacy and safety by CalliSpheres versus HepaSpheres for drug-eluting bead transarterial chemoembolization in unresectable large hepatocellular carcinoma patients. Drug Deliv 2021;28:1356-62. [PMID: 34180755 DOI: 10.1080/10717544.2021.1943057] [Reference Citation Analysis]
360 Won JK, Yu SJ, Hwang CY, Cho SH, Park SM, Kim K, Choi WM, Cho H, Cho EJ, Lee JH, Lee KB, Kim YJ, Suh KS, Jang JJ, Kim CY, Yoon JH, Cho KH. Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. Hepatology 2017;66:855-68. [PMID: 28439950 DOI: 10.1002/hep.29237] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 4.4] [Reference Citation Analysis]
361 Barbier CE, Garske-román U, Sandström M, Nyman R, Granberg D. Selective internal radiation therapy in patients with progressive neuroendocrine liver metastases. Eur J Nucl Med Mol Imaging 2016;43:1425-31. [DOI: 10.1007/s00259-015-3264-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
362 Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P. Small hepatocellular carcinomas and thrombocytopenia. Oncology 2012;83:331-8. [PMID: 23006906 DOI: 10.1159/000341533] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
363 Zhang R, Shen L, Zhao L, Guan Z, Chen Q, Li W. Combined transarterial chemoembolization and microwave ablation versus transarterial chemoembolization in BCLC stage B hepatocellular carcinoma. Diagn Interv Radiol 2018;24:219-24. [PMID: 29792289 DOI: 10.5152/dir.2018.17528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
364 Li L, Kan X, Zhao Y, Liang B, Ye T, Yang L, Zheng C. Radiomics Signature: A potential biomarker for the prediction of survival in Advanced Hepatocellular Carcinoma. Int J Med Sci 2021;18:2276-84. [PMID: 33967603 DOI: 10.7150/ijms.55510] [Reference Citation Analysis]
365 Villalobos A, Wagstaff W, Guo M, Zhang J, Bercu Z, Whitmore MJ, Cristescu MM, Majdalany BS, Wedd J, Akce M, Magliocca J, Kokabi N. Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma. Can J Gastroenterol Hepatol 2021;2021:9926704. [PMID: 34336728 DOI: 10.1155/2021/9926704] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
366 Song MJ, Bae SH, Chun HJ, Choi JY, Yoon SK, Park JY, Han KH, Kim YS, Yim HJ, Um SH, Chung WJ, Hwang JS, Cho S, Eun JR. A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2015;75:739-46. [DOI: 10.1007/s00280-015-2692-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
367 Zheng X, Ren Y, Hu H, Qian K. Transarterial Chemoembolization Combined With Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma After Curative Resection: A 10-Year Single-Center Comparative Study. Front Oncol 2021;11:713432. [PMID: 34568043 DOI: 10.3389/fonc.2021.713432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
368 Lee S, Jung J, Park JH, Kim SY, Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee HC, Park HH, Kim JH, Yoon SM. Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. BMC Cancer 2022;22:175. [PMID: 35172769 DOI: 10.1186/s12885-022-09263-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
369 Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group., HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology 2019;97:277-85. [PMID: 31307035 DOI: 10.1159/000501281] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 15.7] [Reference Citation Analysis]
370 Zhang S, Zhao G, Dong H. Effect of Radiofrequency Ablation with Interventional Therapy of Hepatic Artery on the Recurrence of Primary Liver Cancer and the Analysis of Influencing Factors. J Oncol 2021;2021:3392433. [PMID: 34691177 DOI: 10.1155/2021/3392433] [Reference Citation Analysis]
371 Song DS, Choi JY, Yoo SH, Kim HY, Song MJ, Bae SH, Yoon SK, Chun HJ, Choi BG, Lee HG. DC Bead Transarterial Chemoembolization Is Effective in Hepatocellular Carcinoma Refractory to Conventional Transarteral Chemoembolization: A Pilot Study. Gut Liver 2013;7:89-95. [PMID: 23424047 DOI: 10.5009/gnl.2013.7.1.89] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
372 Park C, Chu HH, Kim JH, Kim SY, Alrashidi I, Gwon DI, Yoon HK, Kim N. Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function. J Vasc Interv Radiol 2020;31:1998-2006.e1. [PMID: 32988715 DOI: 10.1016/j.jvir.2020.04.017] [Cited by in Crossref: 7] [Article Influence: 3.5] [Reference Citation Analysis]
373 Meyer T, Johnson P. Trial endpoints for systemic therapy in patients with hepatocellular carcinoma. J Hepatol 2019;70:1060-1. [PMID: 30943424 DOI: 10.1016/j.jhep.2019.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
374 Andersson M, Jalnefjord O, Montelius M, Rizell M, Sternby Eilard M, Ljungberg M. Evaluation of response in patients with hepatocellular carcinoma treated with intratumoral dendritic cell vaccination using intravoxel incoherent motion (IVIM) MRI and histogram analysis. Acta Radiol 2021;:2841851211065935. [PMID: 34904868 DOI: 10.1177/02841851211065935] [Reference Citation Analysis]
375 Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, Breatta AD, Gandini G, Nani R, Gasparini D, Cucchetti A, Bolondi L, Trevisani F, PRECISION ITALIA STUDY GROUP. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255-264. [PMID: 24937669 DOI: 10.1038/bjc.2014.199] [Cited by in Crossref: 264] [Cited by in F6Publishing: 235] [Article Influence: 33.0] [Reference Citation Analysis]
376 Kayaleh R, Krzyston H, Rishi A, Naziri J, Frakes J, Choi J, El-Haddad G, Parikh N, Sweeney J, Kis B. Transarterial Radioembolization Treatment of Pancreatic Cancer Patients with Liver-Dominant Metastatic Disease Using Yttrium-90 Glass Microspheres: A Single-Institution Retrospective Study. J Vasc Interv Radiol. 2020;31:1060-1068. [PMID: 32534978 DOI: 10.1016/j.jvir.2019.11.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
377 Fujimori M, Takaki H, Nakatsuka A, Uraki J, Yamanaka T, Hasegawa T, Shiraki K, Takei Y, Sakuma H, Yamakado K. Survival with up to 10-year follow-up after combination therapy of chemoembolization and radiofrequency ablation for the treatment of hepatocellular carcinoma: single-center experience. J Vasc Interv Radiol 2013;24:655-66. [PMID: 23428356 DOI: 10.1016/j.jvir.2012.12.009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
378 Byun HK, Kim N, Seong J. Optimal Timing of Radiotherapy after Incomplete Transarterial Chemoembolization for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma. Yonsei Med J 2021;62:409-16. [PMID: 33908211 DOI: 10.3349/ymj.2021.62.5.409] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
379 Thillai K, Srikandarajah K, Ross P. Regorafenib as treatment for patients with advanced hepatocellular cancer. Future Oncol. 2017;13:2223-2232. [PMID: 28766967 DOI: 10.2217/fon-2017-0204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
380 Boulin M, Ciboulet A, Guiu B, Maillard E, Bonnetain F, Minello A, Gagnaire A, Lepage C, Krause D, Hillon P, Bedenne L, Cercueil JP, Chauffert B, Jouve JL. Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. Dig Liver Dis 2011;43:905-11. [PMID: 21802381 DOI: 10.1016/j.dld.2011.06.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
381 Colombo M, Raoul J, Lencioni R, Galle PR, Zucman-rossi J, Bañares R, Seehofer D, Neuhaus P, Johnson P. Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma: a European perspective. European Journal of Gastroenterology & Hepatology 2013;25:639-51. [DOI: 10.1097/meg.0b013e32835e33bb] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
382 Saito T, Murotani K. Statistical handling of death events in the analysis of time to progression: A review of oncology journals. Contemp Clin Trials 2022;119:106858. [PMID: 35868502 DOI: 10.1016/j.cct.2022.106858] [Reference Citation Analysis]
383 Wang C, Lu Y, Wang H, Gao X, Bai W, Qu J, Xu G, Zhang Z, Zeng Z, Zhou L, An L, Lv J, Yang Y. Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma. Exp Ther Med 2012;4:188-96. [PMID: 23139708 DOI: 10.3892/etm.2012.569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
384 Kim DY, Lee HW, Kang W, Kim GM, Won JY, Yun M. Metabolic activity assessment by 18 F-fluorodeoxyglucose positron emission tomography in patients with hepatocellular carcinoma undergoing Yttrium-90 transarterial radioembolization. J Gastroenterol Hepatol 2021;36:1679-84. [PMID: 33226706 DOI: 10.1111/jgh.15357] [Reference Citation Analysis]
385 Loi M, Comito T, Franzese C, Desideri I, Dominici L, Lo Faro L, Clerici E, Franceschini D, Baldaccini D, Badalamenti M, Reggiori G, Lobefalo F, Scorsetti M. Charlson comorbidity index and G8 in older old adult(≥80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy. J Geriatr Oncol 2021;12:1100-3. [PMID: 33461945 DOI: 10.1016/j.jgo.2021.01.001] [Reference Citation Analysis]
386 Kudo M, Ueshima K, Chiba Y, Ogasawara S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kumada T, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Kanai F, Arai Y. Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer 2019;8:505-19. [PMID: 31799207 DOI: 10.1159/000503032] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
387 Müller L, Hahn F, Mähringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, Weinmann A, Galle PR, Mittler J, Pinto Dos Santos D, Pitton MB, Düber C, Fehrenbach U, Auer TA, Gebauer B, Kloeckner R. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United European Gastroenterol J 2021. [PMID: 34918471 DOI: 10.1002/ueg2.12188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
388 Dromain C, Vullierme MP, Hicks RJ, Prasad V, O'Toole D, de Herder WW, Pavel M, Faggiano A, Kos-Kudla B, Öberg K, Krejs GJ, Grande E, Niederle B, Sundin A. ENETS consensus guidelines for synoptic reporting of radiology studies. J Neuroendocrinol 2021;:e13044. [PMID: 34693574 DOI: 10.1111/jne.13044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
389 Zheng K, Fu S, Leng B, Cui Y, Yang R, Cao G, Xu L, Li W, Li Y, Zhu X, Gao S, Liu P, Wang X. Signal enhancement ratio of CE-MRI: a potential biomarker of survival after hepatic arterial infusion chemotherapy in biliary tract cancers. Insights Imaging 2022;13. [DOI: 10.1186/s13244-022-01188-6] [Reference Citation Analysis]
390 Llovet JM, Decaens T, Raoul J, Boucher E, Kudo M, Chang C, Kang Y, Assenat E, Lim H, Boige V, Mathurin P, Fartoux L, Lin D, Bruix J, Poon RT, Sherman M, Blanc J, Finn RS, Tak W, Chao Y, Ezzeddine R, Liu D, Walters I, Park J. Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study. JCO 2013;31:3509-16. [DOI: 10.1200/jco.2012.47.3009] [Cited by in Crossref: 386] [Cited by in F6Publishing: 218] [Article Influence: 42.9] [Reference Citation Analysis]
391 Caputo F, Dadduzio V, Tovoli F, Bertolini G, Cabibbo G, Cerma K, Vivaldi C, Faloppi L, Rizzato MD, Piscaglia F, Celsa C, Fornaro L, Marisi G, Conti F, Silvestris N, Silletta M, Lonardi S, Granito A, Stornello C, Massa V, Astara G, Delcuratolo S, Cascinu S, Scartozzi M, Casadei-Gardini A. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. PLoS One 2020;15:e0232449. [PMID: 32379785 DOI: 10.1371/journal.pone.0232449] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
392 Bhatti ABH, Naqvi W, Khan NY, Zia HH, Dar FS, Khan ZA, Rana A. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion. J Cancer Res Clin Oncol 2021. [PMID: 34117916 DOI: 10.1007/s00432-021-03665-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
393 Aujay G, Debordeaux F, Blanc JF, Lapuyade B, Papadopoulos P, Bordenave L, Trillaud H, Pinaquy JB. 18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma. Nucl Med Commun 2021;42:633-8. [PMID: 33660694 DOI: 10.1097/MNM.0000000000001383] [Reference Citation Analysis]
394 Qiu X, Li M, Wu L, Xin Y, Mu S, Li T, Song K. Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Cancer Manag Res 2020;12:7983-92. [PMID: 32943932 DOI: 10.2147/CMAR.S233448] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
395 Løitegård T, Berntzen DT, Thiis-Evensen E. The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms. Ann Nucl Med 2019;33:147-52. [PMID: 30406360 DOI: 10.1007/s12149-018-1316-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
396 Sansone V, Tovoli F, Casadei-Gardini A, Di Costanzo GG, Magini G, Sacco R, Pressiani T, Trevisani F, Rimini M, Tortora R, Nardi E, Ielasi L, Piscaglia F, Granito A. Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib. Clin Transl Gastroenterol 2021;12:e00286. [PMID: 33443944 DOI: 10.14309/ctg.0000000000000286] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
397 Bucalau AM, Tancredi I, Verset G. In the Era of Systemic Therapy for Hepatocellular Carcinoma Is Transarterial Chemoembolization Still a Card to Play? Cancers (Basel) 2021;13:5129. [PMID: 34680278 DOI: 10.3390/cancers13205129] [Reference Citation Analysis]
398 Colombo M, Sangiovanni A. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2015;35 Suppl 1:129-138. [PMID: 25529098 DOI: 10.1111/liv.12713] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
399 Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019;72:28-36. [PMID: 30447470 DOI: 10.1016/j.ctrv.2018.11.002] [Cited by in Crossref: 72] [Cited by in F6Publishing: 81] [Article Influence: 18.0] [Reference Citation Analysis]
400 Adachi T, Nouso K, Miyahara K, Oyama A, Wada N, Dohi C, Takeuchi Y, Yasunaka T, Onishi H, Ikeda F, Nakamura S, Shiraha H, Takaki A, Takabatake H, Fujioka SI, Kobashi H, Takuma Y, Iwadou S, Uematsu S, Takaguchi K, Hagihara H, Okada H; Okayama Liver Cancer Group. Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib. J Gastroenterol Hepatol. 2019;34:1081-1087. [PMID: 30402928 DOI: 10.1111/jgh.14535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
401 Niizeki T, Iwamoto H, Shirono T, Shimose S, Nakano M, Okamura S, Noda Y, Kamachi N, Hiroyuki S, Sakai M, Kuromatsu R, Koga H, Torimura T. Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion. Cancers (Basel) 2021;13:4450. [PMID: 34503259 DOI: 10.3390/cancers13174450] [Reference Citation Analysis]
402 Manzia TM, Lai Q, Iesari S, Perera MTPR, Komuta M, Carvalheiro A, Shah T, Angelico R, Quaranta C, Nicolini D, Montalti R, Scarpelli M, Palmieri G, Orlacchio A, Vivarelli M, Angelico M, Lerut J, Tisone G. Impact of remnant vital tissue after locoregional treatment and liver transplant in hepatocellular cancer patients, a multicentre cohort study. Transpl Int 2018. [PMID: 29572974 DOI: 10.1111/tri.13153] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
403 Kobayashi S, Fukushima T, Ueno M, Moriya S, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Suzuki M, Uojima H, Hidaka H, Kusano C, Suzuki M, Morimoto M. A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma. BMC Cancer 2022;22:517. [PMID: 35525913 DOI: 10.1186/s12885-022-09625-x] [Reference Citation Analysis]
404 Jang JH, Lee JW, Hong JT, Jin YJ. Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy. J Hepatocell Carcinoma 2015;2:123-9. [PMID: 27508201 DOI: 10.2147/JHC.S44380] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
405 Du F, Jiang R, Gu M, He C, Guan J. The clinical application of 320-detector row CT in transcatheter arterial chemoembolization (TACE) for hepatocellular carcinoma. Radiol med 2015;120:690-4. [DOI: 10.1007/s11547-015-0523-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
406 Goggi JL, Ramasamy B, Tan YX, Hartimath SV, Tang JR, Cheng P, Msallam R, Chacko A, Hwang YY, Robins EG, Bogdanov A. Granzyme B PET Imaging Stratifies Immune Checkpoint Inhibitor Response in Hepatocellular Carcinoma. Molecular Imaging 2021;2021:1-8. [DOI: 10.1155/2021/9305277] [Reference Citation Analysis]
407 Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baère T, Dodd GD. Image-guided tumor ablation: standardization of terminology and reporting criteria--a 10-year update. J Vasc Interv Radiol. 2014;25:1691-705.e4. [PMID: 25442132 DOI: 10.1016/j.jvir.2014.08.027] [Cited by in Crossref: 253] [Cited by in F6Publishing: 243] [Article Influence: 31.6] [Reference Citation Analysis]
408 Iezzi R, Pompili M, Rinninella E, Annicchiarico E, Garcovich M, Cerrito L, Ponziani F, De Gaetano A, Siciliano M, Basso M, Zocco MA, Rapaccini G, Posa A, Carchesio F, Biolato M, Giuliante F, Gasbarrini A, Manfredi R; HepatoCatt Study Group. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib. Eur Radiol. 2019;29:1285-1292. [PMID: 30171360 DOI: 10.1007/s00330-018-5692-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
409 Li J, Zhang L, Sun Z, Ge Y, Xiao H, Xie Q, Hu S. Iodine-125 seed implantation for residual hepatocellular carcinoma or cholangiocellular carcinoma in challenging locations after transcatheter arterial chemoembolization: Initial experience and findings. J Contemp Brachytherapy 2020;12:233-40. [PMID: 32695194 DOI: 10.5114/jcb.2020.96863] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
410 Kim SH, Won KS, Choi BW, Jo I, Zeon SK, Chung WJ, Kwon JH. Usefulness of F-18 FDG PET/CT in the Evaluation of Early Treatment Response After Interventional Therapy for Hepatocellular Carcinoma. Nucl Med Mol Imaging. 2012;46:102-110. [PMID: 24900042 DOI: 10.1007/s13139-012-0138-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
411 Pitton MB, Kloeckner R, Ruckes C, Wirth GM, Eichhorn W, Wörns MA, Weinmann A, Schreckenberger M, Galle PR, Otto G, Dueber C. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2015;38:352-60. [PMID: 25373796 DOI: 10.1007/s00270-014-1012-0] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 6.5] [Reference Citation Analysis]
412 Tampaki M, Ionas E, Hadziyannis E, Deutsch M, Malagari K, Koskinas J. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 31952209 DOI: 10.3390/cancers12010212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
413 Reig M, Torres F, Rodriguez-lope C, Forner A, Llarch N, Rimola J, Darnell A, Ríos J, Ayuso C, Bruix J. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. Journal of Hepatology 2014;61:318-24. [DOI: 10.1016/j.jhep.2014.03.030] [Cited by in Crossref: 146] [Cited by in F6Publishing: 142] [Article Influence: 18.3] [Reference Citation Analysis]
414 Groisberg R, Hong DS, Holla V, Janku F, Piha-Paul S, Ravi V, Benjamin R, Kumar Patel S, Somaiah N, Conley A, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S, Herzog C, Meric-Bernstam F, Subbiah V. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget 2017;8:39254-67. [PMID: 28424409 DOI: 10.18632/oncotarget.16845] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 8.8] [Reference Citation Analysis]
415 Akutsu N, Sasaki S, Takagi H, Motoya M, Shitani M, Igarashi M, Hirayama D, Wakasugi H, Yamamoto H, Kaneto H, Yonezawa K, Yawata A, Adachi T, Hamamoto Y, Shinomura Y. Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy. Int J Clin Oncol 2015;20:105-10. [PMID: 24744262 DOI: 10.1007/s10147-014-0691-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
416 Facciorusso A, Del Prete V, Antonino M, Crucinio N, Neve V, Di Leo A, Carr BI, Barone M. Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. Dig Liver Dis. 2014;46:1014-1019. [PMID: 25085684 DOI: 10.1016/j.dld.2014.07.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 5.0] [Reference Citation Analysis]
417 Bae JS, Lee JM, Yoon JH, Kang HJ, Jeon SK, Joo I, Lee KB, Kim H. Evaluation of LI-RADS Version 2018 Treatment Response Algorithm for Hepatocellular Carcinoma in Liver Transplant Candidates: Intraindividual Comparison between CT and Hepatobiliary Agent-enhanced MRI. Radiology 2021;299:336-45. [PMID: 33650901 DOI: 10.1148/radiol.2021203537] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
418 Vande Lune P, Abdel Aal AK, Klimkowski S, Zarzour JG, Gunn AJ. Hepatocellular Carcinoma: Diagnosis, Treatment Algorithms, and Imaging Appearance after Transarterial Chemoembolization. J Clin Transl Hepatol 2018;6:175-88. [PMID: 29951363 DOI: 10.14218/JCTH.2017.00045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
419 Bujold A, Dawson LA. Stereotactic radiation therapy and selective internal radiation therapy for hepatocellular carcinoma. Cancer Radiother. 2011;15:54-63. [PMID: 21239204 DOI: 10.1016/j.canrad.2010.11.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
420 Halazun KJ, Sapisochin G, von Ahrens D, Agopian VG, Tabrizian P. Predictors of outcome after liver transplantation for hepatocellular carcinoma (HCC) beyond Milan criteria. Int J Surg. 2020;82S:61-69. [PMID: 32707331 DOI: 10.1016/j.ijsu.2020.07.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 Kim N, Kim HJ, Won JY, Kim DY, Han KH, Jung I, Seong J. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma. Radiother Oncol. 2019;131:81-87. [PMID: 30773192 DOI: 10.1016/j.radonc.2018.12.013] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 8.8] [Reference Citation Analysis]
422 Boatta E, Corona M, Cannavale A, Fanelli F, Cirelli C, de Medici L. Endovascular treatment of hepatocellular carcinoma with drug eluting microparticles (DC-Beads): CT evaluation of response to the treatment. Indian J Radiol Imaging 2013;23:126-33. [PMID: 24082476 DOI: 10.4103/0971-3026.116564] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
423 Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M. Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation. World J Gastroenterol 2017;23:3690-701. [PMID: 28611522 DOI: 10.3748/wjg.v23.i20.3690] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
424 Spina JC, Hume I, Pelaez A, Peralta O, Quadrelli M, Garcia Monaco R. Expected and Unexpected Imaging Findings after 90Y Transarterial Radioembolization for Liver Tumors. Radiographics 2019;39:578-95. [PMID: 30844345 DOI: 10.1148/rg.2019180095] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
425 Lee JH, Lee IJ, Kim HB, Park B, Kim BH, Park JW, Kim CM. Efficacy and safety of transarterial chemoembolisation with cone-beam CT in patients with hepatocellular carcinoma within the Milan criteria: a retrospective cohort study. Clin Radiol 2019;74:407.e19-28. [PMID: 30837076 DOI: 10.1016/j.crad.2019.01.024] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
426 Liu B, Chen H, Li W; Cochrane Hepato-Biliary Group. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013345] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
427 Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study. Hepatology 2021;74:2342-52. [PMID: 33739462 DOI: 10.1002/hep.31819] [Cited by in Crossref: 50] [Cited by in F6Publishing: 33] [Article Influence: 50.0] [Reference Citation Analysis]
428 Dorn DP, Bryant MK, Zarzour J, Smith JK, Redden DT, Saddekni S, Abdel Aal AK, Gray S, White J, Eckhoff DE, DuBay DA. Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function. HPB (Oxford) 2014;16:648-55. [PMID: 25072067 DOI: 10.1111/hpb.12194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
429 Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12(10): 738-753 [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
430 Bera K, Velcheti V, Madabhushi A. Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications. Am Soc Clin Oncol Educ Book 2018;38:1008-18. [PMID: 30231314 DOI: 10.1200/EDBK_199747] [Cited by in Crossref: 28] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
431 Guo Z, Zhong N, Xu X, Zhang Y, Luo X, Zhu H, Zhang X, Wu D, Qiu Y, Tu F. Prediction of Hepatocellular Carcinoma Response to Transcatheter Arterial Chemoembolization: A Real-World Study Based on Non-Contrast Computed Tomography Radiomics and General Image Features. J Hepatocell Carcinoma 2021;8:773-82. [PMID: 34277508 DOI: 10.2147/JHC.S316117] [Reference Citation Analysis]
432 Shunmugaperumal T, Thenrajan RS, Sharma R. Multifunctional nanosized emulsions for theragnosis of life threatening diseases. Nanostructures for Drug Delivery. Elsevier; 2017. pp. 579-617. [DOI: 10.1016/b978-0-323-46143-6.00019-1] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
433 Hidaka H, Nakazawa T, Kaneko T, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Watanabe M, Shibuya A, Koizumi W. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study. J Gastroenterol 2012;47:1030-5. [DOI: 10.1007/s00535-012-0563-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
434 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Naganuma A, Tanaka T, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group., HCC 48 Group (Hepatocellular Carcinoma Experts from 48 Clinics in Japan. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis. Hepatol Res 2022;52:308-16. [PMID: 34799975 DOI: 10.1111/hepr.13734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
435 Leal JN, Gonen M, Covey AM, Erinjeri JP, Getrajdman G, Sofocleous CT, D'Angelica M, DeMatteo RP, Abou-Alfa GK, Jarnagin WR, Fong Y, Brown KT. Locoregional Therapy for Hepatocellular Carcinoma with and without Extrahepatic Spread. J Vasc Interv Radiol 2015;26:1112-21. [PMID: 26038273 DOI: 10.1016/j.jvir.2015.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
436 Arora A, Kumar A. Treatment Response Evaluation and Follow-up in Hepatocellular Carcinoma. J Clin Exp Hepatol. 2014;4:S126-S129. [PMID: 25755604 DOI: 10.1016/j.jceh.2014.05.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
437 Colecchia A, Schiumerini R, Cucchetti A, Cescon M, Taddia M, Marasco G, Festi D. Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol 2014; 20(20): 5935-5950 [PMID: 24876717 DOI: 10.3748/wjg.v20.i20.5935] [Cited by in CrossRef: 96] [Cited by in F6Publishing: 97] [Article Influence: 12.0] [Reference Citation Analysis]
438 Wang PM, Hsu WC, Chung NN, Chang FL, Jang CJ, Fogliata A, Scorsetti M, Cozzi L. Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular carcinoma patients. Radiat Oncol 2014;9:18. [PMID: 24410988 DOI: 10.1186/1748-717X-9-18] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
439 Covey AM, Hussain SM. Liver-Directed Therapy for Hepatocellular Carcinoma: An Overview of Techniques, Outcomes, and Posttreatment Imaging Findings. American Journal of Roentgenology 2017;209:67-76. [DOI: 10.2214/ajr.17.17799] [Cited by in Crossref: 16] [Cited by in F6Publishing: 6] [Article Influence: 3.2] [Reference Citation Analysis]
440 Nojiri S, Kusakabe A, Fujiwara K, Shinkai N, Matsuura K, Iio E, Miyaki T, Nomura T, Sobue S, Sano H, Hasegawa I, Ohno T, Takahashi Y, Orito E, Joh T. Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma. Cancer Manag Res 2012;4:423-9. [PMID: 23293537 DOI: 10.2147/CMAR.S38684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
441 Zhou B, He N, Hong J, Yang T, Ng DM, Gao X, Yan K, Fan X, Zheng Z, Chen P, Zheng J, Zheng Q. HIFU for the treatment of gastric cancer with liver metastases with unsuitable indications for hepatectomy and radiofrequency ablation: a prospective and propensity score-matched study. BMC Surg 2021;21:308. [PMID: 34253213 DOI: 10.1186/s12893-021-01307-y] [Reference Citation Analysis]
442 Galle PR, Tovoli F, Foerster F, Wörns MA, Cucchetti A, Bolondi L. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. J Hepatol 2017;67:173-83. [PMID: 28323121 DOI: 10.1016/j.jhep.2017.03.007] [Cited by in Crossref: 100] [Cited by in F6Publishing: 108] [Article Influence: 20.0] [Reference Citation Analysis]
443 Agopian VG, Morshedi MM, Mcwilliams J, Harlander-locke MP, Markovic D, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Hiatt JR, Busuttil RW. Complete Pathologic Response to Pretransplant Locoregional Therapy for Hepatocellular Carcinoma Defines Cancer Cure After Liver Transplantation: Analysis of 501 Consecutively Treated Patients. Annals of Surgery 2015;262:536-45. [DOI: 10.1097/sla.0000000000001384] [Cited by in Crossref: 69] [Cited by in F6Publishing: 37] [Article Influence: 9.9] [Reference Citation Analysis]
444 Kaneko S, Tsuchiya K, Kurosaki M, Kirino S, Inada K, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Watakabe K, Okada M, Wang W, Shimizu T, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Izumi N. Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. Hepatol Res 2019;50:137-43. [DOI: 10.1111/hepr.13416] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
445 Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:3351. [PMID: 35884412 DOI: 10.3390/cancers14143351] [Reference Citation Analysis]
446 Brunocilla PR, Brunello F, Carucci P, Gaia S, Rolle E, Cantamessa A, Castiglione A, Ciccone G, Rizzetto M. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol. 2013;30:345. [PMID: 23263829 DOI: 10.1007/s12032-012-0345-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
447 Salman A, Simoneau E, Hassanain M, Chaudhury P, Boucher LM, Valenti D, Cabrera T, Nudo C, Metrakos P. Combined sorafenib and yttrium-90 radioembolization for the treatment of advanced hepatocellular carcinoma. Curr Oncol 2016;23:e472-80. [PMID: 27803608 DOI: 10.3747/co.23.2827] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
448 Gerwing M, Krähling T, Schliemann C, Harrach S, Schwöppe C, Berdel AF, Klein S, Hartmann W, Wardelmann E, Heindel WL, Lenz G, Berdel WE, Wildgruber M. Multiparametric Magnetic Resonance Imaging for Immediate Target Hit Assessment of CD13-Targeted Tissue Factor tTF-NGR in Advanced Malignant Disease. Cancers (Basel) 2021;13:5880. [PMID: 34884988 DOI: 10.3390/cancers13235880] [Reference Citation Analysis]
449 Kim JH, Choi EK, Yoon HK, Ko GY, Sung KB, Gwon DI. Transcatheter arterial chemoembolization for hepatic recurrence after curative resection of pancreatic adenocarcinoma. Gut Liver 2010;4:384-8. [PMID: 20981218 DOI: 10.5009/gnl.2010.4.3.384] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
450 Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, Brown DB, Walker TG, Silberzweig JE, Baerlocher MO, Echenique AM, Midia M, Mitchell JW, Padia SA, Ganguli S, Ward TJ, Weinstein JL, Nikolic B, Dariushnia SR; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol 2017;28:1210-1223.e3. [PMID: 28669744 DOI: 10.1016/j.jvir.2017.04.025] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
451 Kuo YH, Yen YH, Chen YY, Kee KM, Hung CH, Lu SN, Hu TH, Chen CH, Wang JH. Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure. Front Oncol 2021;11:683341. [PMID: 34136408 DOI: 10.3389/fonc.2021.683341] [Reference Citation Analysis]
452 Sabet A, Ahmadzadehfar H, Bruhman J, Sabet A, Meyer C, Wasmuth JC, Pieper CC, Biersack HJ, Ezziddin S. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET. Nuklearmedizin. 2014;53:39-45. [PMID: 24777354 DOI: 10.3413/nukmed-0622-13-09] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
453 Syha R, Grözinger G, Grosse U, Maurer M, Zender L, Horger M, Nikolaou K, Ketelsen D. C-arm computed tomography parenchymal blood volume measurement in evaluation of hepatocellular carcinoma before transarterial chemoembolization with drug eluting beads. Cancer Imaging. 2015;15:22. [PMID: 26715200 DOI: 10.1186/s40644-015-0057-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
454 Kim HC, Kim YJ, Lee JH, Suh KS, Chung JW. Feasibility of Boosted Radioembolization for Hepatocellular Carcinoma Larger than 5 cm. J Vasc Interv Radiol 2019;30:1-8. [PMID: 30293734 DOI: 10.1016/j.jvir.2018.07.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
455 Yang Y, Lin K, Liu L, Qian Y, Yang Y, Yuan S, Zhu P, Huang J, Liu F, Gu F, Fu S, Jiang B, Liu H, Pan Z, Lau WY, Zhou W. Impact of preoperative TACE on incidences of microvascular invasion and long-term post-hepatectomy survival in hepatocellular carcinoma patients: A propensity score matching analysis. Cancer Med 2021;10:2100-11. [PMID: 33650288 DOI: 10.1002/cam4.3814] [Reference Citation Analysis]
456 Tang A, Cruite I, Mitchell DG, Sirlin CB. Hepatocellular carcinoma imaging systems: why they exist, how they have evolved, and how they differ. Abdom Radiol (NY) 2018;43:3-12. [PMID: 28840293 DOI: 10.1007/s00261-017-1292-3] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
457 Minami Y, Yagyu Y, Murakami T, Kudo M. Tracking Navigation Imaging of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using Three-Dimensional Cone-Beam CT Angiography. Liver Cancer. 2014;3:53-61. [PMID: 24804177 DOI: 10.1159/000343858] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
458 Geier A, Schadde E, Müllhaupt B. [Current therapeutic strategies for hepatocellular carcinoma]. MMW Fortschr Med 2012;154:63-7; quiz 68-9. [PMID: 22957387 DOI: 10.1007/s15006-012-0931-4] [Reference Citation Analysis]
459 N'Kontchou G, Nault JC, Sutter O, Bourcier V, Coderc E, Grando V, Nahon P, Ganne-Carrié N, Diallo A, Sellier N, Seror O. Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results. Liver Cancer 2019;8:172-85. [PMID: 31192154 DOI: 10.1159/000489319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
460 Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S. Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis. Clin Exp Gastroenterol 2020;13:385-96. [PMID: 33061517 DOI: 10.2147/CEG.S256691] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
461 Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35152830 DOI: 10.1080/13543784.2022.2042253] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
462 Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, Yevich S, Joskin J, Gelli M, Barbé R, Lamartina L, Tissot H, Scoazec JY, Malka D, Ducreux M, Baudin E, de Baère T, Tselikas L. Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. Cancers (Basel) 2021;13:5366. [PMID: 34771531 DOI: 10.3390/cancers13215366] [Reference Citation Analysis]
463 Seki A, Hori S, Shimono C. Management of vascular lake phenomenon on angiography during chemoembolization with superabsorbent polymer microspheres. Jpn J Radiol. 2015;33:741-748. [PMID: 26493810 DOI: 10.1007/s11604-015-0486-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
464 Zhan C, Ruohoniemi D, Shanbhogue KP, Wei J, Welling TH, Gu P, Park JS, Dagher NN, Taslakian B, Hickey RM. Safety of Combined Yttrium-90 Radioembolization and Immune Checkpoint Inhibitor Immunotherapy for Hepatocellular Carcinoma. J Vasc Interv Radiol 2020;31:25-34. [PMID: 31422022 DOI: 10.1016/j.jvir.2019.05.023] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
465 Yoo SH, Kwon JH, Nam SW, Lee JY, Kim YW, Shim DJ, Lee SW, Jang JW. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin. Cancer Control 2020;27:1073274820935843. [PMID: 32583687 DOI: 10.1177/1073274820935843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Kuo YC, Kohi MP, Naeger DM, Tong RT, Kolli KP, Taylor AG, Laberge JM, Kerlan RK, Fidelman N. Efficacy of TACE in TIPS patients: comparison of treatment response to chemoembolization for hepatocellular carcinoma in patients with and without a transjugular intrahepatic portosystemic shunt. Cardiovasc Intervent Radiol. 2013;36:1336-1343. [PMID: 23864021 DOI: 10.1007/s00270-013-0698-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
467 Teng W, Jeng WJ, Yang HI, Chen WT, Hsieh YC, Huang CH, Lin CC, Lin CY, Lin SM, Sheen IS. Interferon Is Superior to Direct Acting Antiviral Therapy in Tertiary Prevention of Early Recurrence of Hepatocellular Carcinoma. Cancers (Basel) 2019;12:E23. [PMID: 31861706 DOI: 10.3390/cancers12010023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
468 Meriggi F, Graffeo M. Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. Cancers (Basel) 2021;13:584. [PMID: 33540870 DOI: 10.3390/cancers13030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
469 El-Gazzaz G, Sourianarayanane A, Menon KVN, Sanabria J, Hashimoto K, Quintini C, Kelly D, Eghtesad B, Miller C, Fung J. Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies. Hepatobiliary & Pancreatic Diseases International. 2013;12:34-41. [PMID: 23392796 DOI: 10.1016/s1499-3872(13)60003-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
470 Halappa VG, Bonekamp S, Corona-Villalobos CP, Li Z, Mensa M, Reyes D, Eng J, Bhagat N, Pawlik TM, Geschwind JF. Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology. 2012;264:285-294. [PMID: 22627601 DOI: 10.1148/radiol.12112142] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
471 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Aujay G, Etchegaray C, Blanc J, Lapuyade B, Papadopoulos P, Pey M, Bordenave L, Trillaud H, Saut O, Pinaquy J. Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma. Diagnostic and Interventional Imaging 2022. [DOI: 10.1016/j.diii.2022.01.009] [Reference Citation Analysis]
473 Zhao M, Li X, Wang J, Li W, Huang Z. Retroperitoneal schwannoma treated with percutaneous computed tomography-guided radiofrequency ablation. J Neurosurg Spine 2012;17:173-6. [PMID: 22657948 DOI: 10.3171/2012.4.SPINE111061] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
474 Sasaki R, Nagata K, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Soyama A, Hidaka M, Eguchi S, Shigeno M, Yamashima M, Yamamichi S, Ichikawa T, Kugiyama Y, Yatsuhashi H, Nakao K. Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma. Cancers 2022;14:827. [DOI: 10.3390/cancers14030827] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
475 Zheng JS, Long J, Sun B, Lu NN, Fang D, Zhao LY, Du N. Transcatheter arterial chemoembolization combined with radiofrequency ablation can improve survival of patients with hepatocellular carcinoma with portal vein tumour thrombosis: extending the indication for ablation? Clin Radiol. 2014;69:e253-e263. [PMID: 24581962 DOI: 10.1016/j.crad.2014.01.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
476 Kudo M, Ikeda M, Takayama T, Numata K, Izumi N, Furuse J, Okusaka T, Kadoya M, Yamashita S, Ito Y, Kokudo N. Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. J Gastroenterol 2016;51:1150-60. [PMID: 27106231 DOI: 10.1007/s00535-016-1204-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
477 Li X, Zhang X, Shi L, Huang G, Lin M, Xie X, Xu M. Feeding Vessel Ablation: A Novel Subsegmental Devascularization Technique for the Treatment of Hepatocellular Carcinoma Located at the Liver Marginal Angle. Ultrasound Med Biol 2021:S0301-5629(21)00490-7. [PMID: 34972571 DOI: 10.1016/j.ultrasmedbio.2021.11.011] [Reference Citation Analysis]
478 Monsky W, Keravnou C, Averkiou M. Contrast-enhanced ultrasound to ultrasound fusion during microwave ablation: feasibility study in a perfused porcine liver model. J Ultrasound 2019;22:323-35. [PMID: 30811016 DOI: 10.1007/s40477-019-00366-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
479 Yang Z, Chen G, Cui Y, Xiao G, Su T, Yu J, Zhang Z, Han Y, Yang K, Jin L. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study. Cancer Biol Ther 2019;20:321-7. [PMID: 30332553 DOI: 10.1080/15384047.2018.1529099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
480 Kim TH, Park JW, Kim YJ, Kim BH, Woo SM, Moon SH, Kim SS, Lee WJ, Kim DY, Kim CM. Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol 2014;190:882-90. [PMID: 24638270 DOI: 10.1007/s00066-014-0643-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
481 Cho CW, Choi GS, Kim JM, Kwon CHD, Kim DJ, Joh JW. Clinical usefulness of transarterial chemoembolization response prior to liver transplantation as predictor of optimal timing for living donor liver transplantation. Ann Surg Treat Res 2018;95:111-20. [PMID: 30079328 DOI: 10.4174/astr.2018.95.2.111] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
482 Kang WH, Hwang S, Song GW, Lee YJ, Kim KH, Ahn CS, Moon DB, Jung DH, Park GC, Lee SG. Prognostic effect of transarterial chemoembolization-induced complete pathological response in patients undergoing liver resection and transplantation for hepatocellular carcinoma. Liver Transpl 2017;23:781-90. [PMID: 28240808 DOI: 10.1002/lt.24752] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
483 Ou MC, Liu YS, Chuang MT, Lin CY, Huang LT, Lin CY. Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolisation in patients with large hepatocellular carcinoma. Clin Radiol 2019;74:295-300. [PMID: 30635122 DOI: 10.1016/j.crad.2018.12.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
484 Giorgio A, Amendola F, Calvanese A, Ingenito E, Santoro B, Gatti P, Ciracì E, Matteucci P, Giorgio V. Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy. J Ultrasound 2019;22:53-8. [PMID: 30843171 DOI: 10.1007/s40477-019-00372-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
485 Xiao L, Liu Q, Zhao W, Pang H, Zeng Q, Chen Y, Zhao J, Mei Q, He X. Chemoembolisation with polyvinyl alcohol for advanced hepatocellular carcinoma with portal vein tumour thrombosis and arterioportal shunts: efficacy and prognostic factors. Clin Radiol 2018;73:1056.e17-22. [PMID: 30224186 DOI: 10.1016/j.crad.2018.08.002] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
486 Jeong SO, Kim EB, Jeong SW, Jang JY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim YJ, Goo DE, Park SY. Predictive Factors for Complete Response and Recurrence after Transarterial Chemoembolization in Hepatocellular Carcinoma. Gut Liver 2017;11:409-16. [PMID: 28208001 DOI: 10.5009/gnl16001] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
487 Choi WS, Chang W, Lee M, Hur S, Kim HC, Jae HJ, Chung JW, Choi JW. Spectral CT-Based Iodized Oil Quantification to Predict Tumor Response Following Chemoembolization of Hepatocellular Carcinoma. J Vasc Interv Radiol 2021;32:16-22. [PMID: 33162309 DOI: 10.1016/j.jvir.2020.09.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
488 Li J, Xie Q, Wang W, Hua Y, Cheng Y, Li L, Zhu X. CT-guided implantation of 125I seeds (permanent brachytherapy) for metastatic tumors of the hepatic portal system: Effectiveness and safety in 13 patients. Brachytherapy 2016;15:224-30. [DOI: 10.1016/j.brachy.2015.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
489 Song MJ, Chun HJ, Song DS, Kim HY, Yoo SH, Park CH, Bae SH, Choi JY, Chang UI, Yang JM, Lee HG, Yoon SK. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57:1244-1250. [PMID: 22824821 DOI: 10.1016/j.jhep.2012.07.017] [Cited by in Crossref: 135] [Cited by in F6Publishing: 141] [Article Influence: 13.5] [Reference Citation Analysis]
490 Lin J, Li X, Shi X, Zhang L, Liu H, Liu J, Wang K, Shen F. Nomogram for predicting pathologic complete response after transarterial chemoembolization in patients with hepatocellular carcinoma. Ann Transl Med 2021;9:1130. [PMID: 34430571 DOI: 10.21037/atm-21-1120] [Reference Citation Analysis]
491 Page AJ, Cosgrove DC, Philosophe B, Pawlik TM. Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2014;23:289-311. [DOI: 10.1016/j.soc.2013.10.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 5.0] [Reference Citation Analysis]
492 Yamashita H, Onishi H, Murakami N, Matsumoto Y, Matsuo Y, Nomiya T, Nakagawa K. Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma. J Radiat Res. 2015;56:561-567. [PMID: 25691453 DOI: 10.1093/jrr/rru130] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.9] [Reference Citation Analysis]
493 Herreras J, Di Maira T, Vinaixa C, San Juan F, Rubín Á, Berenguer M. Milan-out Criteria and Worse Intention-to-Treat Outcome Postliver Transplantation. Transplant Direct 2019;5:e487. [PMID: 31723582 DOI: 10.1097/TXD.0000000000000934] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
494 Fields TD, Philips P, Scoggins CR, Tatum C, Kelly L, Mcmasters KM, Martin RCG. Multi-disciplinary Concurrent Management of Recurrent Hepatocellular Therapy is Superior to Sequential Therapy. World J Surg 2017;41:1331-9. [DOI: 10.1007/s00268-016-3844-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
495 Mazzeo S, Cervelli R, Elisei R, Tarantini G, Cappelli C, Molinaro E, Galleri D, De Napoli L, Comite C, Cioni R, Vitti P, Caramella D. mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study. J Endocrinol Invest 2018;41:1389-99. [PMID: 29687416 DOI: 10.1007/s40618-018-0886-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
496 Mähringer‐kunz A, Wagner F, Hahn F, Weinmann A, Brodehl S, Schotten S, Hinrichs JB, Düber C, Galle PR, Pinto dos Santos D, Kloeckner R. Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study. Liver Int 2019;40:694-703. [DOI: 10.1111/liv.14380] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
497 Yaghmai V, Miller FH, Rezai P, Benson AB 3rd, Salem R. Response to treatment series: part 2, tumor response assessment--using new and conventional criteria. AJR Am J Roentgenol 2011;197:18-27. [PMID: 21701006 DOI: 10.2214/AJR.11.6581] [Cited by in Crossref: 42] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
498 Adhoute X, Penaranda G, Raoul JL, Sellier F, Castellani P, Oules V, Perrier H, Lefolgoc G, Pol B, Campanile M. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol. 2018;30:368-375. [PMID: 29384796 DOI: 10.1097/meg.0000000000001082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
499 Badar W, Van Ha T, Zangan S, Navuluri R, Pillai A, Baker T, Ahmed O. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. Gastrointest Tumors 2020;7:144-50. [PMID: 33173778 DOI: 10.1159/000508386] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
500 Mu L, Chapiro J, Stringam J, Geschwind JF. Interventional Oncology in Hepatocellular Carcinoma: Progress Through Innovation. Cancer J 2016;22:365-72. [PMID: 27870678 DOI: 10.1097/PPO.0000000000000227] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
501 Lock M, Malayeri AA, Mian OY, Mayr NA, Herman JM, Lo SS. Computed tomography imaging assessment of postexternal beam radiation changes of the liver. Future Oncol 2016;12:2729-39. [PMID: 27576360 DOI: 10.2217/fon-2016-0165] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
502 Fleckenstein FN, Schernthaner RE, Duran R, Sohn JH, Sahu S, Zhao Y, Hamm B, Gebauer B, Lin M, Geschwind JF, Chapiro J. 3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival. Eur Radiol 2016;26:3243-52. [PMID: 26762942 DOI: 10.1007/s00330-015-4168-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
503 Zhang YF, Guo RP, OuYang HY, Shen JX, Zhao J, Tan GS, Le Y, Wei W, Shi M. Target lesion response predicts survival of patients with hepatocellular carcinoma retreated with transarterial chemoembolization. Liver Int 2016;36:1516-24. [PMID: 27105296 DOI: 10.1111/liv.13149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
504 Hayano K, Fuentes-Orrego JM, Sahani DV. New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol 2014; 20(12): 3059-3068 [PMID: 24696594 DOI: 10.3748/wjg.v20.i12.3059] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
505 Patidar Y, Mukund A, Sarin SK; Basavaraj 1. Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Tertiary Care Center Experience. Indian J Radiol Imaging 2021;31:270-6. [PMID: 34556907 DOI: 10.1055/s-0041-1734367] [Reference Citation Analysis]
506 Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH. Liver Metastases in the Era of Molecular Targeted Therapy: New Faces of Treatment Response. American Journal of Roentgenology 2013;201:W15-28. [DOI: 10.2214/ajr.12.9498] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
507 Zhao H, Zhai X, Chen Z, Wan X, Chen L, Shen F, Ling C. Transarterial chemoembolization combined with Jie-du granule preparation improves the survival outcomes of patients with unresectable hepatocellular carcinoma. Oncotarget 2017;8:45234-41. [PMID: 28423370 DOI: 10.18632/oncotarget.16804] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
508 Iavarone M, Colombo M. HBV infection and hepatocellular carcinoma. Clin Liver Dis. 2013;17:375-397. [PMID: 23905811 DOI: 10.1016/j.cld.2013.05.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
509 Fiorentini G, Sarti D, Nani R, Aliberti C, Fiorentini C, Guadagni S. Updates of colorectal cancer liver metastases therapy: review on DEBIRI.Hepat Oncol. 2020;7:HEP16. [PMID: 32273974 DOI: 10.2217/hep-2019-0010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
510 Dai QS, Gu HL, Ye S, Zhang YJ, Lin XJ, Lau WY, Peng ZW, Chen MS. Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol Clin Oncol. 2014;2:1047-1054. [PMID: 25279196 DOI: 10.3892/mco.2014.391] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
511 Choi JH, Chung WJ, Bae SH, Song DS, Song MJ, Kim YS, Yim HJ, Jung YK, Suh SJ, Park JY, Kim DY, Kim SU, Cho SB. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol. 2018;82:469-478. [PMID: 29982870 DOI: 10.1007/s00280-018-3638-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 6.5] [Reference Citation Analysis]
512 Gjoreski A, Popova-Jovanovska R, Eftimovska-Rogac I, Vejseli J. Safety Profile and Efficacy of Chemoembolization with Doxorubicin - Loaded Polyethylene Glycol Microspheres in Patients with Hepatocellular Carcinoma. Open Access Maced J Med Sci 2019;7:742-6. [PMID: 30962831 DOI: 10.3889/oamjms.2019.179] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
513 Wang Y, Ma L, Yuan Z, Zheng J, Li W. Percutaneous thermal ablation combined with TACE versus TACE monotherapy in the treatment for liver cancer with hepatic vein tumor thrombus: A retrospective study. PLoS One. 2018;13:e0201525. [PMID: 30063737 DOI: 10.1371/journal.pone.0201525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
514 Liao R, Zhang XD, Li GZ, Qin KL, Yan X. Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma. J Gastrointest Oncol 2020;11:747-59. [PMID: 32953158 DOI: 10.21037/jgo-20-59] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
515 Tipaldi MA, Ronconi E, Lucertini E, Krokidis M, Zerunian M, Polidori T, Begini P, Marignani M, Mazzuca F, Caruso D, Rossi M, Laghi A. Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features. Diagnostics (Basel) 2021;11:956. [PMID: 34073545 DOI: 10.3390/diagnostics11060956] [Reference Citation Analysis]
516 Sacco R. Assessment of radiologic response to targeted therapies in patients with hepatocellular carcinoma. Future Oncol. 2014;10:2073-2079. [PMID: 25396778 DOI: 10.2217/fon.14.92] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
517 Makary MS, Kapke J, Yildiz V, Pan X, Dowell JD. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases. J Vasc Interv Radiol 2016;27:1298-304. [PMID: 27499157 DOI: 10.1016/j.jvir.2016.05.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
518 Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology 2011;140:1410-26. [PMID: 21406195 DOI: 10.1053/j.gastro.2011.03.006] [Cited by in Crossref: 310] [Cited by in F6Publishing: 310] [Article Influence: 28.2] [Reference Citation Analysis]
519 Liu X, Liao G, Luo X, Song W, Zhang H, Chen H, Cai S, Guo D. Hepatocellular Carcinoma With Different Areas of Right Retroperitoneal Space Invasion: Evaluation of Transcatheter Arterial Chemoembolization Efficacy and Blood Supply Characteristics. Front Oncol 2020;10:539692. [PMID: 33072569 DOI: 10.3389/fonc.2020.539692] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
520 Si ZM, Wang GZ, Qian S, Qu XD, Yan ZP, Liu R, Wang JH. Combination Therapies in the Management of Large (≥ 5 cm) Hepatocellular Carcinoma: Microwave Ablation Immediately Followed by Transarterial Chemoembolization. J Vasc Interv Radiol 2016;27:1577-83. [PMID: 27103146 DOI: 10.1016/j.jvir.2016.02.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
521 Wallace MC, Sek K, Francis RJ, Samuelson S, Ferguson J, Tibballs J, Asad A, Preen DB, MacQuillan G, Garas G, Adams LA, Jeffrey GP. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy. Dig Dis Sci 2020;65:647-57. [PMID: 31440998 DOI: 10.1007/s10620-019-05781-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
522 Dalah E, Tai A, Oshima K, Hall WA, Erickson B, Li XA. PET-based Treatment Response Assessment for Neoadjuvant Chemoradiation in Pancreatic Adenocarcinoma: An Exploratory Study. Transl Oncol 2018;11:1104-9. [PMID: 30015263 DOI: 10.1016/j.tranon.2018.06.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
523 Campani C, Vitale A, Dragoni G, Arena U, Laffi G, Cillo U, Giannini EG, Tovoli F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Mega A, Guarino M, Gasbarrini A, Svegliati-Baroni G, Foschi FG, Biasini E, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Farinati F, Trevisani F, Marra F. Time-Varying mHAP-III Is the Most Accurate Predictor of Survival in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization. Liver Cancer 2021;10:126-36. [PMID: 33977089 DOI: 10.1159/000513404] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
524 Martin RC 2nd, Scoggins CR, Schreeder M, Rilling WS, Laing CJ, Tatum CM, Kelly LR, Garcia-Monaco RD, Sharma VR, Crocenzi TS, Strasberg SM. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer. 2015;121:3649-3658. [PMID: 26149602 DOI: 10.1002/cncr.29534] [Cited by in Crossref: 76] [Cited by in F6Publishing: 57] [Article Influence: 10.9] [Reference Citation Analysis]
525 Paiella S, De Pastena M, D'Onofrio M, Crinò SF, Pan TL, De Robertis R, Elio G, Martone E, Bassi C, Salvia R. Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. Transl Gastroenterol Hepatol 2018;3:80. [PMID: 30505967 DOI: 10.21037/tgh.2018.10.05] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
526 Piñero F, Thompson MA, Diaz Telli F, Trentacoste J, Padín C, Mendizabal M, Colaci C, Gonzalez Campaña A, Pages J, Montal S, Barreiro M, Fauda M, Podestá G, Perotti JP, Silva M. LI-RADS 4 or 5 categorization may not be clinically relevant for decision-making processes: A prospective cohort study. Ann Hepatol 2020;19:662-7. [PMID: 32683095 DOI: 10.1016/j.aohep.2020.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
527 Choi JH, Seo DW, Song TJ, Park DH, Lee SS, Lee SK, Kim MH. Utility of Contrast-Enhanced Harmonic Endoscopic Ultrasound for the Guidance and Monitoring of Endoscopic Radiofrequency Ablation. Gut Liver 2020;14:826-32. [PMID: 32000466 DOI: 10.5009/gnl19123] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 13.0] [Reference Citation Analysis]
528 Sangro B. Chemoembolization and radioembolization. Best Practice & Research Clinical Gastroenterology 2014;28:909-19. [DOI: 10.1016/j.bpg.2014.08.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
529 Liu G, Xia F, Fan G, Yu J, Bao L, Zhang C, Chi R, Zhang T, Wang L, Shen F, Wang D. Type 2 diabetes mellitus worsens the prognosis of intermediate-stage hepatocellular carcinoma after transarterial chemoembolization. Diabetes Res Clin Pract 2020;169:108375. [PMID: 32827592 DOI: 10.1016/j.diabres.2020.108375] [Reference Citation Analysis]
530 Wu LF, Rao SX, Xu PJ, Yang L, Chen CZ, Liu H, Huang JF, Fu CX, Halim A, Zeng MS. Pre-TACE kurtosis of ADCtotal derived from histogram analysis for diffusion-weighted imaging is the best independent predictor of prognosis in hepatocellular carcinoma. Eur Radiol 2019;29:213-23. [PMID: 29922932 DOI: 10.1007/s00330-018-5482-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
531 Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. Eur J Gastroenterol Hepatol 2021;32:261-8. [PMID: 32282541 DOI: 10.1097/MEG.0000000000001734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
532 Choi TW, Kim HC, Lee JH, Yu SJ, Kang B, Hur S, Lee M, Jae HJ, Chung JW. The Safety and Clinical Outcomes of Chemoembolization in Child-Pugh Class C Patients with Hepatocellular Carcinomas. Korean J Radiol. 2015;16:1283-1293. [PMID: 26576118 DOI: 10.3348/kjr.2015.16.6.1283] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
533 Vesselle G, Quirier-Leleu C, Velasco S, Charier F, Silvain C, Boucebci S, Ingrand P, Tasu JP. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2016;26:1640-1648. [PMID: 26455721 DOI: 10.1007/s00330-015-3982-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
534 Mourad M, Mabrut J, Chellakhi M, Lesurtel M, Prevost C, Ducerf C, Rode A, Merle P, Mornex F, Mohkam K. Neoadjuvant conformal radiotherapy before liver transplantation for hepatocellular carcinoma: a propensity score matched analysis of postoperative morbidity and oncological results. Future Oncology 2019;15:2517-30. [DOI: 10.2217/fon-2019-0127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
535 Cura M, Heithaus E. Efficacy and safety of transarterial chemoembolization with 70- to 150-μm drug-eluting beads alone or in combination with 100- to 300-μm drug-eluting beads. Proc (Bayl Univ Med Cent) 2018;31:428-31. [PMID: 30948972 DOI: 10.1080/08998280.2018.1499363] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
536 Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. [PMID: 29433850 DOI: 10.1016/S0140-6736(18)30207-1] [Cited by in Crossref: 1304] [Cited by in F6Publishing: 854] [Article Influence: 326.0] [Reference Citation Analysis]
537 Tang Q, Huang W, Liang J, Xue J. Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study. Front Oncol 2021;11:646410. [PMID: 34307128 DOI: 10.3389/fonc.2021.646410] [Reference Citation Analysis]
538 Zhong H, Hu R, Jiang YS. Evaluation of short- and medium-term efficacy and complications of ultrasound-guided ablation for small liver cancer. World J Clin Cases 2022; 10(14): 4414-4424 [DOI: 10.12998/wjcc.v10.i14.4414] [Reference Citation Analysis]
539 Kielar A, Fowler KJ, Lewis S, Yaghmai V, Miller FH, Yarmohammadi H, Kim C, Chernyak V, Yokoo T, Meyer J, Newton I, Do RK. Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm. Abdom Radiol (NY) 2018;43:218-30. [PMID: 28780679 DOI: 10.1007/s00261-017-1281-6] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 15.8] [Reference Citation Analysis]
540 Jena R, Narain TA, Singh UP, Srivastava A. Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma. Indian J Urol 2021;37:125-32. [PMID: 34103794 DOI: 10.4103/iju.IJU_268_20] [Reference Citation Analysis]
541 Gonzalez-guindalini FD, Botelho MPF, Harmath CB, Sandrasegaran K, Miller FH, Salem R, Yaghmai V. Assessment of Liver Tumor Response to Therapy: Role of Quantitative Imaging. RadioGraphics 2013;33:1781-800. [DOI: 10.1148/rg.336135511] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 5.3] [Reference Citation Analysis]
542 Zaitoun MMA, Elsayed SB, Zaitoun NA, Soliman RK, Elmokadem AH, Farag AA, Amer M, Hendi AM, Mahmoud NEM, Salah El Deen D, Alsowey AM, Shahin S, Basha MAA. Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma >3-<5 cm. Int J Hyperthermia 2021;38:248-56. [PMID: 33615957 DOI: 10.1080/02656736.2021.1887941] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
543 Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics 2012;6:207-19. [PMID: 22904613 DOI: 10.2147/BTT.S23907] [Cited by in Crossref: 5] [Cited by in F6Publishing: 27] [Article Influence: 0.5] [Reference Citation Analysis]
544 Liu D, Liu M, Su L, Wang Y, Zhang X, Long H, Kuang M, Xie X, Lin M. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome. J Vasc Interv Radiol 2019;30:1879-86. [PMID: 31669087 DOI: 10.1016/j.jvir.2019.07.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
545 Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, Grossi G, Bhoori S, Mazzaferro V. Comparative efficacy of sorafenib vs best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol. 2013;59:59-66. [PMID: 23500153 DOI: 10.1016/j.jhep.2013.02.026] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 9.2] [Reference Citation Analysis]
546 Kellock T, Liang T, Harris A, Schellenberg D, Ma R, Ho S, Yap WW. Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment. Br J Radiol 2018;91:20170118. [PMID: 29334232 DOI: 10.1259/bjr.20170118] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
547 Yang Z, Suda G, Maehara O, Ohara M, Yoshida S, Hosoda S, Kimura M, Kubo A, Tokuchi Y, Fu Q, Yamada R, Kitagataya T, Suzuki K, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Ohnishi S, Sakamoto N. Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2022;14:232. [PMID: 35008398 DOI: 10.3390/cancers14010232] [Reference Citation Analysis]
548 Choo SP, Chowbay B, Ng QS, Thng CH, Lim C, Hartono S, Koh TS, Huynh H, Poon D, Ang MK, Chang S, Toh HC. A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma. Eur J Cancer 2013;49:999-1008. [PMID: 23265712 DOI: 10.1016/j.ejca.2012.11.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
549 Vutien P, Dodge J, Bambha KM, Nordstrom EM, Gralla J, Campbell K, Levek C, Nydam T, Fix O, Ioannou G, Biggins SW. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma–Initial, Maximum, Last Classification. Liver Transpl 2019;25:559-70. [DOI: 10.1002/lt.25422] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
550 Lee BC, Jeong YY, Heo SH, Kim HO, Park C, Shin SS, Cho SB, Koh YS. Gadoxetic Acid-Enhanced MRI Features for Predicting Treatment Outcomes of Early Hepatocellular Carcinoma (< 3 cm) After Transarterial Chemoembolization. Acad Radiol 2022:S1076-6332(21)00483-9. [PMID: 35151549 DOI: 10.1016/j.acra.2021.10.012] [Reference Citation Analysis]
551 He M, Li Q, Zou R, Shen J, Fang W, Tan G, Zhou Y, Wu X, Xu L, Wei W, Le Y, Zhou Z, Zhao M, Guo Y, Guo R, Chen M, Shi M. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 2019;5:953-960. [PMID: 31070690 DOI: 10.1001/jamaoncol.2019.0250] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 31.0] [Reference Citation Analysis]
552 Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, Bae SH, Choi JY, Yoon SK. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol 2017;9:615-26. [PMID: 28974984 DOI: 10.1177/1758834017728018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
553 Liu SF, Lu CR, Cheng HD, Xi HQ, Cui JX, Li JY, Shen WS, Chen L. Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis. Chin Med J (Engl). 2015;128:2194-2201. [PMID: 26265613 DOI: 10.4103/0366-6999.162497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
554 Abdelrahman AS, Ekladious MEY, Badran EM, Madkour SS. Liver imaging reporting and data system (LI-RADS) v2018: Reliability and agreement for assessing hepatocellular carcinoma locoregional treatment response. Diagn Interv Imaging 2022:S2211-5684(22)00118-8. [PMID: 35787988 DOI: 10.1016/j.diii.2022.06.007] [Reference Citation Analysis]
555 Noda S, Iida H, Fujimoto T, Wakasugi Y, Yabuta N, Sudou M, Hira D, Tani M, Andoh A, Morita SY, Terada T. Exploratory analysis of target concentration of lenvatinib in the treatment of hepatocellular carcinoma. Cancer Chemother Pharmacol 2021;88:281-8. [PMID: 33928425 DOI: 10.1007/s00280-021-04286-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
556 Yildiz I, Deniz S, Ozer A, Caliskan K. Trans-Arterial Chemoembolization with 50 μm Degradable Starch Microspheres Versus 300–500 μm Drug Eluting Beads in Hepatocellular Carcinoma: A Comparative Analysis of Initial Treatment Outcomes. Journal of the Belgian Society of Radiology 2022;106:10. [DOI: 10.5334/jbsr.2594] [Reference Citation Analysis]
557 Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy. Radiology. 2013;268:431-439. [PMID: 23616632 DOI: 10.1148/radiol.13121637] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
558 Bock B, Hasdemir D, Wandrer F, Rodt T, Manns MP, Schulze-Osthoff K, Bantel H. Serum cell death biomarker mirrors liver cancer regression after transarterial chemoembolisation. Aliment Pharmacol Ther 2016;44:747-54. [PMID: 27485159 DOI: 10.1111/apt.13758] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
559 Shimose S, Kawaguchi T, Tanaka M, Iwamoto H, Miyazaki K, Moriyama E, Suzuki H, Niizeki T, Shirono T, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Lenvatinib prolongs the progression-free survival time of patients with intermediate-stage hepatocellular carcinoma refractory to transarterial chemoembolization: A multicenter cohort study using data mining analysis. Oncol Lett 2020;20:2257-65. [PMID: 32782543 DOI: 10.3892/ol.2020.11758] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
560 Stippel DL, Wahba R, Bruns CJ, Bunck A, Baues C, Persigehl T. [Image-guided, minimally invasive surgery and other local therapeutic procedures for primary liver tumors]. Chirurg 2018;89:872-9. [PMID: 30030546 DOI: 10.1007/s00104-018-0688-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
561 Kim KW, Krajewski KM, Nishino M, Jagannathan JP, Shinagare AB, Tirumani SH, Ramaiya NH. Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging. AJR Am J Roentgenol 2013;201:811-24. [PMID: 24059370 DOI: 10.2214/AJR.12.10240] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 3.1] [Reference Citation Analysis]
562 Maesaka K, Sakamori R, Yamada R, Tahata Y, Imai Y, Oshita M, Ohkawa K, Kodama T, Hikita H, Tatsumi T, Takehara T. Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma. Hepatol Res 2020;50:1275-83. [PMID: 32812315 DOI: 10.1111/hepr.13556] [Reference Citation Analysis]
563 Hong G, Suh KS, Suh SW, Yoo T, Kim H, Park MS, Choi Y, Paeng JC, Yi NJ, Lee KW. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol. 2016;64:852-859. [PMID: 26658686 DOI: 10.1016/j.jhep.2015.11.033] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
564 Planz VB, Lubner MG, Pickhardt PJ. Volumetric analysis at abdominal CT: oncologic and non-oncologic applications. Br J Radiol 2019;92:20180631. [PMID: 30457881 DOI: 10.1259/bjr.20180631] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
565 Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla A, Sangro B, Rodriguez de Lope C, Sala M, Gonzalez C, Huertas C, Minguez B, Ayuso C, Bruix J, Reig M. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology 2018;67:612-22. [PMID: 28898447 DOI: 10.1002/hep.29515] [Cited by in Crossref: 41] [Cited by in F6Publishing: 34] [Article Influence: 10.3] [Reference Citation Analysis]
566 Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-70. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
567 Cao S, Zou Y, Lyu T, Fan Z, Guan H, Song L, Tong X, Wang J. Long-term outcomes of combined transarterial chemoembolization and radiofrequency ablation versus RFA monotherapy for single hepatocellular carcinoma ≤3 cm: emphasis on local tumor progression. Int J Hyperthermia 2022;39:1-7. [PMID: 34937501 DOI: 10.1080/02656736.2021.1998660] [Reference Citation Analysis]
568 Catalano O, Izzo F, Vallone P, Sandomenico F, Albino V, Nunziata A, Fusco R, Petrillo A. Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience. Acta Radiol 2015;56:133-42. [PMID: 24523360 DOI: 10.1177/0284185114521108] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
569 Galizia MS, Töre HG, Chalian H, McCarthy R, Salem R, Yaghmai V. MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques. Acad Radiol 2012;19:48-54. [PMID: 22054801 DOI: 10.1016/j.acra.2011.09.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
570 Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? Cancers (Basel). 2019;11. [PMID: 30781391 DOI: 10.3390/cancers11020230] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
571 Kamal A, Elmoety AAA, Rostom YA, Shater MS, Lashen SA. Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study. Clin Exp Hepatol 2021;7:66-73. [PMID: 34027117 DOI: 10.5114/ceh.2021.104397] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
572 Raoul JL, Park JW, Kang YK, Finn RS, Kim JS, Yeo W, Polite BN, Chao Y, Walters I, Baudelet C, Lencioni R. Using Modified RECIST and Alpha-Fetoprotein Levels to Assess Treatment Benefit in Hepatocellular Carcinoma. Liver Cancer 2014;3:439-50. [PMID: 26280005 DOI: 10.1159/000343872] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
573 Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Xu HF, Gao QZ, Yang RJ. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma. Immunotherapy 2021;13:1395-405. [PMID: 34607482 DOI: 10.2217/imt-2021-0192] [Reference Citation Analysis]
574 Yuan H, Liu F, Li X, Guan Y, Wang M. Angio-CT-Guided Transarterial Chemoembolization Immediately in Combination with Radiofrequency Ablation for Large Hepatocellular Carcinoma. Acad Radiol 2019;26:224-31. [PMID: 29907399 DOI: 10.1016/j.acra.2018.04.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
575 Faraji F, Gaba RC. Radiologic Modalities and Response Assessment Schemes for Clinical and Preclinical Oncology Imaging. Front Oncol 2019;9:471. [PMID: 31214510 DOI: 10.3389/fonc.2019.00471] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
576 Wang H, Miranda Cona M, Chen F, Li J, Yu J, Feng Y, Peeters R, De Keyzer F, Marchal G, Ni Y. Comparison between nonspecific and necrosis-avid gadolinium contrast agents in vascular disrupting agent-induced necrosis of rodent tumors at 3.0T. Invest Radiol. 2011;46:531-538. [PMID: 21577133 DOI: 10.1097/rli.0b013e31821a2116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
577 Di Costanzo GG, Tortora R, De Luca M, Galeota Lanza A, Lampasi F, Tartaglione MT, Picciotto FP, Imparato M, Mattera S, Cordone G. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol. 2013;30:446. [PMID: 23307255 DOI: 10.1007/s12032-012-0446-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
578 Han Y, Liu J, Pan J, Chen H, Tan N, Kang Q, Yang Y, Xu X, Li W. Prognosis and Risk Factors of Recurrence in HBV-Related Small Hepatocellular Carcinoma After Stereotactic Body Radiation Therapy. Front Oncol 2022;12:903355. [DOI: 10.3389/fonc.2022.903355] [Reference Citation Analysis]
579 Shim JH, Han S, Shin YM, Yu E, Park W, Kim KM, Lim YS, Lee HC. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria. J Vasc Interv Radiol 2013;24:316-25. [PMID: 23312990 DOI: 10.1016/j.jvir.2012.10.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
580 Schoenberg MB, Ehmer U, Umgelter A, Bucher JN, Koch DT, Börner N, Nieß H, Denk G, De Toni EN, Seidensticker M, Andrassy J, Angele MK, Werner J, Guba MO. Liver transplantation versus watchful waiting in hepatocellular carcinoma patients with complete response to bridging therapy - a retrospective observational study. Transpl Int 2021;34:465-73. [PMID: 33368655 DOI: 10.1111/tri.13808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
581 Yu SJ, Kwon JH, Kim W, Yoon J, Lee JM, Lee JY, Cho EJ, Lee J, Kim HY, Jung YJ, Kim YJ. Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. Journal of Clinical Gastroenterology 2018;52:e18-26. [DOI: 10.1097/mcg.0000000000000841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
582 Reicher J, Mafeld S, Priona G, Reeves HL, Manas DM, Jackson R, Littler P. Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead. Cardiovasc Intervent Radiol 2019;42:1563-70. [PMID: 31455987 DOI: 10.1007/s00270-019-02317-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
583 Mastrandrea G, Laface C, Fazio V, Lopetuso M, Falagario G, Molinari P, Ranieri G, Gadaleta CD. A case report of cryoablation and electrochemotherapy in kidney cancer. Medicine (Baltimore) 2021;100:e27730. [PMID: 34766579 DOI: 10.1097/MD.0000000000027730] [Reference Citation Analysis]
584 Lee CH, Hung SP, Hong JH, Chang JT, Tsang NM, Chan KM, Tseng JH, Huang SC, Lin SM, Lien JM, Liu NJ, Lin CC, Chen WT, Chen WY, Chen PJ, Huang BS. How small is TOO small? New liver constraint is needed- Proton therapy of hepatocellular carcinoma patients with small normal liver. PLoS One 2018;13:e0203854. [PMID: 30204800 DOI: 10.1371/journal.pone.0203854] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
585 Fröhlich E, Muller R, Cui X, Schreiber-dietrich D, Dietrich CF. Dynamic Contrast-Enhanced Ultrasound for Quantification of Tissue Perfusion. Journal of Ultrasound in Medicine 2015;34:179-96. [DOI: 10.7863/ultra.34.2.179] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 5.6] [Reference Citation Analysis]
586 Öcal O, Schinner R, Schütte K, de Toni EN, Loewe C, van Delden O, Vandecaveye V, Gebauer B, Zech CJ, Sengel C, Bargellini I, Gasbarrini A, Sangro B, Pech M, Malfertheiner P, Ricke J, Seidensticker M; SORAMIC study group. Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib. Cancer Imaging 2022;22:1. [PMID: 34983668 DOI: 10.1186/s40644-021-00439-x] [Reference Citation Analysis]
587 Ruiz de Galarreta M, Bresnahan E, Molina-Sánchez P, Lindblad KE, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi AD, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst AO, Monga SP, Brown BD, Villanueva A, Llovet JM, Merad M, Lujambio A. β-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma. Cancer Discov 2019;9:1124-41. [PMID: 31186238 DOI: 10.1158/2159-8290.CD-19-0074] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
588 Park HJ, Kim JH, Choi SY, Lee ES, Park SJ, Byun JY, Choi BI. Prediction of Therapeutic Response of Hepatocellular Carcinoma to Transcatheter Arterial Chemoembolization Based on Pretherapeutic Dynamic CT and Textural Findings. AJR Am J Roentgenol. 2017;209:W211-W220. [PMID: 28813195 DOI: 10.2214/ajr.16.17398] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 7.8] [Reference Citation Analysis]
589 Lee JY, Lee BC, Kim HO, Heo SH, Shin SS, Jeong YY. Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma. Sci Rep 2021;11:24076. [PMID: 34911966 DOI: 10.1038/s41598-021-01839-6] [Reference Citation Analysis]
590 Yamaguchi T, Seki T, Inokuchi R, Kawamura R, Murata M, Matsuzaki K, Nakashima O, Kumabe T, Okazaki K. S-1 monotherapy in a patient with cholangiolocellular carcinoma: A case report. Mol Clin Oncol 2016;5:762-6. [PMID: 28105354 DOI: 10.3892/mco.2016.1049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
591 Vernuccio F, Godfrey D, Meyer M, Williamson HV, Salama JK, Niedzwiecki D, Stephens SJ, Ronald J, Palta M, Marin D. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. AJR Am J Roentgenol 2019;213:1232-9. [PMID: 31613663 DOI: 10.2214/AJR.18.20842] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
592 Cucchetti A, Cescon M, Bigonzi E, Piscaglia F, Golfieri R, Ercolani G, Cristina Morelli M, Ravaioli M, Daniele Pinna A. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy. Liver Transpl. 2011;17:1344-1354. [PMID: 21837731 DOI: 10.1002/lt.22397] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 6.7] [Reference Citation Analysis]
593 Chapiro J, Wood LD, Lin M, Duran R, Cornish T, Lesage D, Charu V, Schernthaner R, Wang Z, Tacher V, Savic LJ, Kamel IR, Geschwind JF. Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE: diagnostic accuracy of 3D quantitative image analysis. Radiology 2014;273:746-58. [PMID: 25028783 DOI: 10.1148/radiol.14140033] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 8.5] [Reference Citation Analysis]
594 Taussig MD, Irene Koran ME, Mouli SK, Ahmad A, Geevarghese S, Baker JC, Lipnik AJ, Banovac F, Brown DB. Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma. HPB 2017;19:458-64. [DOI: 10.1016/j.hpb.2017.01.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
595 Zhuang BW, Li W, Xie XH, Hu HT, Lu MD, Xie XY. Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis. Jpn J Clin Oncol 2019;49:845-55. [PMID: 31063184 DOI: 10.1093/jjco/hyz069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
596 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015;7:738-52. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Reference Citation Analysis]
597 Lyu T, Wang J, Cao S, Song L, Tong X, Zou Y. Radiofrequency ablation guided by cone beam computed tomography for hepatocellular carcinoma: a comparative study of clinical results with the conventional spiral computed tomography-guided procedure. J Int Med Res 2019;47:3699-708. [PMID: 31248301 DOI: 10.1177/0300060519858010] [Reference Citation Analysis]
598 Kim SS, Kang TW, Song KD, Cho SK, Lee MW, Rhim H, Sinn DH, Jung SH. Radiofrequency ablation and transarterial chemoembolisation as first-line treatment for recurrent hepatocellular carcinoma or isolated intrahepatic recurrent hepatocellular carcinoma in transplanted livers. Clin Radiol 2017;72:141-9. [PMID: 27742104 DOI: 10.1016/j.crad.2016.09.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
599 Zhang Y, Zhang M, Chen M, Mei J, Xu L, Guo R, Lin X, Li J, Peng Z. Association of Sustained Response Duration With Survival After Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. JAMA Netw Open 2018;1:e183213. [PMID: 30646226 DOI: 10.1001/jamanetworkopen.2018.3213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
600 Shaheen M, Hassanain M, Aljiffry M, Cabrera T, Chaudhury P, Simoneau E, Kongkaewpaisarn N, Salman A, Rivera J, Jamal M. Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis. HPB (Oxford). 2012;14:60-66. [PMID: 22151453 DOI: 10.1111/j.1477-2574.2011.00405.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
601 Shindoh J, Kawamura Y, Kobayashi M, Akuta N, Okubo S, Matsumura M, Suzuki Y, Hashimoto M. Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma. J Gastrointest Surg 2022. [PMID: 35715641 DOI: 10.1007/s11605-022-05388-9] [Reference Citation Analysis]
602 Klompenhouwer EG, Dresen RC, Verslype C, Laenen A, De Hertogh G, Deroose CM, Bonne L, Vandevaveye V, Maleux G. Safety and Efficacy of Transarterial Radioembolisation in Patients with Intermediate or Advanced Stage Hepatocellular Carcinoma Refractory to Chemoembolisation. Cardiovasc Intervent Radiol 2017;40:1882-90. [DOI: 10.1007/s00270-017-1739-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
603 Bucalau AM, Tancredi I, Pezzullo M, Covas A, Verset G. Complete response of a hepatocellular carcinoma with complex macrovascular invasion after combined treatment with chemoembolization and immunotherapy: a case report. Acta Gastroenterol Belg 2021;84:371-4. [PMID: 34217191 DOI: 10.51821/84.2.371] [Reference Citation Analysis]
604 Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67. [PMID: 34694454 DOI: 10.1007/s00270-021-02968-1] [Reference Citation Analysis]
605 Yen CJ, Kim TY, Feng YH, Chao Y, Lin DY, Ryoo BY, Huang DC, Schnell D, Hocke J, Loembé AB, Cheng AL. A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2018;7:165-78. [PMID: 29888206 DOI: 10.1159/000486460] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
606 Kim HY, Kim W, Jung YJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Lee HW, Kim H, Yi NJ, Lee KW, Suh KS. A Model for Adaptive Decision Making of "Ablate-and-Wait" Versus Transplantation in Patients With Hepatocellular Carcinoma. J Clin Gastroenterol 2018;52:655-61. [PMID: 29356782 DOI: 10.1097/MCG.0000000000000981] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
607 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Yada N, Hagiwara S, Minami Y, Ida H, Komeda Y, Takenaka M, Sakurai T, Watanabe T, Nishida N, Kudo M. The Overall Survival of Patients with Hepatocellular Carcinoma Correlates with the Newly Defined Time to Progression after Transarterial Chemoembolization. Liver Cancer 2017;6:227-35. [PMID: 28626733 DOI: 10.1159/000475777] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
608 Schostak M. [When is cytoreductive nephrectomy not beneficial for patients with metastatic renal cell carcinoma?]. Urologe A 2017;56:610-6. [PMID: 28314968 DOI: 10.1007/s00120-017-0363-y] [Reference Citation Analysis]
609 Adam SZ, Miller FH. Imaging of the Liver Following Interventional Therapy for Hepatic Neoplasms. Radiologic Clinics of North America 2015;53:1061-76. [DOI: 10.1016/j.rcl.2015.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
610 Kamran AU, Liu Y, Li FE, Liu S, Wu JL, Zhang YW. Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma: A Single Center Retrospective Study. Medicine (Baltimore) 2015;94:e2154. [PMID: 26717358 DOI: 10.1097/MD.0000000000002154] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
611 Wang H, Zhu X, Zhao Y, Dong D, Li L, Cai Y, Li Y, Wang W. Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma. BMC Cancer 2022;22:771. [PMID: 35840914 DOI: 10.1186/s12885-022-09819-3] [Reference Citation Analysis]
612 Qu S, Zhang X, Wu Y, Meng Y, Pan H, Fang Q, Hu L, Zhang J, Wang R, Wei L, Wu D. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Front Oncol 2022;12:874473. [DOI: 10.3389/fonc.2022.874473] [Reference Citation Analysis]
613 Lee YK, Jung KS, Kim DY, Choi JY, Kim BK, Kim SU, Park JY, Ahn SH, Han KH, Kim GM. Conventional versus drug-eluting beads chemoembolization for hepatocellular carcinoma: Emphasis on the impact of tumor size. J Gastroenterol Hepatol. 2017;32:487-496. [PMID: 27503585 DOI: 10.1111/jgh.13501] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
614 de la Torre AN, Contractor S, Castaneda I, Cathcart CS, Razdan D, Klyde D, Kisza P, Gonzales SF, Salazar AM. A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect. J Hepatocell Carcinoma 2017;4:111-21. [PMID: 28848723 DOI: 10.2147/JHC.S136652] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
615 Kim HM, Kim HC, Woo S, Son KR, Cho SW, Chung JW. Chemoembolization for hepatocellular carcinoma supplied by a lumbar artery. Cardiovasc Intervent Radiol 2015;38:121-8. [PMID: 24849301 DOI: 10.1007/s00270-014-0906-1] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
616 Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, Zhang H, Zhao J, Yao A, Wu X, Wu C, Ji G, Liu X, Zhu F, Qin L, Xiao X, Deng Z, Kong X, Li S, Yu Y, Xi W, Deng W, Qi C, Liu H, Pu L, Wang P, Wang X. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. J Immunother Cancer 2022;10:e004656. [DOI: 10.1136/jitc-2022-004656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
617 Huang J, Huang W, Zhan M, Guo Y, Liang L, Cai M, Lin L, He M, Lian H, Lu L, Zhu K. Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1445-58. [PMID: 34858889 DOI: 10.2147/JHC.S339379] [Reference Citation Analysis]
618 Lai Q, Avolio AW, Graziadei I, Otto G, Rossi M, Tisone G, Goffette P, Vogel W, Pitton MB, Lerut J; on behalf of the European Hepatocellular Cancer Liver Transplant Study Group. Alpha-fetoprotein and modified response evaluation criteria in Solid Tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation: Alpha-Fetoprotein Increase and m RECIST Progression. Liver Transpl 2013;19:1108-18. [DOI: 10.1002/lt.23706] [Cited by in Crossref: 121] [Cited by in F6Publishing: 124] [Article Influence: 13.4] [Reference Citation Analysis]
619 Chang W, Lu S, Rau K, Huang C, Lee K. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients. The Kaohsiung Journal of Medical Sciences 2018;34:391-9. [DOI: 10.1016/j.kjms.2018.03.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
620 Park H, Kim SU, Park JY, Kim DY, Ahn SH, Chon CY, Han KH, Seong J. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. Liver Int. 2014;34:313-321. [PMID: 23895043 DOI: 10.1111/liv.12274] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
621 Ronald J, Gupta RT, Marin D, Wang Q, Durocher NS, Suhocki PV, Kim CY. Progression of Treated versus Untreated Liver Imaging Reporting and Data System Category 4 Masses after Transcatheter Arterial Embolization Therapy. Journal of Vascular and Interventional Radiology 2018;29:598-606. [DOI: 10.1016/j.jvir.2017.11.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
622 Finkelmeier F, Czauderna C, Perkhofer L, Ettrich TJ, Trojan J, Weinmann A, Marquardt JU, Vermehren J, Waidmann O. Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers. J Cancer Res Clin Oncol 2019;145:253-9. [DOI: 10.1007/s00432-018-2780-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
623 Hasan S, Thai N, Uemura T, Kudithipudi V, Renz P, Abel S, Kirichenko AV. Hepatocellular carcinoma with child Pugh-A Cirrhosis treated with stereotactic body radiotherapy. World J Gastrointest Surg 2017; 9(12): 256-263 [PMID: 29359031 DOI: 10.4240/wjgs.v9.i12.256] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
624 Vouche M, Salem R, Lewandowski RJ, Miller FH. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC? Abdom Imaging 2015;40:1471-80. [DOI: 10.1007/s00261-014-0295-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
625 Spada F, Squadroni M, Lorizzo K, Farris A, Fazio N. Clinical Response after Sorafenib for Hepatocellular Carcinoma in Elderly Patients: A Report of Two Cases. Tumori 2012;98:e53-6. [DOI: 10.1177/030089161209800224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
626 Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol 2021:S0168-8278(21)01903-6. [PMID: 34256065 DOI: 10.1016/j.jhep.2021.07.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
627 Facciorusso A, Abd El Aziz MA, Cincione I, Cea UV, Germini A, Granieri S, Cotsoglou C, Sacco R. Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study. Biomedicines 2020;8:E399. [PMID: 33050084 DOI: 10.3390/biomedicines8100399] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
628 Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 Selective Internal Radiation Therapy with Glass Microspheres for Hepatocellular Carcinoma: Current and Updated Literature Review. Korean J Radiol. 2016;17:472-488. [PMID: 27390539 DOI: 10.3348/kjr.2016.17.4.472] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
629 Naganuma A, Hoshino T, Ohno N, Ogawa Y, Murakami T, Horiguchi S, Uehara D, Suzuki Y, Hatanaka T, Kudo T, Ishihara H, Sato K, Kakizaki S, Takagi H. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma. In Vivo 2019;33:155-61. [PMID: 30587616 DOI: 10.21873/invivo.11452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
630 Montalti R, Mimmo A, Rompianesi G, Di Gregorio C, Serra V, Cautero N, Ballarin R, Spaggiari M, Tarantino G, D'Amico G, De Santis M, De Pietri L, Troisi RI, Gerunda GE, Di Benedetto F. Absence of viable HCC in the native liver is an independent protective factor of tumor recurrence after liver transplantation. Transplantation 2014;97:220-6. [PMID: 24056629 DOI: 10.1097/TP.0b013e3182a8607e] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
631 Yang JF, Lo CH, Lee MS, Lin CS, Dai YH, Shen PC, Chao HL, Huang WY. Stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy in the treatment of hepatocellular carcinoma with portal vein invasion: a retrospective analysis. Radiat Oncol 2019;14:180. [PMID: 31640728 DOI: 10.1186/s13014-019-1382-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
632 Hongo F, Yamada Y, Ueda T, Nakmura T, Naya Y, Kamoi K, Okihara K, Ichijo Y, Miki T, Yamada K, Ukimura O. Preoperative lipiodol marking and its role on survival and complication rates of CT-guided cryoablation for small renal masses. BMC Urol 2017;17:10. [PMID: 28100214 DOI: 10.1186/s12894-017-0199-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
633 Kaneko S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Takeguchi T, Takeguchi Y, Nakanishi H, Itakura J, Takahashi Y, Himeno Y, Kurosaki M, Izumi N. Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. JGH Open 2020;4:1183-90. [PMID: 33319054 DOI: 10.1002/jgh3.12420] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
634 Ippolito D, Querques G, Okolicsanyi S, Franzesi CT, Strazzabosco M, Sironi S. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. Eur J Radiol 2017;90:34-41. [PMID: 28583645 DOI: 10.1016/j.ejrad.2017.02.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
635 Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik SW, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC). Liver Int. 2013;33:327-337. [PMID: 23331661 DOI: 10.1111/liv.12083] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
636 Ruzzenente A, Guglielmi A, Sandri M, Campagnaro T, Valdegamberi A, Conci S, Bagante F, Turcato G, D'Onofrio M, Iacono C. Surgical resection versus local ablation for HCC on cirrhosis: results from a propensity case-matched study. J Gastrointest Surg. 2012;16:301-11; discussion 311. [PMID: 22095524 DOI: 10.1007/s11605-011-1745-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
637 White JA, Redden DT, Bryant MK, Dorn D, Saddekni S, Abdel Aal AK, Zarzour J, Bolus D, Smith JK, Gray S, Eckhoff DE, DuBay DA. Predictors of repeat transarterial chemoembolization in the treatment of hepatocellular carcinoma. HPB (Oxford) 2014;16:1095-101. [PMID: 25158123 DOI: 10.1111/hpb.12313] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
638 Sager S, Akgün E, Uslu-beşli L, Asa S, Akovali B, Sahin O, Yeyin N, Demir M, Abuqbeitah M, Gülsen F, Sayman H, Sönmezoglu K. Comparison of PERCIST and RECIST criteria for evaluation of therapy response after yttrium-90 microsphere therapy in patients with hepatocellular carcinoma and those with metastatic colorectal carcinoma. Nuclear Medicine Communications 2019;40:461-8. [DOI: 10.1097/mnm.0000000000001014] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
639 Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano RS. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. Journal of Vascular and Interventional Radiology 2018;29:1369-75. [DOI: 10.1016/j.jvir.2018.04.030] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
640 Eriguchi T, Takeda A, Tateishi Y, Tsurugai Y, Sanuki N, Ebinuma H, Horita N. Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and meta-analysis of propensity score studies. Hepatol Res 2021;51:813-22. [PMID: 33856722 DOI: 10.1111/hepr.13647] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
641 Iwazawa J, Ohue S, Hashimoto N, Mitani T. Comparison of the Number of Image Acquisitions and Procedural Time Required for Transarterial Chemoembolization of Hepatocellular Carcinoma with and without Tumor-Feeder Detection Software. Radiol Res Pract 2013;2013:580839. [PMID: 23984066 DOI: 10.1155/2013/580839] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
642 Granata V, Fusco R, Avallone A, Filice F, Tatangelo F, Piccirillo M, Grassi R, Izzo F, Petrillo A. Critical analysis of the major and ancillary imaging features of LI-RADS on 127 proven HCCs evaluated with functional and morphological MRI: Lights and shadows. Oncotarget 2017;8:51224-37. [PMID: 28881643 DOI: 10.18632/oncotarget.17227] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
643 Cheng RG, Bhattacharya R, Yeh MM, Padia SA. Irreversible Electroporation Can Effectively Ablate Hepatocellular Carcinoma to Complete Pathologic Necrosis. Journal of Vascular and Interventional Radiology 2015;26:1184-8. [DOI: 10.1016/j.jvir.2015.05.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
644 Dobrzycka M, Spychalski P, Rostkowska O, Wilczyński M, Kobiela P, Grąt M, Dell'Acqua V, Høyer M, Jereczek-Fossa BA. Stereotactic body radiation therapy for early-stage hepatocellular carcinoma - a systematic review on outcome. Acta Oncol 2019;58:1706-13. [PMID: 31464155 DOI: 10.1080/0284186X.2019.1657942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
645 Li J, Zhang L, Xu W, Wang T, Zhou L, Xie Q, Wang W, Hua Y. Computed tomography-guided implantation of 125I seeds brachytherapy for recurrent multiple pulmonary oligometastases: initial experience and results. J Contemp Brachytherapy 2017;9:132-8. [PMID: 28533801 DOI: 10.5114/jcb.2017.67023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
646 Li L, Cheng N, Huang X, Weng X, Jiao Y, Liu J, Guo W. Efficacy and safety of endovascular brachytherapy combined with transarterial chemoembolization for the treatment of hepatocellular carcinoma patients with type III or IV portal vein tumor thrombosis. World J Surg Oncol 2022;20:30. [PMID: 35109883 DOI: 10.1186/s12957-022-02495-4] [Reference Citation Analysis]
647 Gao J, Zhen R, Liao H, Zhuang W, Guo W. Pharmacokinetics of continuous transarterial infusion of 5-fluorouracil in patients with advanced hepatocellular carcinoma. Oncol Lett. 2018;15:7175-7181. [PMID: 29725440 DOI: 10.3892/ol.2018.8242] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
648 Yamada T, Minami T, Tateishi R, Koike K. Limited efficacy of atezolizumab and bevacizumab for hepatocellular carcinoma previously treated with tyrosine kinase inhibitor. Liver Int 2021;41:2233-4. [PMID: 34288369 DOI: 10.1111/liv.15010] [Reference Citation Analysis]
649 Qiu Z, Shen L, Jiang Y, Qiu J, Xu Z, Shi M, Yu Z, Ma Y, He W, Zheng Y, Li B, Wang G, Yuan Y. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Ann Transl Med 2021;9:283. [PMID: 33708910 DOI: 10.21037/atm-20-5360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
650 Burra P, Freeman R. Trends in liver transplantation 2011. J Hepatol 2012;56 Suppl 1:S101-11. [PMID: 22300460 DOI: 10.1016/S0168-8278(12)60011-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
651 Choi JW, Kim HC, Lee JH, Yu SJ, Cho EJ, Kim MU, Hur S, Lee M, Jae HJ, Chung JW. Cone Beam CT-Guided Chemoembolization of Probable Hepatocellular Carcinomas Smaller than 1 cm in Patients at High Risk of Hepatocellular Carcinoma. J Vasc Interv Radiol. 2017;28:795-803.e1. [PMID: 28302348 DOI: 10.1016/j.jvir.2017.01.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
652 Reig M, Matilla A, Bustamante J, Castells L, de La Mata M, Delgado M, Moreno JM, Forner A, Varela M. Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma. Gastroenterol Hepatol. 2010;33:741-752. [PMID: 20851505 DOI: 10.1016/j.gastrohep.2010.05.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
653 Wasnik AP. Tumor Response Criteria-Radiological Implications. Acad Radiol 2018;25:1361-2. [PMID: 30122626 DOI: 10.1016/j.acra.2018.07.011] [Reference Citation Analysis]
654 Kim MP, Yang JK, Jun BG, Kim YD, Cheon GJ, Jung HJ, Yoo JJ, Kim SG, Kim YS, Jeong SW, Jang JY, Kim HS, Lee SH. Effect of antiviral therapy in patients with low HBV DNA level on transarterial chemoembolization for hepatocellular carcinoma. J Viral Hepat 2021;28:1011-8. [PMID: 33759295 DOI: 10.1111/jvh.13508] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
655 Park MS, Kim SU, Park JY, Kim do Y, Ahn SH, Han KH, Chon CY, Seong J. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol. 2013;71:165-173. [PMID: 23079897 DOI: 10.1007/s00280-012-1993-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
656 Kim SS, Cho HJ, Nam JS, Kim HJ, Kang DR, Won JH, Kim J, Kim JK, Lee JH, Kim BH, Lee MY, Cho SW, Cheong JY. Plasma MicroRNA-21, 26a, and 29a-3p as Predictive Markers for Treatment Response Following Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma. J Korean Med Sci 2018;33:e6. [PMID: 29215815 DOI: 10.3346/jkms.2018.33.e6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
657 Shiozawa K, Watanabe M, Ikehara T, Shimizu R, Shinohara M, Igarashi Y, Sumino Y. Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography. J Med Ultrason (2001) 2017;44:101-7. [PMID: 27837395 DOI: 10.1007/s10396-016-0757-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
658 Zocco MA, Garcovich M, Lupascu A, Di Stasio E, Roccarina D, Annicchiarico BE, Riccardi L, Ainora ME, Ponziani F, Caracciolo G. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol. 2013;59:1014-1021. [PMID: 23811306 DOI: 10.1016/j.jhep.2013.06.011] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
659 Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Medicine (Baltimore). 2015;94:e688. [PMID: 25860213 DOI: 10.1097/md.0000000000000688] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
660 Ma Y, Chen Z, Zhu W, Yu J, Ji H, Tang X, Yu H, Fan L, Liang B, Li R, Li J, Li Z, Lin M, Niu L. Chemotherapy plus concurrent irreversible electroporation improved local tumor control in unresectable hilar cholangiocarcinoma compared with chemotherapy alone. Int J Hyperthermia 2021;38:1512-8. [PMID: 34767740 DOI: 10.1080/02656736.2021.1991008] [Reference Citation Analysis]
661 Rich NE, Parvathaneni A, Sen A, Odewole M, Arroyo A, Mufti AR, Kerr TA, Grant L, Tujios SR, Mayo MJ, Lee WM, Yang JD, Yokoo T, Gopal P, Hoshida Y, Zhu H, Yopp AC, Marrero JA, Singal AG. High Neutrophil-Lymphocyte Ratio and Delta Neutrophil-Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer. Dig Dis Sci 2021. [PMID: 33939138 DOI: 10.1007/s10620-021-07001-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
662 Xie F, Mao J, Zhao H. Comparison of Therapy in Advanced Hepatocellular Carcinoma Based on Clear Definition and Accurate Subgroup Data. JAMA Oncol 2021;7:940-1. [PMID: 33830172 DOI: 10.1001/jamaoncol.2021.0531] [Reference Citation Analysis]
663 Choi J, Lee D, Shim JH, Kim KM, Lim YS, Lee YS, Lee HC. Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma.PLoS One. 2020;15:e0229696. [PMID: 32130270 DOI: 10.1371/journal.pone.0229696] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
664 Yi C, Chen L, Lin Z, Liu L, Shao W, Zhang R, Lin J, Zhang J, Zhu W, Jia H, Qin L, Lu L, Chen J. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC. Hepatology 2021;74:2544-60. [PMID: 34036623 DOI: 10.1002/hep.31921] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 21.0] [Reference Citation Analysis]
665 Chen WT, Lin SM, Lee WC, Wu TJ, Lin CC, Shen CH, Chang ML, Lin CL, Yeh CT. GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial. Hepatol Int 2022. [PMID: 34982369 DOI: 10.1007/s12072-021-10283-7] [Reference Citation Analysis]
666 Bae WK, Lee BC, Kim HJ, Lee JJ, Chung IJ, Cho SB, Koh YS. A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma. Front Immunol 2022;13:879452. [PMID: 35720374 DOI: 10.3389/fimmu.2022.879452] [Reference Citation Analysis]
667 Lu W, Jin XL, Yang C, Du P, Jiang FQ, Ma JP, Yang J, Xie P, Zhang Z. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther. 2017;18:433-438. [PMID: 28548587 DOI: 10.1080/15384047.2017.1323589] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
668 Kim HD, Shim JH, Kim GA, Shin YM, Yu E, Lee SG, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. J Hepatol 2015;62:1076-84. [PMID: 25529626 DOI: 10.1016/j.jhep.2014.12.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
669 Ayuso C, Rimola J, García-Criado A. Imaging of HCC. Abdom Imaging. 2012;37:215-230. [PMID: 21909721 DOI: 10.1007/s00261-011-9794-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
670 Kaseb AO. Grant, deny, or reassess the role of yttrium-90 in hepatocellular carcinoma? The Lancet Oncology 2017;18:1560-1. [DOI: 10.1016/s1470-2045(17)30687-3] [Reference Citation Analysis]
671 Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR. Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treat Rev. 2018;68:16-24. [PMID: 29783126 DOI: 10.1016/j.ctrv.2018.05.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 17.0] [Reference Citation Analysis]
672 Hassanin TM, Fouad Y, Hassnine A, Eisawy M, Farag N, Abdel Ghany W. Quality of Life after Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Compared with Transcatheter Arterial Chemoembolization alone. Asian Pac J Cancer Prev 2021;22:1255-61. [PMID: 33906320 DOI: 10.31557/APJCP.2021.22.4.1255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
673 Zhu Y, Sun P, Wang K, Xiao S, Cheng Y, Li X, Wang B, Li J, Yu W, Cheng Y. Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China. Cancer Cell Int 2021;21:503. [PMID: 34537075 DOI: 10.1186/s12935-021-02200-7] [Reference Citation Analysis]
674 Goh MJ, Kang W, Jeong WK, Sinn DH, Gwak GY, Paik YH, Choi MS, Lee JH, Koh KC, Paik SW. Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. Sci Rep 2022;12:7647. [PMID: 35538112 DOI: 10.1038/s41598-022-11736-1] [Reference Citation Analysis]
675 Feng D, Hui X, Shi-Chun L, Yan-Hua B, Li C, Xiao-Hui L, Jie-Yu Y. Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular carcinoma. Oncotarget 2017;8:96649-55. [PMID: 29228559 DOI: 10.18632/oncotarget.20029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
676 von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H. First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation. Diagnostics (Basel) 2016;6:E44. [PMID: 27916795 DOI: 10.3390/diagnostics6040044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
677 Akhlaghpoor S, Aziz-Ahari A, Amoui M, Tolooee S, Poorbeigi H, Sheybani S. Short-term effectiveness of radiochemoembolization for selected hepatic metastases with a combination protocol. World J Gastroenterol 2012; 18(37): 5249-5259 [PMID: 23066320 DOI: 10.3748/wjg.v18.i37.5249] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
678 de Rosamel L, Blanc JF. Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2017;22:175-90. [PMID: 28604110 DOI: 10.1080/14728214.2017.1336538] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
679 Meyer T, Palmer DH, Cheng A, Hocke J, Loembé A, Yen C. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib. Liver Int 2017;37:1047-55. [DOI: 10.1111/liv.13359] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
680 Becker LS, Maschke SK, Dewald CLA, Meine TC, Winther HBM, Kirstein MM, Kloeckner R, Meyer BC, Wacker F, Hinrichs JB. Two-dimensional parametric parenchymal blood flow in transarterial chemoembolisation for hepatocellular carcinoma: perfusion change quantification and tumour response prediction at 3 months post-intervention. Clin Radiol 2021;76:160.e27-33. [PMID: 33028487 DOI: 10.1016/j.crad.2020.09.012] [Reference Citation Analysis]
681 Yu JI, Park HC, Lim DH, Choi Y, Jung SH, Paik SW, Kim SH, Jeong WK, Kim YK. The role of diffusion-weighted magnetic resonance imaging in the treatment response evaluation of hepatocellular carcinoma patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2014;89:814-821. [PMID: 24969795 DOI: 10.1016/j.ijrobp.2014.03.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [